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Abstract 
Major depressive disorder (MDD) affects 300 million people worldwide and is a major 
contributor to the global burden of disease. The aetiology of depression, emerging through a 
gene x environment interaction, is still incompletely understood which prevents tailoring of 
treatment approaches. In addition to MDD core symptoms, such as anhedonia (a diminished 
anticipation or experience of pleasure), depressed patients suffer from a plethora of 
manifestations including cognitive impairments, which occur primarily in the domains of 
executive function, attention and memory. Patients remitted from affective symptoms of MDD 
often continue to display cognitive impairments. These cognitive deficits are the longest 
present residual symptom, predict treatment response and increase risk of relapse. 
Consequently, cognitive impairments need to be targeted more effectively by antidepressants 
for complete remission from MDD. Clinically relevant animal models are essential for 
developing, tailoring and testing such novel, pro-cognitive antidepressants. 
This PhD project aimed to establish a preclinical screening platform for the testing of 
pro-cognitive antidepressants, to improve understanding of MDD risk factors and consequent 
symptom development, and finally, to focus on clinical relevance of the applied techniques. 
The chronic mild stress (CMS) rodent model of depression was used, known for 
displaying the core symptom anhedonia, but also for a high construct, face and predictive 
validity. The environmental MDD risk factor ‘stress’ induces an anhedonic-like phenotype in 
a subgroup of exposed rats, whereas another subgroup of rats is resilient, as determined by the 
sucrose consumption test. The cognitive performance of different rat strains, including CMS 
anhedonic-like and resilient rats, was assessed employing the touchscreen operant platform, 
which was developed based on the Cambridge neuropsychological test automated battery 
(CANTAB) for assessing cognition in humans. Furthermore, a group of anhedonic-like rats 
was treated with the antidepressant vortioxetine, which acts as both a pro-cognitive and 
antidepressant treatment. Our results showed that stress exposure induced anhedonia in albino 
and pigmented rat strains, although stress did not affect cognitive performance of pigmented 
rats in a simple pairwise discrimination touchscreen task. Applying a more complex paired-
associates learning touchscreen task revealed impaired cognitive performance in the CMS 
anhedonic-like but not in the resilient phenotype. Furthermore, vortioxetine treatment reversed 
anhedonia in the CMS model and altered executive functions in treated rats. The expression 
of genes involved in the stress response, affective disorders and neuronal plasticity was altered 
in the prefrontal cortex and hippocampus owned to treatment and hedonic state. Thus, we have 
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demonstrated that the CMS model exhibits both stress-induced cognitive alterations and 
depression-associated cognitive impairments in touchscreen tasks. Furthermore, touchscreen 
testing was sufficiently sensitive to detect alterations in cognitive performance due to 
pharmacological intervention. Overall, we established a potential platform for pro-cognitive 
antidepressant drug screening. 
Furthermore, brain derived neurotrophic factor (BDNF), involved in learning and 
memory, was examined in the context of depression. BDNF is reduced in MDD patients as 
well as in preclinical models in response to stress. Although this suggests that BDNF 
contributes to the aetiology of depression, studies including mice heterozygous for BDNF 
(BDNF+/-) have generated conflicting results. BDNF+/- rats may provide a more suitable model 
as (1) rats have a greater behavioural repertoire than mice, (2) classical behaviour tests are 
designed for rats, and (3) rats, like humans, produce peripheral BDNF. We found anhedonia 
and mild signs of anxiety in BDNF+/- rats, accompanied by prefrontal and hippocampal 
changes in expression of genes relevant in psychiatric disorders and underpinning learning. 
Thus, behavioural and molecular findings in BDNF+/- rats complement existing literature and 
suggest that rats are a more suitable model in BDNF research than mice.  
Overall, the project uncovered environmental and genetic manifestations of risk factors 
in translational models and established a novel tool for translational pro-cognitive 
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Dansk resume 
Depression udgør en af de største byrder i forhold til det samlede sygdomsbillede på 
verdensplan, hvor 300 millioner mennesker lider af denne sygdom. Selvom ætiologien bag 
depression er foreslået, at skyldes gen-miljø interaktion, så er det fulde sygdomsbillede stadig 
ukendt, hvilket forhindrer nye behandlingsmuligheder. Udover kernesymptomerne på 
depression, så som anhedoni (manglende evne til at føle glæde og lyst), lider depressive 
patienter af adskillige andre symptomer heriblandt svækket kognitive funktioner, hvor det 
primært er indlæring, opmærksomhed og hukommelsen, som er svækket. Patienter udviser 
ofte fortsat svækket kognitive funktioner selvom de er i bedring. De svækkede kognitive 
funktioner er de mest udbredte tilbageværende symptomer for depression efter bedring og 
bliver brugt til at forudsige behandlingsrespons samt forudsige en forøget risiko for recidiv. 
Derfor skal fremtidigt antidepressiv behandling være mere effektiv målrettet mod de kognitive 
funktioner for at forhindre risici for recidiv. Klinisk relevante dyremodeller er essentielle for 
udvikling af sådanne nye forbedrende antidepressive behandlingsmuligheder.  
Formålet med dette ph.d. projekt er at undersøge en præklinisk screeningsplatform til 
evaluering af kognitive antidepressive midler, at øge forståelsen for risikofaktorer for 
depression og udvikling af de efterfølgende symptomer, samt at vurdere den klinisk relevans 
af de anvendte teknikker.  
Kronisk mild stress (forkortet CMS for Chronic Mild Stress), som er en rottemodel for 
depression, bliver brugt i dette projekt, da den er velkendt for at inducere kernesymptomet for 
depression, anhedoni, men også for at have højt validitet. Stress, som er en miljømæssige 
risikofaktor for depression, inducerer et anhedonisk-lignende fænotype en i undergruppe af de 
stress-eksponerede rotter, mens en anden undergruppe forbliver upåvirket, og kaldes resiliente. 
Disse grupper bestemmes ud fra sukrose-indtaget fra en sukrose indtagelsestest (sucrose 
consumption test). De kognitive funktioner af forskellige rotteracer, herunder de anhedonisk-
lignende rotter og de resiliente rotter, blev vurderet ved brug af en touch screen platform, som 
er baseret på Cambridge neuropsykologisk test (forkortet CANTAB for Cambridge 
Neuropsychological Test Automated Battery), der bruges til at teste kognitive funktioner i 
mennesker. Ligeledes blev en gruppe af de anhedonisk-lignende rotter behandlet med det 
unikke antidepressive middel, vortioxetin, som både virker på de kognitive funktioner og har 
en antidepressiv virkning. Vores resultater viser, at stress-eksponering inducerer anhedoni i 
albino og pigmenterede rottestammer, mens stress ikke påvirker de kognitive funktioner i den 
pigmenterede rottestamme ved en simpel touch screen diversitetstest. Ved at bruge en mere 
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kompleks touch screen indlæringsassociation test har vi vist, at de anhedonisk-lignende rotter 
har nedsat kognitive funktioner i forhold til den resiliente fænotype. Ligeledes har vi vist, at 
behandling med vortioxetin modvirker den anhedonisk fænotype i CMS modellen samt ændrer 
udførelsen af opgaver i touch screen testen. Ekspressionen af gener, som er involveret i 
stressrespons, affektive lidelser og neuronal plasticitet, ses ligeledes ændret i præfrontal cortex 
og hippocampus i forbindelse med vortioxetine behandling. Således har vi vist ved brug af 
touch screen platformen, at CMS modellen forårsager stress-relateret kognitive ændringer og 
forringet kognitiv funktion som også ses ved depression. Derfor er touch screen platformen 
tilstrækkelig sensitiv til at måle ændringer i de kognitive funktioner, som både skyldes stress 
og farmakologisk behandling. Overordnet har vi etableret en potentielt platform, som kan 
bruges til screening af antidepressive behandlinger med fokus på de kognitive funktioner.  
Brain Derived Neurotropic Factor (BDNF), som er involveret i indlæring og 
hukommelse, har tidligere været undersøgt i forbindelse med depression. Tidligere studier har 
vist, at BDNF er reduceret i depressive patienter og i prækliniske dyremodeller, som et respons 
på stress. Selvom dette antyder, at BDNF er involveret i ætiologien bag depression, giver 
studier med BDNF+/- mus modstridende resultater. Derfor ville BDNF+/- rotter muligvis være 
en mere passende model fordi (1) rotter har et større adfærdsrepertoire end mus, (2) klassiske 
adfærdstests er designet til rotter, og (3) rotter producerer perifer BDNF ligesom mennesker. 
Vores resultater viser, at BDNF+/- rotter udviser både anhedoni og milde tegn på angst, samt 
ændringer i ekspressionen af præfrontale og hippocampale gener, som er relevante for 
psykiatriske lidelser og særlig indlæring. Derfor passer adfærden og de molekylære resultater 
fra BDNF+/- rotterne til den allerede eksisterende litteratur, hvilket indikerer, at rotter er mere 
brugbare til undersøgelse af BDNF ekspressionen end mus.  
Overordnet har dette projekt demonstreret miljømæssige og genetiske risikofaktorer for 
depression i translationelle modeller og etableret et nyt translationel værktøj til screening af 
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Lay Abstract 
Depression is a severely disabling disease affecting 300 million people worldwide and their 
social surrounding including family, colleagues and friends. The main symptoms of depression 
are being in a sad mood and showing a decreased interest or experience of pleasure (which is 
called being anhedonic). Depressed patients may also show a variety of other symptoms; 
amongst them are cognitive impairments, such as difficulties in decision-making, paying 
attention, learning or memory. After remission from depression, and normalisation of the 
mood-related symptoms, these cognitive impairments can still persist and continue impact 
day-to-day life. Everyday tasks may be perceived as more difficult and the risk of having more 
depressive episodes is increased. Therefore, novel antidepressant treatment that helps to 
relieve the cognitive impairments as well as the depression is needed. Furthermore, animal 
models to test the novel treatments on are indispensable. Usually, such treatment effects are 
assessed in animal tests that are specific to the animals’ nature. However, such studies may 
not be clinically relevant nor help to draw conclusions from animal to men.  
Hence, we applied the “touchscreen operant platform”, a touchscreen setup developed 
on a touchscreen setup used in humans (e.g. iPad tests). Rats need to learn that some symbols 
on the touchscreen will be rewarded when chosen, which is similar to the test where humans 
should only touch the correct symbol on their touchscreen. There are different tasks available 
for testing different forms of cognition (e.g. memory, attention). The animal model of 
depression that was used is called the chronic mild stress (CMS) model because it uses mild 
stressors over weeks. This mimics daily stressors in humans that can lead to depression. 
However, not all humans, as not all rats, develop depression; some are resilient to it, which 
makes a good analogy between men and animals.  
We found that different rat strains can lead to different results in the touchscreen 
learning performance. Stressed rats seem to be more impulsive, meaning they touch the screen 
although no symbols are displayed or they do not take as much time as non-stressed rats to 
make their choice on the touchscreen. Surprisingly, these impulsive behaviours were also seen 
in rats that were treated with antidepressants. Very importantly, we found that stressed rats 
that develop depressive-like behaviour, need longer to learn the touchscreen task, whereas rats 
that were stressed but stayed resilient did not take longer than the non-stressed rats to acquire 
the task. This shows us that some cognitive impairments are specific to depression and not to 
a general stress exposure. The antidepressant treatment used in this test did not improve 
learning.  
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Next, we looked at brain-derived neurotrophic factor (BDNF), a protein that is known 
to be expressed at lower levels in the brain of animals exposed to stress and similarly in patients 
with depression. Hence, we were interested if rats designed to have around 50% of the normal 
BDNF levels show depressive-like behaviour. We found that these rats have changes in 
expression levels of genes involved in depression or psychiatric diseases, such as Disc1, 
Fkbp5, GR and Nrg1. Furthermore, the lower-level BDNF rats displayed anxiety-related 
behaviour in some tests and anhedonic-like behaviour. These are important findings since 
anxiety often co-occurs with depression. Hence, we could show how BDNF may be involved 
in altered behaviour and expression levels of other gene; and further untangle the complex 
gene-environment interactions that lead to depression in humans. It is important to understand 
these interactions in order to tailor antidepressant treatment for depressed patients with 
showing different sets of symptoms. Furthermore, using stress exposed rats in touchscreen 
tasks we are able to assess the effects of such novel treatments in a clinically relevant model 
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1 INTRODUCTION  
1.1 Major depressive disorder 
Major depressive disorder (MDD) is the leading cause for disability worldwide. Around the 
globe, there are more than 300 million people that suffer from depression1. In the adult 
population, an estimate of 6% show a 12-months prevalence for MDD2, whereas the lifetime 
prevalence is approximately around 20%3. Approximately, two times as many women suffer 
from MDD as men2,3. In high-income countries, the life time prevalence is significantly greater 
(14.6%) than in middle- or low-income countries (11.1%)2. MDD explains 8.2% of the global 
years lived with disability and thus occupied the second leading cause for disability in 20104. 
The years lived with disability are still on the rise due to a growing and aging population, 
which was demonstrated by an increase of years lived with disability by 37.5% from 1990 and 
20104. Median disease onset is at 25 years of age, and the high-risk period ranges from mid-
late adolescence until early forties2. However, earlier onset of MDD is associated with 
increased disease severity and recurrence5,6. Furthermore, depression is an episodic disease 
and the poor response of only 50% of patients to a two-step pharmacological treatment 
regimen, as well as persistence of residual symptoms even after remission from MDD, increase 
the risk for relapse and chronicity of the disease7. Overall, MDD is a highly prevalent disease 
and its inefficient cure is of concern. 
MDD patients display a heterogeneity of symptoms. Core symptoms of MDD are a 
depressed mood and anhedonia (a diminished anticipation or experience of pleasure). 
Additionally, patients can suffer from cognitive impairments primarily in attention, executive 
function and memory. A complete list of symptoms used for diagnosis is presented in Table 1. 
“There is an ancient Indian parable of six blind men attempting to describe an 
elephant. Unable to see the giant animal as a whole, each describes the elephant 
according to what he feels with his hands, as either a tree trunk, a wall, and so 
on. In a sense, MDD, and perhaps every psychiatric disorder, is like the 
proverbial elephant. If we make the mistake of equating one small part of a 
larger process with the disease itself, we run the risk of missing the big picture, 
which is that most psychiatric disorders probably represent an interactional 
matrix of many factors, and cannot be reduced to those factors alone.”  
 
               Dean & Keshavan, 2017 
INTRODUCTION 
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The suicide rate is twenty times higher in MDD patients compared to the general 
population8. Furthermore, MDD patients have an increased risk of developing comorbidities, 
such as heart diseases, diabetes mellitus or stroke9,10. The high suicide rate as well as 
occurrence of other comorbidities shorten the life span of MDD patients, which further 
underlines the need for countering depression. MDD treatment is additionally complicated by 
psychiatric comorbidities, for example anxiety disorders, which occur in 60–70% of MDD 
patients during their lifetime11,12. In conclusion, MDD affects many people, reducing their 
quality of life and potentially resulting in a premature death. 
1.1.1 Risk factors: gene x environment interaction 
Although depression research has received much attention and resources, the neurobiological 
mechanisms of MDD are not well understood13. Lack of knowledge is due to the complex gene 
x environment interaction eliciting a heterogeneity of symptoms across patients14,15. Potential 
genetic as well as environmental risk factors are identified; but their interactions resulting in a 
patient-specific MDD pathology remain unknown16 and prevent optimal treatment strategies. 
1.1.1.1 Genetic predisposition 
The heritability of MDD is estimated to be 30–40%16,17 whereas heritability appears to be 
higher in women (40%) than in men (30%)18,19 and is increased two- to threefold in first-degree 
family members20. A family history of depression introduces differences in MDD pathology 
compared to MDD patients without such family history. For example, individuals with a 
family history show an earlier onset of MDD, increased severity of symptoms and higher 
relapse rates20–23. Although such observations indicate a genetic component in MDD 
development, genome-wide association studies (GWAS) keep failing to identify candidate 
genes associated with MDD11,24. The world’s second biggest GWAS in psychiatry was 
conducted in depression research and included over 18 000 people (half of them with MDD) 




Loss of interest or pleasure (Anhedonia) 
Additional 
symptoms 
Body weight changes 
Insomnia/ hypersomnia 
Psychomotor agitation/ retardation 
Fatigue/ Loss of energy 
Feelings of worthlessness and inappropriate/                    
excessive guilt            
Cognitive impairments 
Suicidal thoughts 
Table 1. Diagnostic criteria 
for major depressive episode 
according to DSM-5, the 
Diagnostic and Statistical 
Manual of Mental 
Disorders.67 At least five of 
these symptoms including at 
least one of the core 
symptoms have to present 
nearly every day during a 
two-week period. 
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Still, not one SNP reached significance25. The same result was ascertained in the replication 
phase of the study including close to 7 000 MDD patients and over 50 000 controls targeting 
554 SNPs. This GWAS mega analysis in the European population embodies the biggest MDD 
GWAS study, yet the authors suggest insufficient statistical power as reason for the lack of 
significant findings. They state that the high prevalence of MDD in the population implies 
only moderate genetic changes in MDD patients compared to controls and, thus, demands for 
an even greater sample size25. In the review from Flint and Kendler11, the lack of significant 
findings of candidate genes related to MDD pathogenesis are explained either by 
overestimation of genetic effects in depression or by depression being falsely categorized as 
one disease. MDD might be reflecting a heterogeneity of diseases, which result in similar 
symptoms but are caused by alterations in different pathways. An alternative explanation could 
be that, gene x gene interactions, involving many genes with small effects on their own, 
contribute to the genetic side of MDD26. 
Nonetheless, a few studies observed associations of a genetic predisposition with 
MDD pathology and treatment response. For example, Binder et al.27 discovered that SNPs in 
FK506 binding protein 5 (FKBP5) are associated with treatment response. A specific 
polymorphism (TT genotype at rs1360780) was linked to individuals with a high number of 
depressive episodes but also to a faster response to antidepressants. Polymorphisms in Fkbp5 
can increase its gene expression. Incremented levels of FKBP5 desensitize the hypothalamus-
pituitary-adrenal (HPA) axis’ negative feedback loop via competing with free glucocorticoids 
for binding to the glucocorticoid receptor (GR). Furthermore, the GR polymorphisms BclI and 
ER22/23EK were found to increase risk for MDD in homozygous carriers28. Thus, genetic 
predispositions involved in HPA axis regulation appear to be involved in MDD and treatment 
response. 
Another polymorphism that was associated with MDD pathology is an amino acid 
substitution of valine with methionine at codon 66 (Val66Met) in the brain-derived 
neurotrophic factor (BDNF) gene. Val66Met was increasingly found in MDD patients and 
resulted in an attenuated secretion of the activity-dependent form of BDNF29. Val66Met was 
linked to neuroticism, an affective-state dependent personality trait30, which is associated with 
depression31. Furthermore, Val66Met appears to modulate the impact of stressful life events 
and, to a moderate degree, the impact of childhood adversity on MDD pathogenesis32. Thus, 
polymorphisms in the BDNF gene might create a vulnerability in individuals for developing 
MDD33–35. 
Furthermore, a polymorphism in the promotor region of the serotonin transporter gene 
(5-HTTLPR) is suggested to be involved in MDD pathogenesis. Originally, the polymorphism 
INTRODUCTION 
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in 5-HTTLPR was directly associated with depression. This theory was then modified and it 
was shown that carriers of the polymorphism had an increased risk of developing MDD upon 
exposure to stressful life events36. However, this association seems dependent on the timing 
of the stress experience, the type of stressor and interactions with other genetic 
polymorphisms17,36. Furthermore, carriers show an increased risk to experience multiple-
episodes of MDD, but the risk was not increased for a single-episode37. Overall, the examples 
of polymorphisms in FKBP5, BDNF and 5-HTTPLR illustrate the difficulty when attempting 
to entangle the causal relationship of genetic risk factors and the emergence of MDD 
symptoms due to the environmental interference. 
1.1.1.2 Environmental risk factor -Stress 
Stress is a major environmental risk factor for developing depression14,38. “Stress” can be 
ascribed as the non-specific response of the body to any demand for change and, thus, as a 
threat to the maintenance of the body’s homeostasis33,39,40.  
The brain plays a central role in the stress response: Stressors can be real (e.g. 
predator) or perceived (e.g. phobia). The brain is instrumental in defining a threat, thus a 
stressor, and initiates an appropriate physiological or behavioural response41. Various systems 
are involved in the succeeding stress response. Intensively studied is the hormonal stress 
response regulated by the HPA axis (Figure 1). Sensory input to the hypothalamus leads to 
secretion of corticotropin releasing hormone (CRH) from the paraventricular nucleus. 
Thereupon, the anterior pituitary releases adrenocorticotropic hormone (ACTH), which 
stimulates the adrenal glands to secrete glucocorticoids42,43. GRs are transcription factors, i.e. 
they regulate the transcription of other genes and, thus, are vital for cellular processes. 
Glucocorticoids are involved in important downstream processes for the ‘fight or flight’ 
response, including a rapid energy availability, down-regulation of the immune system and 
enhanced cognition (e.g. increased vigilance)43. A rapid activation of the HPA axis is 
beneficial to cope with an acute stressor and to restore homeostasis. For a healthy stress 
response, the increased HPA axis activation is short-term and quickly terminated in the 
absence of a stressor. Other brain regions are also involved in the regulation of the HPA axis, 
for example, the hippocampus (HPC). Increased levels of glucocorticoids secreted by the HPA 
axis reinforces the inhibitory control of the HPC on the HPA axis and resembles a negative 
Major depressive disorder 
-  5  - 
feedback loop of the HPA axis. 
However, prolonged high levels of stress 
result in long-term hyperactivation of the 
HPA axis, which is associated with 
pathogenesis of neuropsychiatric 
disorders44–46. 
The time point of stress 
exposure is also important. The brain 
undergoes different stages of plasticity 
throughout life depicting distinct phases 
of vulnerability. Stress programming is 
categorized accordingly, such as 
prenatal, early life (neonatal or juvenile) 
or adulthood stress42,47. It was shown that 
early life stress (ELS), such as 
experiencing abuse and witnessing 
violence, increases risk for depression 
later in life17. Thereby, the severity of the 
adverse event during childhood 
correlates with the emergence of MDD 
pathology48. Thus, stress increases the 
individual’s vulnerability to develop 
affective disorders later in life. Markers 
of such a vulnerable phenotype are 
glucocorticoid resistance, increased 
inflammation, central CRH secretion 
and decreased activity of oxytocin49–52. 
Structural and functional changes occur 
in brain regions in response to ELS, 
including a smaller HPC volume53 and 
an increased amygdala activity54. Symptoms and treatment response observed in depressed 
individuals with a background of ELS appear distinct from MDD patients without ELS, 
suggesting MDD in association with ELS as a subtype of depression48,55. 
In adult life, long periods of stressful experience, such as unemployment, poverty and 
family conflicts can induce a depressive episode56. Moreover, chronic stress can impair 
Figure 1. Hypothalamic-pituitary-adrenal (HPA) axis. In 
response to stress, increased levels of arginine 
vasopressin (AVP) and corticotropin-releasing 
hormone (CRH) are released from the hypothalamus. 
This stimulates the release of adrenocorticotropic 
hormone (ACTH) from the anterior pituitary and 
consequently, elevated levels of glucocorticoids are 
released into the blood stream. The free 
glucocorticoids augment the inhibitory control, e.g. 
of the hippocampus on the HPA axis, resembling a 
negative feedback loop. The negative feedback is 
initiated by glucocorticoid (GR) and 
mineralocorticoid receptors (MR).42  
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cognitive function in e.g. HPC-dependent tasks, cognitive flexibility and decision-making57–
59. Exposure to stress can lead to a shift from effortful, resource-demanding behaviour to less 
effortful, habitual cognitive strategies60. Such a shift is beneficial in times of high stress, but a 
failure to adapt in the long-term results in impairment of choosing the most appropriate 
cognitive strategy. Furthermore chronic stress causes dendrites to experience shrinkage in the 
HPC and prefrontal cortex (PFC), while they expand in the amygdala56,59,60. Most likely, 
dendritic changes are modulated by enhanced glucocorticoid secretion by an over-active HPA 
axis61. Furthermore, stress can also decrease neurogenesis in the HPC, a brain region involved 
in learning and memory59. This effect might be linked to BDNF, a growth factor modulating 
neuronal plasticity and its expression is diminished in response to stress62. Thus, the 
neurotrophic hypothesis of depression unifies the gene x environment interaction of MDD 
pathogenesis63. Therefore, stress might be directly responsible for the depression-associated 
cognitive impairments. 
However, it should be clarified that not every individual experiencing prolonged 
periods of stress necessarily develops depression. Genetic predisposition but also 
environmental factors, such as social support, can prevent disease development64. Especially 
the individual’s perception of control – or loss of control over the stressful situation impacts 
the vulnerability to MDD65. Resilience to stress is associated with the ability of an individual 
to consider challenges as opportunities in which one can actively manoeuvre instead of an 
externally imposed burden66. 
1.1.2 Symptoms associated with depression 
Many symptoms are associated with depression. These can emerge in numerous combinations 
in patients enduring depression. The following sections focus on two symptoms: anhedonia 
and cognitive impairments. 
1.1.2.1 Anhedonia 
Anhedonia is one of the two core symptoms of MDD according to DSM-5 and contributes to 
the affective symptoms of depression. Anhedonia is described as a diminished anticipation or 
experience of pleasure in activities found rewarding prior to disease onset67. Brain regions 
involved in anhedonia are the PFC, dorsal striatum, amygdala and nucleus accumbens68. 
Anhedonia is the only negative predictor of time to remission and number of depression free 
days69. In depression research, anhedonia is often assessed by providing a reward-inducing 
experience and testing the subject’s response to it. The rewards can be categorized as primary 
or inherent (such as food or sex), or as secondary rewards (such as money). In clinical studies, 
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mostly secondary rewards are used, whereas in preclinical research mostly primary rewards 
are applied. Together with the very general but also varying definition of anhedonia68, 
comparisons between studies, performance of meta-analyses and translation between clinical 
and preclinical research is intricate. 
Four clinical self-rating scales dominate assessment of anhedonia: Chapman Social 
Anhedonia Scale, Revised Chapman Physical Anhedonia Scale, Fawcett–Clark Pleasure 
Capacity Scale and Snaith–Hamilton Pleasure Scale. However, the criteria of anhedonia is 
inconsistently fulfilled across the four scales (reviewed in Rizvi et al.68). Thus, more recent 
scales were developed (Temporal Experience of Pleasure Scale, Motivation and Pleasure 
Scale-Self, Report, Specific Loss of Interest Scale, Anticipatory and Consummatory 
Interpersonal Pleasure Scale, Dimensional Anhedonia Rating Scale). However, these also 
encompass different foci and, therefore, the Snaith–Hamilton Pleasure Scale remains the most 
frequently used scale in assessing anhedonia although it mainly determines consummatory 
pleasure68. 
Preclinical models utilize the sucrose consumption test (SCT), the sucrose preference 
test (SPT), the place preference test or intracranial self-stimulation (ICSS) to evaluate the 
hedonic state of animals. Assessment of sucrose intake as reflection of the hedonic state was 
carefully evaluated by Willner and colleagues in connection with the chronic mild stress 
(CMS) model70–73. It can be disputed if the preclinical SPT or SCT reflects the subjective 
character comprising anhedonia in humans or if these tests can be reduced to alterations in 
energy seeking or changes in fluid consumption in animals. However, Muscat and Willner70,73 
have extensively evaluated these tests in the context of the CMS model and found the SPT and 
SCT to be a valid tool for assessing anhedonia in animals71.  
In the place preference test, control animals prefer the compartment of a box in which 
something rewarding, e.g. food, was presented on the previous days. In contrast, stressed 
animals do not show a preference for either box compartment. Nevertheless, it is questionable 
if the place preference test is a readout of anhedonia or rather reward-location association 
learning74. 
ICSS resembles the most elegant method for assessing anhedonia. The animal can 
induce activation of a brain region by pressing a lever, which elicits a reward sensation in the 
animal. The degree of effort an animal is willing to perform to receive a reward can be 
determined by modifying the number of lever presses necessary to elicit a reward sensation. 
This makes ICSS the gold standard for testing the abusive risk of drugs. However, ICSS is 
invasive and is inconvenient for models such as the CMS, which employ large numbers of 
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animals. Thus, the SCT or SPT are a valid middle-ground for assessing anhedonia in a reliable 
and straightforward practical manner.  
1.1.2.2 Cognitive impairments in MDD 
Cognition can be depicted as “the mental action or process of acquiring knowledge and 
understanding through thought, experience, and the senses”75. Cognitive processes underlie 
our everyday actions. We intentionally use cognitive functions, like learning and memorising, 
in school or at work. Often, however, cognitive processes are unconscious, such as speech 
production, decision-making or retrieval of short-term or long-term everyday knowledge or 
events. Cognition is a major entity of our life and essential for normal, daily functioning.  
Cognitive function can be severely disturbed in patients with neuropsychiatric 
disorders, such as schizophrenia or depression. In depression, cognitive impairments are not 
listed as a core symptom of MDD67. However, cognitive impairments are a major contributor 
to the deficits in daily functioning in subjects with MDD76, resulting in insufficient work 
performance, household maintenance or upholding of social relationships77. Furthermore, 
cognitive impairments are a prominent residual symptom following remission from depression 
and their persistence prevents success of antidepressant therapy78,79. These findings oppose the 
idea of cognitive impairments being a sole epiphenomenon of depression79–81.  
 
The cognitive domains that appear most impaired are those that require effortful processes82. 
Primarily, cognition is affected in the domains of attention, executive function and 
memory77,80–83.  
Various studies have shown that executive functions are impaired in MDD patients. 
For example, MDD patients displayed deficits in the intradimensional/extradimensional set 
shifting task requiring cognitive flexibility. This deficit was especially evident during the 
extradimensional set shift suggesting impairments in the lateral PFC84. A study introduced the 
concept of “depression-executive dysfunction syndrome”, which refers to the symptoms of 
reduced fluency, impaired visual naming, paranoia, psychomotor retardation and loss of 
interest in activities, based on their research in elderly patients85. The depressive patients with 
executive dysfunctions in the study displayed increased functional disability compared to 
depressed patients with normal executive functions. The authors suggest that executive 
dysfunctions are a substantial part of geriatric depression, likely provoked by deficits in the 
medial frontal lobe85. This emphasises the disabling impact of cognitive impairments on life 
functioning. Furthermore, patients with depression-executive dysfunction syndrome exhibit 
clinically increased risk for relapse and poor treatment response85,86. Moreover, elderly MDD 
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patients demonstrate impairments in executive functions in the trail making test, verbal fluency 
test and go/no-go task. Thus patients showed deficits in semantic fluency, inhibition of 
automated motor reactions, cognitive flexibility and augmented psychomotor slowing79. The 
severity of depression correlated with lower performance in the go/no-go task, assessing 
response inhibition79. Similarly, another study found that adult, but non-elderly, depressed 
patients performed worse in the Stroop (executive attention), visual orienting (attentional 
shift), and continuous concentration (sustained attention) tasks. Performances were poorer in 
severely depressed patients (three or more depressive episodes) compared to patients with one 
or two depressive episodes87. Moreover, other depression-associated processes, such as 
rumination, appear to interfere with the inhibitory executive control, as shown with the random 
number generation task88. Hence, depressed patients fail to execute an inhibitory control over 
the ruminating thoughts and therefore forfeit in task performance. Clearly, executive functions 
are impaired in depressed patients and suggest alterations in the PFC. 
 “Attention” is another cognitive domain that received awareness in depression 
research. Paelecke-Habermann and colleagues87 suggest that normal attentional performance 
is a prerequisite for executive functions. Hence, deficits in executive function might be 
interconnected with impairments in attention. Investigation of the three attentional network 
functions (Figure 2) in acute and remitted depressive patients suggests attentional deficits as 
trait- rather than state-dependent characteristic of MDD87. However, the same study suggests 
independence of deficits in attention and executive function in depression87. Furthermore, the 
concept of a negativity bias is well known in depressed patients. This mechanism was 
proclaimed mainly for memory89, but is already active in attentional processes as shown with 
the dot probe task90. The attentional bias was also prominent for faces91. Depressed patients 
focused more on sad faces and healthy controls more on happy faces. Such a bias in depressed 
individuals might negatively influence interpersonal perception and social functioning. The 
negative bias towards sad faces was still present in patients remitted from depression91. 
Figure 2. Interplay of the 
cognitive domains of attention 
and executive functions. 
Attention is a term that spans 
over three, independent 
networks, which are the basis 
for the five components of 
executive functions. These 
executive components are not 
independent from each other 
and deficits in one impedes the 
other components as well.87 
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Similarly, reading words revealed a negativity bias in depressed patients by being selective 
attentive to socially threatening, but not physically menacing words92. Thus, attentional 
processes can be impaired in depressed patients and, moreover, they redirected the patient’s 
focus towards negative information, which possibly augments the depressive mood of the 
patient. 
Another cognitive domain impaired in association with depression is “memory”. 
Patients with depression performed poorer in a verbal learning test (CVLT-II) during both, the 
learning and recall phase93. Thus, declarative memory was impaired in depressed individuals 
compared to healthy controls. These impairments could neither be explained by verbal nor 
non-verbal IQ scores nor with secondary, strategy-related processes. Impairments in encoding 
and retrieval of verbal memory suggest altered function in medial temporal lobe regions93. In 
non-dementia late-onset MDD patients, memory deficits were clearly observed during the 
acute phase of depression independent of “general” cognitive performance or motivation94. 
Interestingly, only autobiographic memory but not memory for public events was affected in 
these patients. Generally, MDD patients appear particularly affected in explicit compared to 
implicit memory80,81,95. Another study applying the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) revealed that MDD patients performed poor in tasks 
depending on episodic memory, recognition memory, problem solving, spatial recognition 
memory, and attentional set shifting from the CANTAB test battery96–98. Conclusively, 
memory deficits are present in MDD patients, which might be a result of augmented HPA axis 
activity and the consequently prolonged release of corticoids affecting the HPC98,99. 
The severity of cognitive impairments in depression appears to be augmented by the 
severity of depression experienced. Cognitive impairments are impacted by multiple episodes 
versus a single episode, number of recurrent episodes, history of psychotic depression, poor 
response to pharmacotherapy, increased residual symptom severity, younger age at MDD 
onset, and by older age (implying a higher amount of prior depressive episodes or increased 
vulnerability of the brain due to aging processes)98,100. Cognitive impairments are robustly 
found especially in elderly MDD patients98,101,102. However, it remains unclear how 
depression-associated cognitive impairments emerge. They could be a consequence of the 
neuroanatomical changes observed in MDD (reviewed in 1.1.3) or a result of the stress-
induced hypercortisolism77. 
 
Several studies and meta-analyses investigated the alleviation of cognitive impairments after 
remission from the affective symptoms of MDD. Bhalla and colleagues103 found that in late-
life depression, 45% of patients display cognitive impairments one year after remission from 
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the affective symptoms. In fact, 94% of patients with persistent cognitive impairments during 
depression remained affected by these impairments one year following remission103. 
Additionally, 23% of patients newly developed cognitive deficits after remission from 
depression103. Reppermund et al.80 observed cognitive impairments in executive function, 
attention and memory. These cognitive impairments were still present in 57% of patients after 
remission. Furthermore, cognitive performance was not statistically significant different 
between remitted and non-remitted MDD patients80. A study by Jaeger et al.77 found that 6 
months after hospitalization for MDD, 60% of patients exhibited significant neurocognitive 
deficits, which were also a predictor of life functioning disability. A meta-analysis including 
only studies that used the CANTAB test battery for assessing cognitive performance 
discovered that deficits in executive functions and attention as well as small deficits in memory 
persisted in patients remitted from the affective symptoms of MDD81. Furthermore, remission 
from affective symptoms does not result in normal daily functioning, which indicates cognitive 
impairments as a disability factor in MDD pathology77,83,104. Hence, even when remitted from 
depression, patients are still impaired in their daily functioning. This possibly induces lower 
self-esteem and feelings of worthlessness in such individuals, which in turn might trigger 
another depressive episode.  
 
During a three-year period, cognitive symptoms were the most dominant residual symptom of 
MDD. In patients experiencing a depressive episode, cognitive impairments were present 94–
100% of the time, and during a non-depressive period 35–44% of the time105 (Figure 3). This 
long-term study emphasises the predominant appearance of cognitive impairments in the 
pathology of MDD. Furthermore, cognitive impairments appear to be greater with every 
Figure 3. The presence of 
depression-related 
residual symptoms during 
a 3-year follow up. 
Cognitive deficits are a 
predominant residual 
symptom (red), whereas 
the core symptoms of 
depression are less 
present (blue).105 
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episode of MDD and in-between episodes, cognitive symptoms recover less and less6,87 
(Figure 4).  In young and elderly MDD patients, cognitive symptoms predict treatment 
outcome106,107. Furthermore, treated patients perform better in cognitive tasks than 
unmedicated patients, however, medicated patients still perform worse compared to healthy 
controls108, emphasizing the demand for pro-cognitive antidepressants. If cognitive symptoms 
can be mitigated, the risk of relapse can be reduced109,110. So far, treatment with serotonin-
norepinephrine reuptake inhibitors (SNRIs) appears to be superior to selective serotonin 
reuptake inhibitors (SSRIs) in regard to alleviating cognitive deficits, such as episodic and 
working memory111. Both treatments improved attention and executive functions alike, but 
failed to normalize cognitive performance to the level of healthy controls112. These findings 
demonstrate that antidepressants still lack to efficiently target cognitive impairments but 
mainly focused on alleviating the affective symptoms of depression only. In the long-term, it 
is estimated that only 20% of MDD patients fully recover and regain their daily functioning to 
a level prior to depression onset113,114. Thus, normalization of cognitive performance in 
depression is required for complete remission of depression.  
1.1.3 The brain in MDD 
In MDD, brain regions with functional changes are predominantly the PFC, the HPC, the 
amygdala and the nucleus accumbens115.  
The PFC is associated with complex cognitive processes and involved in executive 
functions. These include regulating attention, cognitive flexibility, response inhibition, 
working memory, verbal fluency, decision-making and problem solving amongst others. In 
depressed patients, the PFC shows decreased activity and a reduction in volume116,117. 
Diminished PFC activity was associated with MDD severity117.  
Figure 4. Scheme of major depressive episodes. Illustrated in blue is the episodic nature of the 
affective symptoms. Depression-associated cognitive impairments are displayed in red. Cognitive 
abilities may recover between depressive episodes or increasingly deteriorate with every relapse.6 
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Alterations in the HPC are a robust finding in MDD pathology. The HPC is associated 
with formation of long-term and spatial memory. The HPC is linked directly to the hypothesis 
of stress as a risk factor of depression as it is an inhibitory regulator of the HPA axis activity 
mediated by its glucocorticoid (GR) and mineralocorticoid receptor (MR) actions. In 
depressed patients, reduced volume of the HPC was robustly found in several studies118–120 and 
may be explained by dendritic retraction, cellular shrinkage, apoptosis, reduced number of 
glial cells, lower levels of extracellular fluid content or lower neurogenesis or gliogenesis 
rates61. Volume reduction appears to correlate with the duration of the depressive episodes119–
121. Furthermore, HPC neurogenesis was shown to be decreased in response to stress, increased 
after antidepressant treatment122 and required for antidepressant action123. These findings, in 
both pathology and treatment substantiate a central role of the HPC in MDD.  
Changes in reward sensitivity and anhedonia are suggested to be a consequence of 
alterations in the nucleus accumbens and the ventral tegmental area124. Both areas are involved 
in reward and motivation and it was shown that, e.g. the nucleus accumbens is involved in 
maintaining resilience and response to antidepressants after stress exposure125.  
Generally, it is more likely that MDD pathology is introduced by a network 
dysfunction mode than by single brain lesions126. Imaging studies found that the connectivity 
of brain regions is altered in MDD patients, such as higher activity in the subgenual cingulate 
and thalamus, investigating the default mode network with magnetic resonance imaging 
(MRI)127. Additionally, positron emission tomography (PET) reveals that depressed patients’ 
metabolism is reduced in the lateral PFC, but increased in medial PFC and subgenual 
cingulate128,129. Even in patients remitted from depression, the brain metabolism was altered 
involving an increase in activity in the anterior cingulate, orbitofrontal cortex and medial 
thalamus130. These findings suggest that brain changes do not simply recover after a depressive 
episode and more likely increase vulnerability to experience another subsequent episode. 
1.1.4 Antidepressant treatment 
Antidepressant medication was discovered by serendipity in the 1950s. Patients treated for 
tuberculosis showed signs of elevated mood following treatment with iproniazid131. The first 
antidepressants included monoamine oxidase inhibitors and tricyclic antidepressants, which 
prevent the metabolism or reuptake of monoamines and therefore increase their availability. 
These broad-acting antidepressants were mostly replaced by SSRIs, noradrenaline reuptake 
inhibitors (NRIs) and SNRIs in the 1980s131,132 and are still the most common first-line 
treatment at present. A major detriment of currently used antidepressants is the long period of 
2-4 weeks until therapeutic onset132. Furthermore, with a remission rate as low as 50% in a 
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two-steps treatment regimen, valuable time is lost to find a potent drug for individual patients7. 
Novel antidepressants, such as ketamine, are being constantly investigated, but there has been 
no major breakthrough in antidepressant drug research for nearly 40 years132. Current first-line 
antidepressants insufficiently target all of the potential biological underpinnings of MDD 
pathogenesis, such as dysregulation of the HPA axis, inflammation, or the involvement of 
other neurotransmitter systems, such as glutamate or γ-aminobutyric acid (GABA) but 
primarily focus on symptom relief11,132. As previously mentioned, cognitive impairments were 
identified as a major contributor to the functional disability of MDD patients in daily life and 
remain a main residual symptom of MDD. However, antidepressant treatment with pro-
cognitive characteristics is rare. A candidate drug for targeting affective symptoms as well as 
cognitive impairments in MDD is vortioxetine. 
1.1.4.1 Vortioxetine 
Vortioxetine ((1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine, Lu AA21004) is an 
antidepressant that was approved by the FDA and European Medicines Agency for treatment 
of MDD in 2013133. Vortioxetine has a multimodal mechanism of action by being a serotonin 
transporter (SERT) inhibitor; serotonin (5-HT)3, 5-HT7 and 5-HT1D receptor antagonist; 5-
HT1B receptor partial agonist; and 5-HT1A receptor agonist133. The pro-cognitive effects of 
vortioxetine are attributed to its actions on the 5-HT1A, 5-HT1B, 5-HT3, 5-HT7 receptors; 
additionally to relieving the affective symptoms of depression133,134. 
In fact, seven out of ten studies in humans show that vortioxetine is superior to placebo 
in alleviating the affective symptoms of MDD and superior to agomelatine, an atypical 
antidepressant133,135,136. Furthermore, vortioxetine improved performance in the cognitive 
domains of executive function, attention, memory, processing speed, and verbal learning 
compared to placebo treatment in elderly MDD patients137. Executive function, attention, 
processing speed, learning and memory were also improved by vortioxetine compared to 
placebo treatment in non-elderly MDD patients138. Thus, these results suggest that vortioxetine 
has a unique treatment profile in targeting both, the affective and cognitive symptoms 
associated with MDD. Moreover, improvement on the cognitive symptoms appears to be a 
direct effect of treatment and not a by-product of alleviated mood symptoms133. 
Preclinically, the antidepressant effect of vortioxetine was demonstrated in several 
behavioural rodent studies. Vortioxetine has an antidepressant effect in the forced-swim test 
(FST), social interaction, fear-induced vocalization, novelty suppressed feeding and open field 
(OF) test. These effects were observed after acute treatment with vortioxetine; and in the FST, 
OF and novelty suppressed feeding test also after chronic administration139,140. In the clinic, 
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classical antidepressants need to be given chronically to elicit an effect, thus, there is some 
divergence between preclinical and clinical studies. Pro-cognitive effects of vortioxetine 
treatment were also observed in behaviour studies. Phencyclidine-induced deficits in the 
attentional set-shifting test were reversed by vortioxetine 141,142. Similarly, vortioxetine 
prevented chronic cold intermittent stress-induced cognitive impairments in the reversal 
learning task for cognitive flexibility143. Furthermore, vortioxetine treatment prevented age-
related deficits in the object placement test assessing spatial memory144. Novel object 
recognition and spontaneous alternation behaviour (SAB) was rescued by acute vortioxetine 
treatment in 5-HT depleted rats134,145. Treated, but otherwise naïve rats showed memory 
improvements in the contextual fear conditioning and the novel object recognition test due to 
acute vortioxetine treatment146. Thus, vortioxetine appears to have a pro-cognitive effect on 
memory and executive functions. 
The pro-cognitive effects of vortioxetine are supported by electrophysiological studies 
and may unravel the biological mechanisms involved. Dale et al.147 show that vortioxetine 
amplifies theta-burst long-term potentiation (LTP) in HPC slices determined by patch-clamp 
recordings and increased theta power in the frontal cortex of awake rats assessed by 
electroencephalography. Interestingly, acute administration of vortioxetine reduced LTP 
provoked by high frequency stimulation in anaesthetised, naïve rats but prevented stress-
induced derogation of LTP in pre-treated rats148. Additionally, vortioxetine stimulates 
neurogenesis and neuron maturation in mice and rats more rapidly than with other 
antidepressants, such as the SSRI Fluoxetine, or compared to vehicle controls139,148. Thus, on 
a molecular level, vortioxetine improves functional processes commonly associated with 
cognitive performance. 
1.2 Animal models of depression 
Animal models are a corner stone for clinical research. Compared to clinical research, animal 
models allow for better control of the environment the organism is exposed to, for 
manipulation of fundamental parts of the organism (e.g. knock-out of a gene), greater 
homogeneity of experimental groups, the study of long-term effects and generational effects 
in a shorter time-period, first stage drug testing, and the use of invasive techniques. Therefore, 
animal models provide insight to the causal relationships in disease pathogenesis. 
Preclinical models try to mimic a specific human condition. However, it is often 
difficult to fully examine and model all modalities of psychiatric diseases in animals. Thus, 
the concept of “validities” was introduced to elucidate which criteria of the human condition 
are fulfilled. Ideally, an animal model should encompass predictive, face, and construct 
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validity149. Construct validity requires that similar neurobiological underpinnings result in 
similar symptoms clinically and preclinically. It is often supplemented by aetiological validity, 
meaning the aetiological origin of the condition is the same in the preclinical and clinical 
condition. Face validity entails the bridging of clinical symptoms with the animal’s 
behavioural phenotype. Finally, predictive validity demands that treatment, which is non-
/effective in the clinic, provokes the same action in the preclinical model132,149,150. These 
primary validities can be extended to introduce relevant criteria for specific animal models. 
For example, “population validity”, which describes that only a subpopulation of animals 
should exhibit a vulnerable phenotype in response to an external stimuli, i.e. that only some 
animals should display a depressive-like phenotype due to exposure to environmental risk 
factors to match the situation in humans151. 
1.2.1 Difficulties in modelling depression 
Some difficulties arise when modelling depression in animals. MDD symptoms, such as 
weight changes or altered sleep architecture can be readily assessed in animals. However, 
“internal” symptoms including feelings of worthlessness, inappropriate guilt or suicidal 
thoughts, which are typically assessed by questionnaire or oral communication in humans, are 
challenging to model and evaluate in animals. Additionally, the inter-patient heterogeneity of 
symptoms further exacerbates preclinical MDD modelling. Still, various depression models 
have been established exhibiting different aspects of clinical depression. In the following, 
preclinical models are presented, subdivided into environmental and genetic paradigms. 
1.2.2 Genetic models 
Genetic models can be created by targeted gene manipulation or by selective breeding of 
animals with a relevant trait. Genetic models include knock-down, knock-out or 
overexpression of a candidate gene. These gene manipulations can be genome-wide or 
conditionally expressed in a specific tissue or cell type. Single-gene modifications allow for 
investigating the causal relationship of a gene in disease symptomatology or in treatment 
efficacy. An example model is the genetic modification of the Bdnf gene in mice and rats. 
The BDNF gene is of particular interest in MDD. For example, the BDNF 
polymorphism Val66Met, which results in attenuated BDNF activity, was linked to MDD 
pathology29. Furthermore, BDNF levels were found reduced in the PFC and HPC of MDD 
patients’ post-mortem tissue152. Accordingly, BDNF was proposed as a candidate gene of 
MDD, which ensued in a plethora of clinical and preclinical studies.  
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A full knock-out of the Bdnf gene in mice was attempted in 1994, but was 
developmentally lethal153, thus, heterozygote knock-out mice were developed (BDNF+/-). 
These mice were behaviourally indifferent from wild types (WTs) regarding behavioural 
despair in the FST, anxiety in elevated plus-maze (EPM), elevated zero-maze, light-dark box 
and novel cage test or anhedonia in the SPT154,155. BDNF+/- mice were slower to escape in the 
learned helplessness paradigm, but this finding might be ascribed to a lower pain sensitivity 
demonstrated with the hot plate test155. In a different study, however, BDNF+/- mice showed 
anxious-like traits in the novel object test in the OF and displayed increased anxiety in the 
light-dark box156. Overall, studies using BDNF+/- mice provided conflicting results and 
therefore findings should be interpreted cautiously. Since behavioural tests for rodents were 
originally designed for rats but not mice132, behavioural investigation of BDNF+/- rats might 
be more appropriate. This has been achieved recently and a temporal and region-specific 
knock-down (KD) of BDNF in Sprague Dawley rats led to depression-associated behavioural 
changes. BDNF KD in the dorsal dentate gyrus (DG) elicited anhedonia in the SPT, 
behavioural despair in the FST, cognitive impairments in the Morris water maze (MWM) and 
decreased locomotor activity157. Whereas BDNF KD in the ventral subiculum only induced 
anhedonia and BDNF KD in the HPC CA3 region did not alter any of these readouts157. Naïve 
congenital BDNF+/- rats displayed no behavioural alterations in the EPM or FST, but showed 
anxiety-related behaviour by spending less time in the centre of the OF. Chronic corticosterone 
treatment, simulating stress in these BDNF+/- rats resulted in an anxiolytic effect in the EPM. 
In the OF, BDNF+/- rats displayed decreased locomotor activity, which was further diminished 
after corticosterone treatment. Therefore, this study suggests an involvement of BDNF and its 
interaction with stress in an anxiety-related phenotype158. These findings were complemented 
by another study applying a Pavlovian fear conditioning paradigm. BDNF+/- rats displayed a 
weaker association of a foot shock with a neutral light stimulus. Furthermore, retrieval of the 
association in an MRI scanner revealed decreased activation of the amygdala in BDNF+/- 
rats159, thus suggesting altered emotional fear processing. Moreover, cognition was impaired 
in BDNF+/- rats as demonstrated in the Y-maze for short-term spatial memory and in the 
acoustic startle prepulse response inhibition associated with disrupted sensorimotor gating, a 
symptom in many neuropsychiatric disorders. However, novel object recognition assessing 
memory was not impaired160. Overall, findings in BDNF+/- rats appear more consistent than in 
mice, but still no evident depressive-like phenotype could be associated with these rats. 
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By contrast, findings about the interaction of antidepressant treatment and BDNF 
levels are robust63. BDNF+/- mice as well as mice with an induced BDNF knock-out showed 
resistance to antidepressant treatment161–163 suggesting sufficiently high BDNF levels are 
requirement for antidepressant drug efficacy. In contrast, overexpression of the BDNF gene in 
mice resulted in antidepressant-like behaviour in the FST164. Furthermore, infusion of BDNF 
in the midbrain of rats resulted in an antidepressant-like effect in the learned helplessness 
paradigm and the FST165. In conclusion, genetic modification of BDNF suggests a negative 
relationship of BDNF levels and MDD pathogenesis as illustrated in Figure 5. 
Generally, a caveat of genetic models, which innately display disease symptoms, is 
that the literature evidently suggests a gene x environment interaction causes MDD. However, 
generating genetic modifications might be helpful to uncover predispositions in animals, 
which lead to disease pathogenesis in the event of an environmental trigger132. Therefore, the 
following section addresses preclinical depression models constructed by manipulating the 
animal’s environment. 
1.2.3 Environmental models 
Stress is a main environmental risk factor for inducing depression in humans166,167. Thus, stress 
has been extensively used to induce a depressive-like phenotype in animals. However, the term 
“stress” covers a plethora of different micro-stressors and protocols, which are often lab-
specifically modified. Hence, different stress protocols result in a variety of depression-related 
Figure 5. The relationship of brain-derived neurotrophic factor (BDNF) levels and depression pathology. 
Reduced cerebral BDNF levels are found in depressed suicide victims, whereas antidepressant treatment 
requires and increases BDNF levels.316 
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phenotypes. On the one hand, such a variety possibly covers divergent subtypes of MDD, but 
can also exacerbate comparisons of study results and meta-analyses. Well-known stress 
models in preclinical depression research include the CMS168,169, chronic unpredictable mild 
stress model (CUMS), learned helplessness (LH), social defeat (such as the resident-intruder 
paradigm) and early life stress (ELS, such as maternal separation)132,170,171. Paradigms that are 
based on or include social stressors in their protocol appear to mimic the human condition 
more closely than non-social stress protocols172. In the following, different stress models are 
presented. 
1.2.3.1 Early life stress 
ELS attempts to model adverse childhood events in humans, such as abuse, neglect or parental 
loss. In humans as well as in rodents, such events can induce a vulnerable predisposition for 
developing neuropsychiatric diseases, including depression and anxiety, later in life17,132.  
ELS encompasses a plethora of models across the early life span including prenatal, 
early postnatal or juvenile stress paradigms173. A frequently applied paradigm of ELS is 
maternal separation, in which the mother is separated from its pups for a limited time inducing 
psychological and physiological stress to the pups174. Endocrinological and behavioural 
changes are observed immediately after separation and into adult life. Separation results in an 
altered HPA axis activity (a prolonged, hypo- or hyperactive response to acute stress and 
novelty) and disturbs the dopaminergic, noradrenergic and mesolimbic system.175–178. 
Behaviourally, pups display an altered sleep architecture, weight changes, altered avoidance 
learning and increased anxiety179–181. 
However, divergences in the resulting pup phenotype are reported, such as HPA axis 
hypo- or hyperactivity. These divergences result from differences in the ELS protocol 
including duration of maternal separation, a single versus multiple separation sessions, pup 
age during separation and age of endocrinological assessment, pup gender but also the choice 
of the control group (undisturbed, handled or litter-mates) to which the experimental group is 
compared to175. Furthermore, maternal behaviour, i.e. pup care, is influenced by litter size182 
and litter gender composition183,184. Finally, a caveat of the ELS model is that brain maturation 
is less developed in rodents than in primates after birth complicating translation between 
species42. Consequently, ELS models appear prone to high phenotype variability due to 
unstandardized protocols. Besides this caveat, ELS is the best approach to model depression 
with childhood trauma, a subtype of MDD17. 
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1.2.3.2 Learned helplessness 
The LH model is thought to model a unique cognitive aspect of depression –the perceived loss 
of control over an aversive situation185. In the LH paradigm, animals receive electric shocks 
without being able to escape the situation. However, once the option for escape exists, i.e. cage 
door open, animals still do not attempt to escape due to their previous inevitable experience186. 
This led to the term “learned helplessness”. It was shown that it is the uncontrollable aspect 
and not the foot shock per se that defines the depressive-like phenotype187. Loss of control is 
likely processed in the ventromedial PFC188. Consequently, sensation of an uncontrollable 
stressor desensitizes the 5-HT1A receptor in the dorsal raphe nucleus resulting in an altered 
behavioural phenotype189. LH animals display anhedonia, agitation, sleep disturbances, 
reduced sex drive and weight loss. Antidepressants can reverse LH behaviour190. However, it 
was reported that these behavioural deficits only persist for few days191 preventing testing of 
chronic treatment. 
1.2.3.3 Chronic social defeat 
Generally, social defeat models induce social avoidance behaviour by exposing a subordinate 
animal to a dominant animal. Different social defeat models exist involving one or more 
subordinate animals and can be used to apply acute or chronic stress132,192,193. Social defeat 
paradigms provoke social withdrawal, a symptom known to accompany MDD pathology. This 
symptom is reversed by chronic but not acute antidepressant treatment194. Furthermore, the 
chronic social defeat model provokes susceptible as well as resilient phenotypes differing in 
social interaction and anhedonic-like behaviour, increased immobility in the tail suspension 
and FST and increased anxiety in the OF test, sleep architecture, lower body weight, increased 
CRH levels in the paraventricular nucleus and decreased MR levels in the HPC193,195. 
Anhedonic-like behaviour and behavioural despair were renormalized with chronic citalopram 
(SSRI) treatment196. Depending on the study, some of the symptoms, such as anxiety, stress 
reactivity, behavioural despair or body weight are indifferent between both social defeat 
groups possibly due to differently defining susceptibility and resilience193,195. Not all studies 
separated the social defeat group192,196–198, and of those only some observe a depressive-like 
phenotype196,197 . A critical view of this model suggests the social defeat model as model of 
stress rather than a model of depression since animals display an increased startle amplitude, 
which is characteristic of the post-traumatic stress disorder and thus non-specific to 
depression199. 
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1.2.3.4 Chronic mild stress model 
The CMS paradigm has been extensively studied and is well known for exhibiting the MDD 
core symptom anhedonia in rodents. The model was first introduced by Katz and Hersh in 
1981200. They applied stressors that are considered to be comparatively severe. Willner71,73 
modified the protocol by abandoning the severe stressors for milder ones and, thus, the 
paradigm mimics more closely everyday stressful situations in humans. Micro-stressors in 
recent CMS protocols include, dampened bedding, changes in illumination (e.g. lights on 
during the dark phase), stroboscopic light, food and water deprivation, grouping of two CMS 
rats (resident-intruder) and cage tilting132,201. The micro-stressors are applied in an 
unpredictable order and time point of the day, introducing the element of uncertainty, which 
in itself is a core element on the asperity of stress perception65. Furthermore, the episodic 
nature of depression can be modelled by cessation and reintroduction of stress exposure. CMS 
exposed, depressive-like animals respond to chronic antidepressant treatment but not acute 
administration of antidepressants, demonstrating good predictive validity201. 
Typically, the CMS protocol is applied over several weeks and the animals’ reward 
sensitivity is monitored with the SPT or SCT. Thereby, alterations in reward sensitivity 
induced by stress exposure can be traced within each rat. Individual rats respond differently to 
the stress exposure and a spectrum of phenotypes develops. The strongest phenotypes display 
either the MDD core symptom anhedonia, shown by reduced reward sensitivity (~40% of rats), 
or are resilient and maintain their reward sensitivity as prior to stress onset (~20% of rats)201. 
Resilience is another feature of the CMS paradigm that demonstrates the clinical pertinence of 
the model; likewise, only a subset of humans develops MDD associated with stress challenges. 
Furthermore, rats that are stress exposed but resilient in their hedonic state allow for the 
distinction of stress- and depression-specific alterations. This distinction is not addressed in 
every preclinical model and often the stress-exposed group is taken synonymously as 
depressive-like. In the CMS paradigm, usually only the strongest phenotypes, i.e. the rodents 
that show a robust resilient or anhedonic-like phenotype, are used in subsequent experiments. 
CMS exposed rodents also display other behavioural abnormalities. Exploration, 
sexual behaviour, locomotion and aggression are reduced, and sleep architecture is altered in 
CMS susceptible rodents168,202,203, reminiscent of MDD symptomatology. Interestingly, CMS 
exposure promoted anxiolytic-like behaviour in the EPM test202. Social interaction is not 
altered in rats subjected to the CMS paradigm202, although patients with MDD can express 
social withdrawal67. After cessation of CMS for 4–5 weeks rats show spontaneous recovery 
from the stress exposure and depressive-like state201.  
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Various physiological changes can be observed in rats subjected to the CMS 
paradigm. Augmented stress exposure activates the HPA axis, which consequently increases 
release of glucocorticoids attempting to restore homeostasis. However, prolonged 
hyperactivity of the HPA axis can result in adverse alterations, e.g. cerebral atrophy, and 
transition to disease state, such as depression44. Such changes were also observed in the CMS 
model. CMS susceptible, anhedonic-like rats showed increased corticosterone levels for four 
weeks during stress exposure. CMS resilient rats only displayed an initial increase in 
corticosterone at the beginning of the CMS paradigm, but glucocorticoid secretion quickly 
returned to baseline level201,204. CMS exposed rats also display weight changes, weighing less 
than same-aged non-stressed controls201. In classical behavioural paradigms assessing 
cognition, CMS rats (resilient and anhedonic-like) were impaired in the SAB task assessing 
working memory205; displayed a negativity bias in a lever pressing test using an ambiguous 
tone206; but only anhedonic-like rats increased in contextual fear conditioning determining 
long-term memory of aversive stimuli205. Stress exposure did not affect performance in the 
step-down, passive avoidance or cued fear conditioning test205. Thus, CMS rats display 
cognitive alterations in behavioural paradigms involving negativity bias, long-term and 
working memory. 
On a cellular level, CMS anhedonic-like rats showed decreased levels of neurogenesis 
in the ventral HPC compared to non-stress controls122. Neurogenesis was restored in animals 
that responded to antidepressant treatment with escitalopram. Non-responders, determined by 
their persistent anhedonic-like state, continued to show decreased neurogenesis122. Although 
neurogenesis was restored in response to treatment in CMS animals, the number of granule 
cells in the HPC was not207. Moreover, the neuronal growth factor BDNF was decreased 
(protein and gene expression) in CMS exposed animals208. Thus, rectified neurogenesis in 
response to antidepressant treatment in CMS animals complements the bidirectional 
relationship of increased BDNF levels, and thus elevated neuronal plasticity, and 
antidepressant efficacy35. Similar to studies in BDNF+/- animals, molecular findings are robust 
regarding the antidepressant treatment effects but less clear when it comes to the depressive-
like phenotype itself. For example, decreased cell proliferation in the HPC was found in both, 
anhedonic-like and resilient rats and therefore this effect was not specific to the depressive-
like phenotype but a general effect of stress exposure207. Furthermore, pharmacological 
blocking of neurogenesis did not result in a depressive-like phenotype209. Consequently, 
neurogenesis appears implicated in the depressive-like phenotype and involved in treatment 
response although on its own, restricted neurogenesis does not induce depression. 
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Brains of CMS anhedonic-like, resilient and non-stressed controls were analysed with 
magnetic resonance imaging. Anhedonic-like animals displayed altered metabolite levels, 
resilient rats exhibited changes in ventral HPC shape, and both CMS groups possessed subtle 
substructural changes revealed by diffusion kurtosis imaging of the HPC210. Moreover, 
diffusion characteristics were distinct between the anhedonic-like and resilient phenotype in 
the caudate putamen, and increased in CMS rats for axial as well as radial diffusion in the 
caudate putamen and amygdala compared to controls. The volume of the caudate putamen was 
increased in the anhedonic-like compared to the control group211. Thus, the HPC appears to be 
a key region in depression pathology revealing physiological alterations due to stress in 
general as well as to the depression state. 
Limitations of the CMS model include the initial amount of animals needed to obtain 
a sufficient group size of anhedonic-like animals. This is especially the case when multiple 
anhedonic-like groups are required to study, for instance, the efficacy of antidepressant 
treatment. Furthermore, the CMS paradigm is labour-intensive due to the amount of animals 
and the daily application of micro-stressors over weeks. Still, the CMS model has good face, 
predictive, construct and aetiological validity and is thus a unique model for preclinical 
depression research132. 
1.3 Translational testing 
1.3.1 The touchscreen operant platform 
The importance of translation from preclinical research to clinical is being increasingly 
recognised. Initiatives, such as CNTRCIS*, have been established aiming to facilitate 
translational crosstalk. In this context, standardization of tests is central as it facilitates the 
replication and comparison of studies across institutions and uniforms data acquisition for 
meta-analysis. The CANTAB test battery is such a standardized, clinical tool and the most 
frequently applied battery for assessing cognition in MDD research6. Various touchscreen 
tasks allow evaluation of abilities from different cognitive domains. 
Based on CANTAB, the preclinical touchscreen operant platform was developed for 
non-human primates and rodents. The touchscreen operant platform uses the same tests as 
CANTAB adapted for testing in animals (face validity) and, as such, represents one of the 
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most translational tools in preclinical research. Additional advantages to being clinically 
pertinent are objective readouts and minimization of experimenter’s bias. Moreover, exactly 
the same tests can be applied across institutions while visual stimuli can be modified and new 
stimuli or tests can be shared between groups, ensuring standardization. Furthermore, the 
operant conditioning for touchscreen testing is based on appetitive learning instead of adverse 
conditioning, which is frequently used in classical behavioural paradigms. Thus, the operant 
conditioning for touchscreen testing is preferable when working with stress-induced models 
and non-stressed controls due to the use of non-aversive testing. Although the touchscreen 
operant platform was developed in the 1990s, it was not extensively used6,212. However, the 
young field of preclinical touchscreen testing is growing and aims for par for par comparisons 
with clinical research as shown by an elegant study of Nithianantharajah and colleagues213. In 
that study, a modification on the Dlg2 gene was introduced in mice as it is naturally occurring 
in some patients with bipolar disorder, schizophrenia, autism and intellectual disability, and 
the two species were tested in the paired-associates learning (PAL) task. Individuals, human 
and mice, carrying the genetic mutation showed strong cognitive impairments, whereas 
healthy controls were able to learn the PAL task. Thus, results were replicated across species 
applying a touchscreen paradigm. Hence, translational touchscreen testing is at the forefront 
of bridging preclinical and clinical research. 
1.3.1.1 Pairwise discrimination and reversal learning 
The pairwise discrimination (PD) and reversal task requires the association of one of two 
symbols with a reward (S+), whereas the other symbol is non-rewarded (S-). After task 
acquisition, the reward is switched to the previously non-rewarding symbol (S- becomes S+ 
and vice versa)214. Thus, visual discrimination, stimulus-reward association and response 
inhibition during reversal learning is evaluated with this task, as well as perseverative 
behaviour is tested.  
Reversal learning is an interesting component of this task and is composed of two 
different phases: first, perseverative behaviour is tested and, second, evaluation of the new 
stimulus-reward association learning. Animals with orbitofrontal cortex lesions were impaired 
in the first phase (perseveration)215,216 and prelimibic subregions are required for the strategy 
shift in reversal learning216. Likewise, the medial PFC may too be vital for the second phase 
(new stimulus-response association)214,217 and the dorsomedial striatum for the maintenance of 
the new associations216. Hence, although the PD and reversal task is a rather simple test, the 
reversal learning element evaluates domains, such as cognitive flexibility, that are often 
impaired in stress-related disorders.  
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Unmedicated MDD patients displayed no impairments regarding task accuracy but 
showed psychomotor slowing during PD and reversal learning, which correlated with disease 
severity. Furthermore, hyperactivity of the anterior insula and putamen and hypoactivity in the 
PFC, anterior cingulate cortex, thalamus, and inferior parietal cortex were found in MDD 
patients during the PD and reversal task. Therefore, this study indicates functional alterations 
in frontal-striatal and limbic brain areas during PD and reversal learning218. 
Preclinically, one study has indicated that the PD and reversal task might be sensitive 
to affective state-dependent cognitive impairments in the CMS model219. However, many 
animals did not even acquire the first PD learning task limiting the interpretation of the more 
interesting reversal learning step. The high drop-out rate might be explained by the choice of 
rat strain since the included albino Wistar rats might be limited in their visual ability220. 
Another study observed that stress exposure facilitated reversal learning likely by inhibiting 
ventromedial PFC function221 proposing the PD and reversal task as good starting point for 
assessing the effects of CMS in rats. 
1.3.1.2 Paired-associates learning task 
The PAL task for assessing cognition in humans is part of the CANTAB test battery222. On a 
computer screen, various visually equal boxes are displayed. One at a time, the boxes become 
temporarily invisible to reveal a unique pattern underneath the box. After the presentation 
phase, one pattern is displayed in the centre of the computer screen and the participant has to 
indicate underneath which box the equivalent pattern is hidden (Figure 6). The task evaluates 
spatial memory associative learning and was shown to effectively detect cognitive 
impairments in neuropsychiatric disorders, such as schizophrenia, autism or Alzheimer’s 
disease82,223. Cognitive impairments in the PAL task appear to positively correlate with 
restricted daily functioning in schizophrenic patients223. Furthermore, discrimination between 
Alzheimer’s disease, mild cognitive impairment and healthy controls was possible via the PAL 
task, whereas MDD patients and 
controls appeared similar in 
their performance in this 
study224. Similarly, unmedicated 
MDD patients and controls 
completed a comparable number 
of levels in the PAL task, but 
depressed patients completed 
more trials unsuccessfully on the 
Figure 6. Paired-associates learning (PAL) task for humans. 
First, the different patterns are sequentially presented to the 
participant (left screen); then the box matching the pattern 
underneath with the one in the centre needs to be indicated 
(right screen).82 
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first presentation225. In elderly MDD patients, performance in the PAL task was impaired in a 
stimulus set size of six and higher compared to age-matched controls. PAL performance was 
not statistically different to controls in patients recovered from MDD (within-design)96. 
Regarding brain activity, Altered HPC activation was observed in mild cognitive impaired 
patients compared to healthy controls when executing the PAL task in an MRI scanner. 
Structural changes in the HPC, i.e. a decrease in grey matter, might be responsible for the 
functional deficits in this region and inferior cognitive performance226. Furthermore, 
schizophrenic patients‘ PAL performance correlated negatively with HPC volume loss227. 
Patients with frontal lobe and HPC lesions showed impaired performance in the PAL task 
indicating the functional relevance of these brain regions for the task228.  
In the PAL task for rodents, the touchscreen is covered by a mask leaving only three 
windows to touch the screen. The animals need to associate three symbols to three touchscreen 
locations, respectively (Figure 7A). During a trial, two of the three symbols are presented; one 
in its correct location and one in an incorrect location. The animal is required to choose the 
correct pairing to receive a consumable reward. Two versions of the PAL task exist for rodents. 
In the same PAL (sPAL) task, two identical symbols are presented in two of the three windows; 
whereas in the more difficult different PAL (dPAL) task, two out of the three possible symbols 
are shown (Figure 7B). The dPAL task is thought to be HPC-dependent as it requires 
association of a stimulus with a specific location on the touchscreen (similar to the object-in-
place task); whereas the sPAL task is thought to be cue-driven229. A study by Delotterie et 
al.230 observed that a lesion in the dorsal striatum but not in the HPC attenuated acquisition of 
the dPAL task, whereas only post-acquisition lesioning of the HPC debilitated cognitive 
performance in dPAL. They understand this as a different to the human PAL task, which 
requires the HPC also for task acquisition82,226. This 
is an interesting finding because classical object-
location or odour-location tasks require the HPC in 
rodents231. Another study using mice showed that 
post-acquisition lesioning of the HPC impairs 
dPAL performance, but so did pre-acquisition 
lesioning, although to a smaller, but still significant, 
extent232. This suggests that alternative brain 
structures may take over during learning of object-
location association in the dPAL task if the HPC is 
impaired. C-fos staining revealed increased 
activation of the orbitofrontal cortex, the 
Figure 7. Paired-associates task for 
rodents. (A) The three symbols are 
displayed in their correct location (L): 
Spider-L1, Plane-L2, Flower-L3. (B) An 
example trial of the dPAL task with the 
spider in the correct and the plane in its 
incorrect location. 
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retrosplenial cortex and the HPC during PAL acquisition229,233,234. Other potential brain areas 
that are implicated in the dPAL task are the entorhinal cortex for encoding the spatial 
component and the perirhinal cortex for object recognition235–237. Furthermore, HPC NMDA 
and AMPA receptor activation is required for dPAL performance229. These receptors as well 
as PFC and HPC functioning are central in cognition, such as executive functions, learning 
and memory. Furthermore,  PFC and HPC function and structure is altered in MDD patients 
as well as in the CMS model122,210,211,238. Accordingly, the dPAL task might be sensitive for 
detecting cognitive alterations in the CMS model similarly to depression-associated cognitive 
impairments in memory, attention and executive function81. 
1.3.2 The model organism 
The term “preclinical research” encompasses a variety of model organisms, such as cells and 
animals. The research question and the experimental technique determine the animal model of 
choice. Therefore, animal models range from relatively simple organisms such as the fruit fly 
to more complex organisms, like non-human primates. In preclinical research, rodent models 
(in particular mice and rats) are frequently applied balancing translational value with time and 
expenditure.  
Commonly, mice and rats are regarded as interchangeable animals only differing in 
size. However, their common ancestor existed approximately at the same time as the ancestor 
of macaque monkeys and great apes, which includes homo sapiens239. Therefore, genetic 
disparity has evolved between the two rodent species. For example, 44% of genes are 
differentially expressed in HPC dendrites of mouse and rat240. Consequently, it is unsurprising 
that mice and rats differ on a cellular level. For instance, rats and humans, unlike mice, highly 
express the 5-HT6 receptor in the basal ganglia additionally to a much higher ligand binding 
affinity of the receptor241. The 5-HT6 receptor appears to be involved in higher cognitive 
processes, like learning and memory, and the modulation of several neurotransmitter systems 
including glutamate, acetylcholine, dopamine, GABA, epinephrine and norepinephrine 
secretion. Furthermore, the 5-HT6 receptor might affect anxiety- and depression-like 
behaviours242. Moreover, plasma of rats and humans but not mice contains BDNF243. 
Peripheral BDNF was shown to affect central cellular signalling as well as depression-related 
affective behaviours244. In summary, the closer physiological similarity of rat to human than 
mouse to human suggests the rat as the more translational model in cognition and depression 
research239. 
Rats and mice also differ in their natural behaviour. In nature, both species live in 
groups. However, rats are less aggressive, less territorial and male hierarchies are less absolute 
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compared to mice. Moreover, female group rearing in mice resulted in increased anxiety in the 
adult offspring, whereas anxiety was reduced in the rat setting239,245,246. Therefore, the rat 
appears to have greater social cognition than the mouse, and is therefore suggested to better 
model the complex social behaviour or social deficits observed in humans239. 
Finally, rats and mice appear to differ in their cognitive performance. In the Morris 
water maze, rats have lower intra-trial variance possibly due to applying spatial learning 
strategies for task acquisition, whereas mice rely partly on swimming around the outside pool 
area247. Thus, rats’ representation of space appears more stable and their learning strategy of 
spatial tasks appears different to mice248,249. Generally, rats seem to acquire learning tasks 
faster than mice250,251 suggesting the rat’s learning ability to being more sophisticated and 
therefore closer to the human cognition239. Conclusively, the rat compared to the mouse 
appears to be a more relevant model for MDD-related and cognitive research.
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2 AIMS 
Many people suffer from MDD worldwide. However, antidepressant treatment is suboptimal, 
with therapeutic relief commencing only after 2–4 weeks of treatment and only 50% of patients 
responding to a two-step treatment regimen. Challenges in optimizing antidepressant 
medication result from the lack of understanding of MDD pathogenesis caused by a complex 
gene x environment interaction and emerging in a heterogeneity of symptoms between 
patients. Finally, antidepressants primarily target the affective symptoms of depression, while 
more and more studies demonstrate that depression-associated cognitive impairments persist 
after remission and decrease daily functioning as well as increase risk of relapse. Thus, the 
demand is high for pro-cognitive antidepressants to approach a complete remission from 
MDD. Essential for the development and testing of such pro-cognitive antidepressants are a 
better understanding of symptom aetiology and valid preclinical models for drug screening. 
Therefore, this PhD project aimed to further investigate the relationship of risk factors 
and symptom development by applying environmental as well as genetic risk factors in MDD 
pathogenesis. Furthermore, we aimed to design translational studies with clinical relevance. 
First, this was implemented by employing a rat instead of a mouse model for preclinical BDNF 
research and, second, by applying the touchscreen operant platform, which is based on the 
CANTAB test battery for assessing cognition in humans. Finally, the aim has been to establish 
a preclinical platform for pro-cognitive drug screening. 
 




The preclinical touchscreen platform for testing cognitive performance is proposed to be more 
translational to human testing, more standardized, objective in its readout and better 
transferable across institutes than classical tests214. At present, preclinical touchscreen testing 
has been scarcely applied in depression- and anxiety research6. A caveat of the vision-based 
touchscreen testing is the requirement of sufficient visual accuracy, which is known to be 
poorer in albino strains. Furthermore, the touchscreen platform might not be sensitive enough 
for detecting mild cognitive impairments as consequence of stress exposure, such as deficits 
in the PFC252. We therefore compared naïve albino rats with pigmented rats in a simple 
pairwise discrimination and reversal task. Furthermore, pigmented rats were CMS exposed 
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and cognitively examined to investigate the sensitivity of the touchscreen pairwise 
discrimination task. We anticipated that albino rats perform poorer than pigmented rats due to 
impaired vision. Furthermore, it was hypothesized that stress exposure would decrease 
cognitive performance suggested by the detrimental effects of stress on brain structure and 
function45,60,61. 
 
a) Are albino rats (e.g. Wistar) suitable for testing cognitive performance in the 
vision-based touchscreen platform compared to pigmented rats (e.g. Long Evans), 
since albinism is associated with poorer vision?  
b) Can the CMS paradigm be transferred from the established Wistar strain to the 
Long Evans rat strain and elicit a comparable, depressive-like phenotype? 




In preclinical models, chronic mild stress was shown to induce anhedonia as well as cognitive 
impairments. However, the stress exposed group is taken synonymously as depressive-like 
group although it was demonstrated that a homogenous response to stress cannot be 
assumed253. Therefore, dissociation of cognitive impairments being a sign of the depressive-
like state or a general consequence of stress exposure is impossible. Stress was shown to 
induce atrophy in the brain including cellular shrinkage, apoptosis, dendritic retraction and 
decreased neurogenesis, which could be the cause of depression-associated cognitive 
impairments. However, synaptic connectivity in the medial PFC appears to be dependent on 
stress responsiveness in the learned helplessness paradigm, which might suggest the linkage 
of cognitive impairments specifically to the depressive-like state254. These hypotheses are 
assessed by including stress exposed resilient and susceptible, i.e. anhedonic-like rats as well 
as non-stressed controls in the study allowing to associate cognitive impairments to stress 
exposure (both CMS groups) or to the depressive-like state (CMS anhedonic-like group only). 
Based on the literature, we predicted that both CMS groups would show cognitive alterations 
with the CMS anhedonic-like, i.e. stress susceptible group being more severely impaired. 
 
a) Are cognitive impairments a consequence of general exposure to CMS or is this 
effect depression-specific? 
b) Which cognitive domains are impaired in CMS anhedonic-like or resilient rats? 
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Study III 
 
The CMS model is well evaluated and comprises good construct, face and predictive validity. 
However, the recently introduced pro-cognitive antidepressant vortioxetine appears 
ineffective in restoring the hedonic state in CMS exposed rats133. Furthermore, vortioxetine 
was proposed to have a direct pro-cognitive effect by its 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 
receptor independent of restoring the affective symptoms133,134. Therefore, we administered 
vortioxetine to CMS anhedonic-like rats and monitored their hedonic state as well as tested 
their cognitive abilities in association with the hedonic state and examined brain gene 
expression. We assumed that vortioxetine rescues the hedonic state in a proportion of rats 
possibly similar to escitalopram treatment122. Furthermore, we predicted that anhedonia-
associated cognitive impairments would renormalize in all treated rats due to the direct pro-
cognitive efficacy. Finally, we anticipated that expression of genes relevant in the stress 
response and psychiatric disease would be similar in the non-stressed control group and in rats 
responding well to vortioxetine. Genes involved in the neuronal growth and structure were 
expected to be higher expressed in treated than non-treated anhedonic-like rats. 
 
a) Can the antidepressant vortioxetine rescue the hedonic state in CMS exposed rats? 
b) Can vortioxetine improve cognition in depressive-like rats? 
c) Is the pro-cognitive effect of vortioxetine dependent on the affective state? 
d) Do hedonic state or treatment alter expression of brain genes relevant for stress 




BDNF is strongly suggested to be involved in the stress response, MDD pathology and 
recovery. However, preclinical studies in mice yielded contradictory results. This can possibly 
be explained by humans but not mice producing peripheral BDNF243, which was shown to 
alter brain gene expression and behaviour244. Rats, like humans, produce peripheral BDNF 
and, therefore, we used the recently introduced BDNF+/- rat to evaluate the effect of lower 
BDNF levels on affective-like behaviours, cognitive performance and brain gene expression. 
We predicted that BDNF+/- rats would display increased depressive- and/or anxiety-like 
behaviours, lower cognitive abilities and altered gene expression relevant in psychiatric 
diseases and the stress response. 
 
a) Do reduced BDNF levels induce pathologic behaviour, such as depression, 
anxiety or cognitive impairments?  
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b) Do reduced BDNF levels alter expression of genes relevant for psychiatric 
disorders and stress response? 
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3 METHODS 
3.1 Summary of methods 
A short overview of the methods employed in each study is provided in the following sections. 
Detailed material and methods (including n-numbers throughout the experiment) can be found 
in the respective manuscripts. 
3.1.1 Study I 
In our facility in Aarhus, the CMS paradigm has been established using Wistar albino rats. 
However, albinism is associated with poor vision and might interfere with cognitive testing in 
the vision-based touchscreen tasks. The impact of rat strain on touchscreen testing was 
determined by comparing the performance of naïve Wistar (n = 12) and pigmented Long Evans 
(LE; n = 12) rats in the pairwise discrimination (PD) and reversal learning task. Reversal 
learning was re-tested for two sessions following a 10-day hiatus to assess long-term memory. 
In addition, we explored if LE rats exhibit a phenotype similar to Wistar rats when subjected 
to CMS. The effect of stress on the LE rats (n = 16) was evaluated with the sucrose 
consumption test (SCT) assessing anhedonia. At the end of the stress paradigm; anxiety-
related behaviour was assessed in the elevated-plus maze (EPM) and open field test (OF) and 
spatial working memory in the spontaneous alternation behaviour (SAB) test. Finally, the 
effect of CMS on cognition was investigated by contrasting the performance of control and 
CMS exposed LE rats in the PD and reversal task including the retention phase. The 
experimental timeline of study I is provided in Figure 8. 
Figure 8. Experimental pipeline study I. After acclimatization to the facility, rats were habituated to 
the sucrose consumption test (SCT). After acquisition of baseline sucrose consumption, the chronic 
mild stress model (CMS) was initiated and SCTs were carried out throughout CMS exposure. In the 
final week of CMS, behaviour was assessed in the elevated-plus maze (EPM), open field (OF) and 
spontaneous alternation behaviour (SAB) task. Subsequently, rats were gradually food deprived for 
ensuing touchscreen pre-training, pairwise discrimination (PD) and reversal task acquisition. Finally, 
rats were retested on the PD reversal task following a 10-day hiatus without touchscreen training. 
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3.1.2 Study II 
Based on the findings in study I, LE rats were used for the CMS paradigm and subsequent 
touchscreen testing. Here, the strongest phenotypes of the CMS exposed rats, defined by an a 
priori criterion for the SCT201, were employed, i.e. CMS resilient (n = 11) and susceptible 
(anhedonic-like; n = 10) rats; as well as non-stressed controls (n = 11). Consequently, we could 
identify if CMS-induced cognitive impairments are specific to the depressive-like phenotype 
or caused by general stress exposure. Furthermore, the different paired-associates learning 
(dPAL) task was applied instead of the PD and reversal task because the latter appeared to be 
too simple for LE rats. A cognitively demanding task is more likely to reveal impairments, 
which may go undetected in less challenging tests255. Next to being more complex, the dPAL 
task involves HPC function. Alterations in the HPC are central in MDD pathology and, 
moreover, the memory component of study I’s PD task appeared to be the only part that might 
have been affected by CMS. A modified (over-night) CMS protocol was applied to 
accommodate for touchscreen pre-training and testing during the day. A two-session-lasting 
retention of the dPAL task was added 10 days after touchscreen acquisition. The experimental 
timeline of study II is provided in Figure 9. 
3.1.3 Study III 
The efficacy of vortioxetine as antidepressant with pro-cognitive efficacy was tested in the 
CMS paradigm by administering vortioxetine incorporated in rat chow to CMS anhedonic-like 
rats five weeks after CMS initiation. Treatment was continued throughout the following four 
weeks of CMS and throughout touchscreen pre-training and dPAL testing. Similar to study II, 
a modified CMS protocol was applied during touchscreen assessment. Bacon instead of sugar-
coated pellets were used as reward for touchscreen operant conditioning allowing for 
continued SCT testing throughout touchscreen assessment. Study III included four groups: 
Figure 9. Experimental pipeline study II. After acclimatization to the facility, rats were habituated to 
the sucrose consumption test (SCT). After acquisition of baseline sucrose consumption, the chronic 
mild stress model (CMS) was initiated and SCTs were carried out throughout CMS exposure. 
Subsequently, rats were gradually food deprived for ensuing touchscreen pre-training and different 
paired-associates learning (dPAL) task acquisition. Finally, rats were retested on the dPAL task for 2 
days following a 10-day hiatus without touchscreen training. A modified, over-night CMS protocol was 
applied throughout food deprivation and touchscreen testing. 
Summary of methods 
-  35  - 
non-stressed controls (n = 10); anhedonic-like, untreated rats (n = 10); anhedonic-like rats 
responding well to vortioxetine treatment and thus restored their hedonic state (responders; n 
= 10); and anhedonic-like rats responding low to vortioxetine treatment and thus remained 
anhedonic-like (low-responders; n = 10) as determined by the SCT. Cognitive performance of 
rats was assessed in the dPAL task. Again, a retention phase of the dPAL task was added ten 
days following acquisition of the task for testing long-term memory. Finally, animals were 
culled 1–3 days after retention and PFC and HPC gene expression was examined with real-
time qPCR. Genes involved in neuropsychiatric disorders, stress response and neuronal 
plasticity were included in the analysis. The experimental timeline of study III is provided in 
Figure 10. 
 
3.1.4 Study IV 
Stressed and depressed subjects show reduced BDNF levels, BDNF is required for 
antidepressant treatment efficacy and also increases in response to antidepressant treatment. 
To evaluate the role of BDNF in MDD pathogenesis, we used rats heterozygous for the BDNF 
gene (BDNF+/-; n = 13) and WT controls (n = 14). Depression- and anxiety-related behaviour 
Figure 10. Experimental pipeline study III. After acclimatization to the facility, rats were habituated to 
the sucrose consumption test (SCT). After acquisition of baseline sucrose consumption, the chronic 
mild stress model (CMS) was initiated and SCTs were carried out throughout the experiment. Rats, that 
decreased their sucrose intake to 70% or less of their baseline, were defined anhedonic-like based on 
an a prior criterion. Two-thirds of the anhedonic-like rats were subjected to treatment with the 
antidepressant vortioxetine. The 30% of highest and lowest responder to treatment, determined by 
the SCT were subjected to pre-training, different-paired associates (dPAL) acquisition and retention 
together with non-treated anhedonic-like rats and controls. Touchscreen training was discontinued for 
10 days after the dPAL task was acquired. Brain tissue was collected 1–3 days following dPAL retention. 
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was assessed with the sucrose preference test (SPT), novelty induced hypophagia (NIH), 
forced-swim test (FST), OF and EPM test. Working and spatial memory were evaluated with 
the SAB and Morris water maze (MWM; WT: n = 5; BDNF+/-: n = 10) test. In naïve rats (WT: 
n = 9; BDNF+/-: n = 10), PFC and HPC expression levels of genes related to neuropsychiatric 
disorders and stress response were investigated. The experimental timeline of study IV is 
provided in Figure 11. 
 
3.2 Critical evaluation of key methods 
In the following sections, the most important methods and models are critically presented to 
allow accurate interpretation of the results. 
3.2.1 Chronic mild stress model 
The chronic mild stress model was presented in detail in section 1.2.3.4. In short, the CMS 
paradigm combines a model with good construct, aetiological, face and predictive validity and 
was declared as one of the most realistic models for mimicking depression in rodents132,169,201. 
A spectrum of phenotypes regarding the hedonic state follows CMS exposure. The strongest 
phenotypes display either the core symptom anhedonia (approximately 40%), or remain 
hedonic, thus, are resilient (approximately 20%)201 allowing for separation of stress- or 
depression-related alterations. This is similar to humans in whom only a fraction of individuals 
develop depression after prolonged periods of stress256. Moreover, anhedonic-like animals 
respond to chronic but not acute antidepressant treatment and not all animals respond equally 
well, similar to the situation in humans. Limitations of the CMS model are its labour-intensive 
modelling and the high number of animals needed to obtain a sufficient amount of anhedonic-
like animals after CMS exposure. Furthermore, if the CMS is discontinued animals recover 
after 4–5 weeks201, which can be used to model the episodic nature of MDD but simultaneously 
Figure 11. Experimental pipeline study IV. Three different cohorts of rats were used as indicated by the 
three arrows. The presented number of days illustrate how much time passed on average between the 
tasks. 
SPT – Sucrose preference test; EPM – Elevated-plus maze; NIH – Novelty-induced hypophagia; 
SAB – Spontaneous alternation behaviour in the Y-maze; FST – Forced-swim test; OF – Open field; 
MWM – Morris water maze. 
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implies that subsequent experimental steps need to be carried out in close proximity to 
cessation of the CMS paradigm. 
3.2.2 BDNF model 
As discussed in 1.1.1, BDNF polymorphisms (e.g. Val66Met) reduce secretion of activity-
dependent BDNF and predispose individuals to MDD pathology29. Furthermore, sufficiently 
high BDNF levels are required for antidepressant drugs to work efficiently161–163. Thus, 
genetically-induced lower levels of BDNF could be a valid model for affective disorders. 
However, studies including mice heterozygous for BDNF produced inconsistent results 
regarding their phenotype257. This might be explained by behavioural tests being designed for 
rats and not mice132, and that rats, like humans, produce peripheral BDNF243, which can 
influence behaviour244. Additionally, rats display a greater behavioural repertoire and are 
therefore more translational to humans than mice. Thus, BDNF+/- rats might be a better and 
more dependable model than mice for translational research. A limitation of genetic models is 
that only one protein is altered to provoke the phenotype, which is unlikely to mimic the 
complex disease aetiology in humans132. However, it allows us to unravel the relationship of 
decreased BDNF levels and the emerging phenotype. 
3.2.3 Touchscreen operant platform 
The touchscreen operant platform and the two tests employed in this PhD project were 
presented in detail in section 1.3.1. The touchscreen tasks are proclaimed to have good face 
validity since rodent tasks were developed to closely resemble the human tasks. However, 
clinical and preclinical tests are not identical. First, task rules can be explained to humans but 
not rodents. Therefore, rodents have to learn the tasks incrementally possibly requiring 
different brain areas to humans. Secondly, animals are motivated to learn the task by food 
reinforcement. This likely requires other brain areas, such as the striatum, to be also activated 
during task acquisition distinguising neuronal correlates of human and animal PAL learning258. 
Thus, although differences in construct validity of the task exist, the medial PFC as well as the 
HPC and dorsal HPC AMPA- and NMDA-receptor activation are required across species to 
successfully acquire and maintain PAL performance224,226–229,258. Technical differences across 
species could be resolved in the future by adjusting the human version of the task, i.e. including 
non-communication of task rules213 and reward. Generally, it was shown that comparable brain 
areas are involved in preclinical and clinical touchscreen tasks assessing cognition and 
motivation213,259,260. Regarding predictive validity, few studies tested treatment in preclinical 
models using the touchscreen platform. An example is the study by Romberg et al.261, which 
METHODS 
-  38  - 
demonstrated that the symptomatic Alzheimer’s drug donepezil rescued accuracy in a mouse 
model of Alzheimer’s disease (3xTgAD). More studies are required to generalize the 
predictive validity of touchscreen testing in disease models. 
Practical aspects of the touchscreen operant platform should be considered besides its 
validity. Although animals can theoretically be tested in a battery of touchscreen tests, tasks 
can interfere with each other and prevent successful acquisition of the subsequent test262. 
Furthermore, some touchscreen tasks take longer to acquire than others and during a battery 
of tests, animals might go through adolescence, adulthood and old age, which likely influences 
cognitive performance. Moreover, touchscreen testing requires pre-training for the animals to 
acquire the operant concept of the touchscreen testing, which adds to the labour-intensive work 
and, specifically in this project, to a longer period between the original CMS protocol and task 
acquisition. Sugar-coated pellets are used as reward for operant conditioning. However, the 
high-sugar content of the reward pellets interfered with the low-sugar content of the sucrose 
solution (1.5%) used for the SCT. Therefore, the hedonic state could not be monitored during 
touchscreen testing. We overcame this problem in study III by using bacon instead of sugar 
pellets, which also led to successful operant learning in the dPAL task. Although the 
touchscreen testing is described as appetitive learning, food restriction and the novel 
touchscreen environment might be stressful for the animals (this issue is examined in study 
III). Finally, although Bussey et al.263 found that albino as well as pigmented rats can be 
equally used for the vision-based touchscreen tasks, another study by Kumar et al.220 suggested 
that albino rats are restricted in their vision and, thus, show a lower performance or fail to 
acquire certain tasks. Hence, touchscreen testing might be limited to pigmented rodent strains, 
particularly in more visual demanding tasks. 
3.2.4 Classical behavioural tests 
Classical behavioural tests were used in study I - IV assessing depression- or anxiety-like 
behaviour and cognition. 
3.2.4.1 Sucrose consumption or preference test 
Sucrose consumption is often used to evaluate the hedonic state in the CMS model. Willner 
and colleagues70 have extensively evaluated the SCT in the context of the CMS model and 
shown that (1) sucrose solution but not total fluid intake is altered in stressed animals; (2) the 
test is not related to caloric intake of sucrose73; (3) results are not due to a global decrease in 
energy intake70,168; (4) food deprivation augments the difference in sucrose consumption 
between controls and stressed animals, but the difference in sucrose intake was also observed 
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in non-food-deprived animals only to a smaller extent70; (5) SCT is supported by other tests 
sensitive to rewarding properties, such as the food place conditioning paradigm70,71; and (6) 
isolated versus paired housing leads to similar results in the SCT tests, but paired housing 
might delay the effect onset of CMS70. An advantage of the SPT to the SCT is that the sucrose 
consumption can be compared to the animal’s water consumption and, thus, is an internal 
control of a general change in fluid intake but also entails more labour in preparing two instead 
of one bottle for each animal. Thus, the SCT was applied in study I-III with an a priori criteria 
defining anhedonia (SCT index† ≤ 0.7) and resilience (SCT index ≥ 0.9)201 and the SPT in 
study IV. 
A caveat of the sucrose test is the requirement for single-housing if the hedonic state of each 
animal needs to be determined. Since animals are commonly single-housed in the CMS 
paradigm, this was no constriction for study I-III, but it may have induced a stressful element 
in animals that are usually group-housed (study IV). Overall, the SCT and SPT are non-
invasive, easy to execute and appear to be a reliable measure of anhedonia. 
3.2.4.2 Elevated plus-maze 
The EPM is commonly used to assess anxiety behaviour in rodents. The fear of the open and 
lit area of the open arms of the EPM competes with the explorative drive within an animal. 
Thus, more time spent on the open arms relates to anxiolytic behaviour. External settings, such 
as light intensity can influence the time spent or percent distance travelled in the open arm, i.e. 
if the light settings are too bright, the time spent in the open arms might be too small to observe 
an effect between groups. 
3.2.4.3 Novelty-induced hypophagia 
The animal is introduced to a novel environment and presented with a familiar food reward, 
for example a chocolate chip. A longer time taken to consume the food reward relates to the 
depressive-like state of the animal. However, it is difficult to ascertain if this behaviour results 
from increased anxiety in a novel environment or from a reduced motivation to consume the 
reward264. Still, this test discloses depression-related behaviour and is an easy to execute 
supplement to other tests, such as the EPM and SPT. 
                                                     
 
† SCT index = respective sucrose intake during CMS/ baseline sucrose intake prior to CMS 
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3.2.4.4 Open Field 
Animals are allowed to explore an open area (round or square) to assess anxiety as well as 
locomotor activity. Animals that are more anxious spend more time in the peripheral zone than 
in the open area of the centre. The test is also used to assess locomotor activity. If differences 
in locomotor activity exist, percent distance travelled in zones should be analysed additionally 
to time spent in a zone. 
3.2.4.5 Forced swim test 
The FST is commonly used to assess behavioural despair and is primarily used for testing 
antidepressant drug efficacy. The concept behind the test is that a rodent placed in a cylinder 
filled with water (24 ± 1 °C) will try to escape but eventually accepts the unavoidable situation. 
A longer time of passively coping with the situation, i.e. floating immobile in the water is an 
index of behavioural despair; whereas active escape attempts demonstrate non-depressive 
behaviour. Although the FST is often used in preclinical depression research, the test is also 
under critic. Critical points are that the test is sensitive not only to chronic but also to acute 
antidepressant treatment, which is unlike the human situation.265 Moreover, swimming 
behaviour can be co-founded by differences in locomotor activity, which need to be assessed 
in another test, for example the OF265. Furthermore, the test is highly stressful for the animals 
and can interfere with subsequent tests. Therefore, the FST was placed last in the behavioural 
test battery of study IV. 
3.2.4.6 Spontaneous alternation behaviour 
Spatial working memory can be assessed with the SAB test. It is based on the assumption that 
rodents prefer to explore a novel over a familiar area. If the previously visited arms are 
remembered well, the animal should sequentially alternate between the three arms of a Y-
maze. However, if an animal shows a generally low number of arm visits, the calculated 
alternation ratio (sequential arm visits/(arm entries-2)) can be distorted. Thus, animals with a 
low number of arm entries might be better excluded from the analysis134,266. 
3.2.5 Drug treatment 
Vortioxetine is a relatively new drug on the market and falls under the category of “other 
antidepressants”. Several preclinical and clinical studies have shown the antidepressant 
efficacy of vortioxetine (see section 1.1.4.1). Furthermore, a direct pro-cognitive effect was 
ascribed to this drug due to its multimodal mechanism of action. The beneficial effect of 
vortioxetine was observed in the domains of memory, executive function and attention and 
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included improvements in tests relevant for the dPAL task, such as object placement test and 
object recognition144–146. 
In study III, vortioxetine was given mixed into rat chow. This oral administration of 
the drug is similar to oral intake of medication in humans and, thus, increases comparability 
between preclinical and clinical studies. Although preclinical and clinical studies provide 
similar results regarding vortioxetine, it should be noted that the binding affinity for 
vortioxetine in the rat is different to humans. The 5-HT1A and 5-HT7 receptors in the rat have 
an affinity of only 7–10% that of humans for vortioxetine267. Furthermore, the elimination 
half-life of vortioxetine in the rat is considerably shorter than in humans: 2.9–3.9 h in rats and 
57 h in humans268. Finally, the bioavailability differs between species with 10% in rats and 
75% in humans268. 
3.2.6 Real-time qPCR 
Real-time qPCR is a highly sensitive method and used for assessing mRNA expression levels 
of genes. The extracted mRNA is reverse transcribed to complementary DNA (cDNA). From 
the cDNA, the target gene is amplified to which the TaqMan probe then binds. The binding of 
the TaqMan probe results in the release of a fluorophore, which fluoresces. The fluorescence 
intensity is monitored and detected once it is greater than the background fluorescence and 
marked by the cycle threshold (Ct). The Ct value is used to compute the relative concentration 
of target gene in each sample using a standard curve. Pivotal is the normalization of target 
genes to reference genes. The latter should be present in a consistent amount throughout the 
sample tissue and thus allow for corrections of RNA integrity, quantity of tissue or 
experimental treatment269. Incorrect normalisation might give inaccurate data across all target 
genes. Although gene expression allows for assessment of gene transcription, mRNA levels 
might not translate consistently to resulting protein levels due to posttranscriptional and 
posttranslational modifications but show in which tissue or region gene expression is altered. 
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4 RESULTS 
In the following, key results of the four studies are presented briefly. Detailed results, 
including statistics, can be found in the four manuscripts, respectively. 
4.1 Strain and stress (Study I) 
Study I aimed to answer if LE rats respond similarly to CMS exposure as Wistar rats; the 
suitability of albino Wistar rats in the vision-based touchscreen tasks compared to pigmented 
LE rats; and, finally, the impact of CMS exposure on the rats’ cognition in translational 
touchscreen tests.  
We found that LE rats react similarly to the CMS paradigm as Wistar rats did. Some 
rats reduced their sucrose intake, thus became anhedonic-like, whereas others remained 
resilient. Furthermore, CMS increased the time that rats spent in the open arms in the EPM 
and increased the number of central crossings in the OF demonstrating anxiolytic behaviour 
of CMS exposed rats. Working memory of the CMS group was indifferent to controls assessed 
in the SAB test. Thus, the CMS paradigm is applicable in albino and pigmented outbred rat 
strains once it is established in a facility. 
Next, the cognitive performances of Wistar and LE controls were compared in the PD 
and reversal task and in the additional retention task. Wistar rats displayed inferior task 
performance in number of sessions to acquire the PD (Figure 12A) and PD reversal task 
(Figure 12B), which was supplemented by a shallower learning curve in both tasks (Figure 
12C–D). Furthermore, accuracy in the first retention session was lower in Wistar compared to 
LE controls (Figure 12E), but memory or relearning performance was similar between the two 
rat strains (Figure 12F). Thus in all three task components, Wistar rats performed poorer than 
LE rats.  
The impact of stress exposure was evaluated by comparing CMS exposed LE rats to 
LE controls. Stress did not impact PD and reversal learning (Figure 12A–D). However, CMS 
exposed rats were the only group that decreased their average accuracy below criterion on 
retention session one (Figure 12E). Although not significant, memory performance was lower 
in CMS rats compared to LE controls, whereas a trend of increased relearning performance 
was observed between the two LE groups (Figure 12F). 
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Figure 12. Pairwise discrimination (PD) and reversal touchscreen task. Strain comparison (Wistar versus 
Long Evans (LE) rats) as well as stress effects (LE controls versus chronic mild stress (CMS) LE) are 
illustrated. Number of session required to learn the (A) PD task and (B) PD reversal task. Learning curves 
of acquiring the (C) PD and (D) PD reversal task. (E) Percent correct answers of the final PD reversal session 
and the two retention sessions. Passing criterion of 80% accuracy is indicated with dotted line. (F) 
Difference in percent correct of the final PD reversal and first retention session (memory); and first and 
second retention session (relearning). Individual data points as well as group mean (± SEM) are displayed. 
Post-hoc comparisons are indicated with ***p < 0.001, **p < 0.01, *p < 0.05, #p < 0.06. 
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4.2 Resilient and susceptible (Study II) 
In study II, we were interested in distinguishing general effects of stress exposure and specific 
effects of depression on cognitive performance. Thus, the performance of CMS exposed 
anhedonic-like and resilient rats was compared. In this study, the touchscreen dPAL task was 
applied, which involves HPC function. Task selection was based on the findings of study I, in 
which stress did not affect task acquisition but impacted memory (trend), a cognitive function 
in which the HPC is centrally involved.  
First, SCTs revealed a segregation of CMS exposed anhedonic-like rats compared to 
both CMS resilient rats and non-stressed controls (Figure 13A). Furthermore, anhedonic-like 
rats needed on average more trials to acquire the dPAL task compared to non-stress controls, 
whereas resilient rats performed comparable to the control group indicated by a trend in the 
one-way ANOVA (Figure 13B). Using effect size (0.415)‡ and sample size calculation§, data 
                                                     
 
‡ https://www.psychometrica.de/effect_size.html#fvalue: effect size using ANOVA (calculation 7) 
§ https://www.anzmtg.org/stats/PowerCalculator/PowerANOVA: power = 0.8, α = 0.05 
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Figure 13. Different paired-associates learning 
(dPAL) task. (A) Sucrose consumption test. (B) 
Number of trials needed to acquire the dPAL 
task. (C) Long-term memory (difference in 
accuracy between last dPAL session and first 
retention session) and relearning performance 
(difference in accuracy between first and second 
retention session). Group mean (±SEM) and 
individual data points are displayed. Statistical 
significance of post-hoc comparisons is 
indicated with ***p < 0.001, *p < 0.05. 
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from this study indicates n = 20 per group would have been required to show significance. 
Thus, anhedonic-like but not resilient rats’ performance was seemingly poorer in the dPAL 
task compared to non-stressed controls. Furthermore, resilient rats showed different cognitive 
alterations in the dPAL task, such as an increased number of redundant screen touches, i.e. 
impaired response inhibition. Moreover, CMS anhedonic-like rats showed a non-significant 
trend for lower performance than controls and resilient rats regarding long-term memory 
(Figure 13C). Overall, we showed that stress affected cognitive function, however only the 
depressive-like group showed inferior cognitive performance. 
4.2.1 Statistical rational 
CMS exposed animals were divided into subgroups depending on their change in their baseline 
sucrose intake in response to stress. Commonly, the extremes to both ends are taken to 
investigate stress-susceptibility and stress-resilience201. In Figure 14, the whole spectrum of 
changes in sucrose intake in CMS animals is shown (n = 148), which appears normal 
distributed. However, Shapiro-Wilk test indicates deviation from normal distribution (p = 
0.004). Considerations are given to two different ways to analyse this data. First, the extremes 
of both ends could be used to study possibly different behavioural and cellular mechanisms of 
resilient and susceptible animals. This approach has been previously used in the CMS201,205,207 
as well as in other stress models193. A disadvantage of only analysing the extremes is that the 
intermediate phenotypes are discarded, which increases the number of animals required for 
the experiment. Alternatively, all animals could be included in the data evaluation performing 
a regression analysis. However, it is possible that the dependent variable is discontinuous. 
Consequently, difficulties in fitting a linear regression could arise, especially if the 
Figure 14. Sucrose intake of chronic 
mild stress (CMS) exposed rats. The 
average sucrose intake of CMS week 
eight and nine indexed to baseline is 
displayed as frequency distribution. 
Rats below an index of 0.7 are 
categorized anhedonic-like and above 
an index of 0.9 as resilient according to 
an a priori criterion.204 
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intermediate group’s readout is similar to one of the extreme phenotypes and more complex 
statistics needs to be applied. 
4.3 Pharmacological intervention (Study III) 
In study III, we aimed to investigate the efficacy of vortioxetine in the CMS model. 
Particularly, we asked if vortioxetine could restore the hedonic state in the anhedonic-like rats, 
normalize depression-associated cognitive impairments and we wanted to determine if any 
pro-cognitive effects were dependent on concomitant restoration of the hedonic sate in 
response to vortioxetine. Finally, expression of genes relevant in neuropsychiatric disorders, 
the stress response and neuronal growth were measured in brain regions involved in depression 
and cognitive processing, the PFC, and the dorsal and ventral HPC. 
SCTs revealed that vortioxetine restores the hedonic state in a proportion of 
anhedonic-like rats whereas others responded only marginally (Figure 15). Different to study 
II, anhedonic-like rats did not take longer to acquire the dPAL task than control rats (Figure 
16A). However, in the control and both treated groups only one rat per group failed to acquire 
the dPAL task, whereas in the anhedonic-like group three rats failed task acquisition and thus, 
were not included in the primary readout of number of trials to pass (Figure 16A). Control rats 
had a longer response latency (Figure 16B), which may resemble enhanced evaluation of the 
stimuli before making a choice. Vortioxetine treated rats displayed an increase in the number 
of redundant screen touches and a greater number of correction trials, suggesting increased 
spontaneous, stereotypic behaviour after vortioxetine treatment (Figure 16C–D). 
Figure 15. Sucrose 
consumption test. The 
sucrose index (respective 
SCT / sucrose baseline) is 
displayed as group mean 
(±SEM). Treatment start is 
indicated with A, food 
reduction commenced at 
time point B and 
touchscreen pre-training 
and training was initiated at 
C. Post-hoc statistical 
significance between 
groups is indicated with 
***p < 0.001. 
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Unexpectedly, memory performance seems impaired in vortioxetine responders and hedonic 
state affected memory performance as well (Figure 17). Although not significant, the 
anhedonic-like rats were the only group not to improve performance on the second day of 
retention, i.e. during the relearning step (Figure 17). Impaired memory in the responder group 
can potentially be associated with overexpression of Gsk3b, which is involved in spatial 
memory and usually reduced after antidepressant treatment, in the dorsal HPC of vortioxetine 
responders. Furthermore, vortioxetine treatment tended to increase Bdnf levels in the dorsal 
HPC, to decrease Homer3 in the ventral HPC and to decrease GR in the PFC. The anhedonic 
state was associated with increased expression of Cofilin 1, participating in neuronal growth, 
in the PFC; with lower Homer2 levels, a dendritic protein, and with a trend of decreased 
transcription factor MR expression in the dorsal HPC. Finally, Cofilin 1 was higher expressed 
Figure 16. Different paired-associates learning (dPAL) task. (A) Number of trials required to learn dPAL 
(one rat per group, but three rats of the anhedonic group had to be excluded due to failure of 
acquiring dPAL within 46 sessions). (B) Median latency to respond to stimuli on the screen. (C) Within 
session learning curve showing the mean number of trials and correction trials per session block for 
each group. (D) Learning curve showing the mean number of redundant touches per trial. In (A–B) 
individual data points are shown. In all graphs, group means (±SEM) are displayed and statistical 
significance of Bonferroni corrected post-hoc comparisons is indicated with ***p < 0.001, **p < 0.01, 
*p < 0.05, #p < 0.07, ‘~’ indicates a significant difference of the respective group to the vortioxetine 
treated  groups and ‘^’ to the untreated control and anhedonic-like group. 
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in anhedonic-like rats compared to controls in the PFC. Thus, expression of genes involved in 
stress response, affective disorders and neuronal plasticity were altered in response to 
vortioxetine as well as the hedonic state. Overall, this study showed that vortioxetine was 
successful in restoring the hedonic state in the CMS model, but also induced a shift from 
cognitive demanding appraisal to stereotypic, habit-like behaviour. Behavioural changes were 
associated by alterations in gene expression due to treatment and hedonic state. 
4.3.1 Statistical rational 
We were interested to investigate the relationship of the affective symptom “anhedonia” and 
cognitive performance. Therefore, rats were grouped into responding low or well to 
vortioxetine (n = 34) by their respective change in sucrose intake (Figure 18) and the 30% of 
highest and lowest responder were subjected to be tested in the dPAL task.   
Figure 18. Sucrose intake of chronic 
mild stress (CMS) anhedonic-like 
vortioxetine treated rats. The average 
sucrose intake of CMS week eight and 
nine, i.e. week three and four of 
treatment is displayed as frequency 
distribution. Rats above an index of 
0.9 are regarded as recovered from 
anhedonia. 
Figure 17. Retention of different paired-
associates learning (dPAL) task. 
Acquisition of dPAL was followed by a 10-
day hiatus and two days of dPAL 
retention. Memory resembles the 
difference of percent correct answers of 
the last dPAL before the hiatus to the 
first retention session. Relearning is the 
difference in percent correct answers of 
the first to the second retention session. 
Individual data points and group means 
(±SEM) are shown. Statistical significance 
of post-hoc comparisons and main effect 
treatment (angular brackets) is indicated 
with **p < 0.01, *p < 0.05. 
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Performance in the dPAL task as well as gene expression levels were analysed by two-
way ANOVA to investigate if the respective changes were caused by treatment (responder and 
low-responder versus control and non-treated anhedonic-like rats) or by the hedonic state 
(control and responder versus anhedonic-like rats and low-responder). This was important to 
investigate since vortioxetine treatment is proclaimed to have a pro-cognitive effect 
independent of recovering the affective symptoms of depression133,134.  
However, the data appears not to be bimodal distributed and Shapiro-Wilk test does 
not indicate a significant deviation from normality (p = 0.164). Therefore, a regression analysis 
within the treatment group might be more appropriate. Consequently, a one-way ANOVA 
would be applied to investigate difference in performance between controls, anhedonic-like 
rats and vortioxetine treated rats (responders and low-responders). Additionally, a regression 
analysis is performed, which is exemplified  here for number of trials to criterion and the mean 
sucrose index of treatment week two to four (i.e. CMS week seven to nine). No relationship 
between number of trials to reach criterion and SCT index was found within the combined 
treatment group (R2 = 0.03, p = 0.495, Figure 19) after testing normality of residuals. 
In theory, there should be no difference regarding the question answered by the two 
analysis. However, problems with regression analysis can arise when the dependent variable 





Figure 19. Linear regression of number of 
trials to criterion and sucrose 
consumption index. Given are the data 
points for all vortioxetine treated rats 
(responder and low-responder) and the 
sucrose intake as average of treatment 
week two to four. 
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4.4 Anhedonia and cognitive performance (Study II and III) 
CMS anhedonic-like and non-stressed control rats were pooled from study II and III to increase 
the n-number per group, and thus statistical power**. Here, results of statistical analysis are 
provided since they cannot be found in any of the manuscripts. 
Anhedonic-like rats tend to require more trials to acquire the dPAL task than non-
stressed control rats (t(34) = 4.10, p = 0.0507; Figure 20A). Effect size†† (Hedges’ g = 0.68) 
and sample size calculations‡‡  from the current data suggest n = 36 would have been required 
to show significance. Furthermore, anhedonic-like rats also needed more correction trials for 
task acquisition compared to controls (t(34) = 4.56, p = 0.040; Figure 20B). These impairments 
in the anhedonic-like group were not due to motivation since the time to collect the reward 
was not statistically significant between groups (Figure 20C). However, anhedonic-like rats 
showed increased spontaneous and, thus, less appraised behaviour demonstrated by the 
shortened median response latency in this group (t(34) = 6.69, p = 0.014; Figure 20D) and 
increased number of redundant screen touches per trial (t(32) = 9.56, p = 0.004; Figure 20E). 
The highest number of correct trials executed in a row per session was not statistically 
significant between controls and anhedonic-like rats. Memory and relearning performance did 
not differ between the groups. Thus, the pooled dPAL data confirms that cognitive 
impairments are present during task acquisition in anhedonic-like rats whereas memory is 
spared. 
                                                     
 
** Summary statistics were performed on animals that acquired the task and outliers (Grubbs’ test, 
α = 0.05 and ROUT test, Q = 1%) were removed. 
†† http://www.socscistatistics.com/effectsize/Default3.aspx 
‡‡ https://www.anzmtg.org/stats/PowerCalculator/PowerTtest: power = 0.8, α = 0.05, independent, 
two-sided 
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Figure 20. Combined data of study II and III. The data for non-stressed controls and CMS exposed 
anhedonic-like rats (untreated) is pooled to increase n-number per group and thus statistical power. 
(A) Number of trials to acquire the dPAL task. (B) Number of correction trials. (C) Time taken to collect 
reward pellet. (D) Median latency to respond to stimuli on the touchscreen. (E) Number of redundant 
touches executed to the screen per trial. (F) The highest number of trials correctly executed in a row 
per session. Individual data points and group means (± SEM) are shown. Significance is indicated with 
**p < 0.01, *p < 0.05. 
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4.5 Brain-derived neurotrophic factor (Study IV) 
Reduced cerebral BDNF levels are found after stress exposure and in depressed patients. Thus, 
we investigated if a genetic reduction in BNDF provoked affective-like behaviour and/or 
cognitive impairments. Furthermore, PFC and HPC expression levels of genes relevant for 
neuropsychiatric disorders and in the stress response were examined. BDNF+/- rats displayed 
anhedonic-like behaviour in the SPT (Figure 21A) and anxiety behaviour in the OF (time spent 
in centre; Figure 21B). No difference in behaviour between BDNF+/- and WT rats occurred in 
the EPM, NIH, FST, SAB or MWM. The transcription factor GR, disrupted in schizophrenia 
1 (Disc1), which is attenuated in psychiatric disease, and neuregulin 1 (Nrg1), involved in 
learning and memory, were upregulated in the PFC of BDNF+/- rats, whereas Fkbp5, a 
regulator of the HPA axis’ negative feedback sensitivity, was downregulated in BDNF+/- rats 
in the HPC (Figure 22). Thus, reduced BDNF levels can be associated with a mild phenotype 
related to affective disorders which may be underpinned by altered gene expression in the 
brain. 
Figure 21. Sucrose preference test and open field (OF) test. (A) Sucrose intake normalised to total fluid 
intake (sucrose solution plus water consumption). (B) Time spent in the centre of the OF arena. 
Individual data points and group means (±SEM) are displayed. Statistical significance is indicated with 
**p < 0.01, *p < 0.05. 
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Figure 22. Prefrontal cortex (PFC) and hippocampal (HPC) gene expression. Individual gene expression 
levels are normalised to the respective group mean of wild type (WT) rats. Individual data points and 
group mean (±SEM) are displayed. Statistical significance is indicated with ***p < 0.001, *p < 0.05. 
 
GR - Glucocorticoid receptor, Nrg1 – Neuregulin 1, Disc1 – Disrupted in Schizophrenia 1, Fkbp5 – FK506 binding 
protein 5 
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5 DISCUSSION 
A detailed discussion regarding the results of each study is given within the respective 
manuscripts. In the following, the results of all four studies are discussed collectively. 
5.1 Strain differences in touchscreen testing 
The first study focused on methodological as well as scientific research questions. One of them 
aimed to determine if rodent strain, specifically albinism, which is associated with poor vision, 
affects performance in the vision-based touchscreen tasks. We found that Wistar albino rats 
performed more poorly than pigmented LE rats in the PD and the PD reversal task, as well as 
during the retention phase (study I). Thus, strain evidently affected touchscreen performance. 
Literature has been conflicting on this topic. For example, one study concluded that albino 
rats’ performance was comparable to pigmented rats applying the PD and reversal task in 
Sprague Dawley and Lister Hooded rats263, whereas another study found that albino rats 
(Wistar and Sprague Dawley) perform significantly worse than the pigmented strains (Lister 
Hooded and Long Evans)220. Our results support the latter study and confirm that albinism is 
accompanied by inferior touchscreen task performance. It is postulated that this is due to poor 
vision in albino strains220, however, results from study I cannot decisively confirm this. In fact, 
albino rats were able to acquire the simple PD and reversal task and therefore were able to 
recognize the stimuli. However, errors could have been made more easily if it was difficult for 
the rats to distinguish between the stimuli. During the PD reversal learning, Wistar rats’ 
performance was superior to LE rats in the first two sessions. Thus, Wistar rats must have 
incorporated the stimulus-reward association from the preceding PD task less strongly or, 
alternatively, they display greater cognitive flexibility. Yet, Wistar rats’ superior performance 
in the PD reversal task was not continued in subsequent sessions, thus, it is more likely that 
Wistar rats had a weaker stimulus-reward association of the PD task. Consequently, Wistar 
rats and possibly other albino strains exhibit inferior touchscreen task performance, which 
might be caused by a combination of poor vision and inferior cognition. This may not 
necessarily be an exclusion criteria for albino strains in vision-based touchscreen task, as long 
as albino strain characteristics are considered in task choice, e.g. tasks with easy 
distinguishable visual stimuli. 
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5.2 The chronic mild stress model 
The CMS model was applied to acquire a better understanding of the risk factor ‘stress’ and 
its effect on cognitive performance. Additionally, the influence of hedonic state, i.e. being 
resilient or anhedonic-like, on cognitive performance was investigated. 
5.2.1 Modelling the affective state 
First, we demonstrated that exposure to stressors, a main environmental risk factor for 
developing MDD in humans, resulted in anhedonic-like behaviour in rats independent of rat 
strain (study I). Anhedonia was only expressed in a fraction of CMS exposed LE rats (37%), 
whereas other LE rats remained hedonic (19%), thus are classified as resilient (study II), which 
is in accordance with previous studies using CMS exposed Wistar rats201,270. Furthermore, 
CMS exposed rats displayed anxiolytic behaviour in the EPM and OF. Anxiety disorders are 
a common comorbidity in MDD pathology271–273, and thus anxiogenic instead of anxiolytic 
behaviour in CMS was expected. However, previous studies show that stressed animals exhibit 
both anxiogenic274,275 as well as anxiolytic behaviour202,276 and, hence overall indicate altered 
emotional processing linked to stress exposure. 
5.2.2 Modelling cognitive impairments 
First, a general effect of stress on cognition was assessed comparing CMS exposed LE rats 
with LE controls (study I). Both groups had similar spatial working memory ability, as tested 
in the SAB task. A previous study using Wistar rats showed that CMS anhedonic-like and 
resilient rats are impaired in the SAB task205. Discrepancies between the two studies might be 
explained by differences in rat strain or, alternatively, the SAB test needs to be supported by 
other tasks to provide a reliable result. Furthermore, the effect of stress on cognitive 
performance was evaluated by applying the PD and PD reversal task (study I). Results from 
this study suggest that stress does not affect cognition. However, our experimental design 
comprised a heterogeneous stress group, including anhedonic as well as resilient rats, which 
may has masked anhedonia-related cognitive impairments. Furthermore, stressed as well as 
non-stressed LE rats required very few sessions to learn the PD and PD reversal task and, thus, 
suggest that this touchscreen task may be too simple to uncover potential mild to moderate 
cognitive impairments.  
 
To avoid ceiling effects in learning, the more complex dPAL task was applied in subsequent 
touchscreen studies. In addition, LE CMS rats were categorized according to their hedonic 
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state and only anhedonic and resilient rats were used, which resemble the strongest CMS 
phenotypes. Anhedonic-like rats tended to take longer to acquire the dPAL task compared to 
controls, whereas resilient rats showed a cognitive performance comparable to the control 
group (study II). Thus, this study demonstrated that cognitive impairments appear to be 
specifically associated with the depressive-like phenotype and not a general consequence of 
stress exposure. Impaired cognitive performance in the anhedonic-like group might be a 
consequence of prolonged high levels of free corticosterone in response to CMS exposure, 
possibly inducing adverse effects on the brain61,204. Briefly, resilient rats have high 
corticosterone levels during stress exposure; however, this initial response is quickly 
terminated and therefore might induce only mild or no adverse effects on the brain204. 
Although not impaired in task acquisition, resilient rats displayed increased impulsive 
behaviour, observed by an elevated number of redundant screen touches compared to 
anhedonic-like or control rats. Impulsivity relates to impairments in response inhibition, an 
executive function of the PFC277–279, which implies that stress may have impaired PFC function 
in CMS resilient rats. Overall, study II uncovered that cognitive impairments are not only a 
consequence of stress exposure per se but are dependent on the rats’ hedonic state. 
To increase group size, and therefore statistical power, data from control and 
anhedonic-like rats was pooled from study II and III. Results confirm that anhedonic-like rats 
were impaired in dPAL acquisition compared to controls, as demonstrated by increased 
number of trials required to acquire the dPAL task. Interestingly, the anhedonic-like group 
appears to be subdivided: rats that required a similar number of trials for dPAL acquisition as 
controls and rats that need more trials than most of the controls. This might be analogous to 
only a proportion of MDD patients are suffering from cognitive impairments81. Since severity 
of cognitive impairments were correlated with severity of depression in humans98,100, the 
stronger cognitively impaired anhedonic-like rats might resemble a more vulnerable subtype 
of depression. A greater group size is required to confirm the two cognitive subtypes in the 
anhedonic-like group and to enable comparisons between subtypes, for example of brain 
structure and endocrinological processes. Still, only controls were able to acquire the dPAL 
task with less than 1000 trials (~32% of control rats), whereas all anhedonic-like rats needed 
more than 1000 trials, indicating a lower cognitive performance in anhedonic-like rats. 
Additionally, cognitive impairments in the anhedonic-like group are demonstrated by an 
increased number of correction trials needed to acquire the dPAL task.  
Shortened median response latency in anhedonic-like compared to control rats in the 
dPAL task suggests abated cognitive appraisal before making a choice. Since MR is implicated 
in appraisal processes280, a trend of decreased MR gene expression in the dorsal HPC of 
DISCUSSION 
-  58  - 
anhedonic-like rats compared to hedonic rats (study IV) supports the behavioural deficits in 
appraisal processes in anhedonic-like rats on a cellular level. The HPC is involved in appraisal 
processes280,281, which further suggests impaired HPC functioning in the anhedonic-like group. 
In this regard it is highly interesting that impairments in HPC function coincides with reduced 
inhibitory control of the HPC over the HPA axis, which is often found in MDD patients44 and 
might occur in anhedonic-like rats as well204. The hypothesis of a changed HPC function is 
also supported by preclinical imaging studies detecting alterations in HPC shape and diffusion 
properties of CMS exposed animals210,211. Thus, the central role of the HPC in depression 
found in preclinical as well as in clinical studies strengthen translational relevance of the CMS 
model in depression research.  
Impaired response inhibition was found in MDD patients and dysfunction correlated 
with severity of depressive symptoms79. Interestingly, we found an increased number of 
redundant screen touches in anhedonic-like rats, which indicates stereotypic or augmented 
habit-like behaviour arising from deficits in response inhibition60. This cognitive process is 
part of PFC’s executive functions60,279 and may suggest altered PFC function in anhedonic-
like rats. Stress has previously been shown to induce a shift from cognitive demanding 
processes to habit-like behaviour, which was accompanied by atrophy in the PFC and 
striatum60. Thus, CMS anhedonic-like rats might have experienced PFC and striatal atrophy 
and as a consequence display increased habit-like behaviour. 
The number of consecutive correct trials per session and collection latency did not 
differ between the two experimental groups. The latter parameter was an important finding 
because a longer collection latency, for example in the anhedonic-like group, could be 
indicative of a reduced motivation to consume the reward and likewise to participate in the 
touchscreen task which would have made it difficult to determine if poorer task performance 
originated from impaired cognition or reduced motivation.   
Altogether, anhedonic-like rats showed cognitive impairments that can be attributed 
to alterations in executive functions, by e.g. impaired response inhibition, a domain of the 
PFC, whereas longer task acquisition might be associated with altered HPC function. Both 
brain regions are known to be altered in MDD118,282 and lesions in these areas lead to increased 
number of errors and trials required to acquire the PAL task in humans228. Thus, our model of 
depression-induced cognitive impairments appears clinically relevant. 
In MDD patients, memory impairments are less evident than deficits in executive 
function or attention81. Although it appears that anhedonic-like rats show deficits in memory 
performance in study II, this finding did not reach statistical significance and was also not 
evident in the pooled data set. From the above mentioned touchscreen parameters, impairments 
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in HPC function appear to present in anhedonic-like rats, which could have affected memory 
performance as well. Although the HPC is central in memory formation, once the memory is 
consolidated, it can become HPC-independent283. Rats were well-trained in the dPAL task and, 
thus, memory might have become HPC-independent.  
5.3 Vortioxetine and the CMS model 
Study III aimed to investigate the efficacy of vortioxetine to restore the hedonic state and 
cognitive performance in CMS anhedonic-like rats. In the majority of clinical studies, 
vortioxetine was superior as antidepressant compared to placebo and superior to agomelatine 
demonstrated in a single study133. In a rodent model of depression, the Flinders Sensitive Line 
rat, the antidepressant effects of vortioxetine were established in the social interaction test, OF 
and FST133. However, as the Flinders Sensitive Line constitutes a selectively bred rat model 
with inherent depression-like phenotype, it may be more relevant to investigate the effects of 
a novel antidepressant in a model with environmentally induced depressive-like behaviour, 
such as the CMS rat. The literature suggests the CMS paradigm as one of the most appropriate 
models for modelling MDD since it fulfils predictive, construct and face validity including the 
MDD core symptom, anhedonia132. Thus, it was important to investigate the efficacy of 
vortioxetine in this model. In study III, we found that vortioxetine successfully restored the 
hedonic phenotype in the majority of rats (65%), whereas the remaining rats responded only 
minimally to the treatment. This response rate appears to be similar or slightly better compared 
to other antidepressants, such as escitalopram (50% response rate) in the CMS model122. Thus, 
this study was first to show treatment efficacy of vortioxetine in the CMS model, which 
appeared to have failed in a different study (personal communication with Papp, reviewed in 
Sanchez et al.133). 
Furthermore, study III uncovered brain gene expression levels change in response to 
chronic vortioxetine treatment. Bdnf expression was increased in the dorsal HPC in rats treated 
with vortioxetine compared to untreated rats, which is complementary to the literature that 
antidepressants elevate BDNF levels284–286. BDNF levels were not decreased in response to 
CMS exposure, i.e. the untreated anhedonic-like phenotype. This was not expected since 
reduced BDNF levels can be found in response to stress284 as well as in MDD patients152. 
However, BDNF is also involved in neuronal plasticity and possible negative effects of CMS 
on BDNF expression might have been neutralized by learning-induced increase of BDNF287 
during dPAL testing. Surprisingly, GR expression was reduced by vortioxetine in the PFC 
(study III). This is unexpected according to the literature, which reports decreased GR protein 
levels in MDD patients. 
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Regarding cognition, vortioxetine has a positive effect in classical behavioural tasks related to 
dPAL testing, such as novel object recognition and spatial working memory in 5-HT-depleted 
rats134,145 and prevents age-induced visuospatial impairments in the novel object placement 
test288. In study III, cognitive impairments associated with the untreated anhedonic-like 
phenotype were less prominent than in study II. However, some touchscreen parameters 
indicate poorer cognitive performance in anhedonic-like rats compared to controls, such as 
increased number of correction trials needed within a session to acquire the dPAL task, which 
was established as a marker of lower cognitive performance in the pooled data set. In study 
III, vortioxetine treatment resulted in an even higher number of correction trials needed for 
task acquisition, which does not support a pro-cognitive effect of vortioxetine treatment. 
Furthermore, stereotypic and less appraised behaviour were a robust finding in vortioxetine 
treated rats. Reduced median response latency as well as an increased number of redundant 
screen touches were characteristic for vortioxetine treated rats. These two touchscreen 
readouts are altered similarly in anhedonic-like rats compared to controls in the pooled data 
set. Taken together, vortioxetine treatment appears to have strengthened depression-associated 
behaviour. However, number of redundant screen touches, but not median response latency, 
was also increased in CMS resilient rats compared to anhedonic-like rats or controls (study 
II). Thus, vortioxetine treatment might introduce some features of the resilient phenotype but 
maybe overcompensate in its efficacy resulting in stereotypic behaviour. Surprisingly, 
stereotypic behaviour was not reported in other vortioxetine studies, which might be due to 
the type of tests applied or that stereotypic behaviour was not assessed or did not interfere with 
task performance.  
Antidepressant treatment, including SSRIs, monoamine oxidase inhibitors and 
tricyclic antidepressants, inhibit Gsk3b expression289,290. This was not observed in study III 
and Gsk3b expression appear even increased in vortioxetine responders in the HPC . However, 
elevated Gsk3b expression is also associated with impairments in spatial memory, object 
recognition and long-term potentiation, which are elements of the dPAL task289,291–293. Thus, 
increased Gsk3b levels in the vortioxetine responder group substantiate behavioural results of 
impaired memory during retention of the dPAL task (study III). Nevertheless, it remains 
unresolved how vortioxetine restored the hedonic state without decreasing Gsk3b levels. This 
might be explained by tissue collection and consequent mRNA levels measurement were 
executed at the endpoint of the experiment whereas the antidepressant treatment effect 
occurred much earlier and thus, temporal dynamic changes in Gsk3b expression might explain 
the discrepancy of Gsk3b mRNA levels. Cofilin 1 expression, involved in reorganization of 
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the neuronal cytoskeleton294 and its dysregulation is associated with cognitive decline295,296, 
was found significantly increased in the PFC of anhedonic-like rats and, although not 
significant, both vortioxetine treated groups displayed a comparable level of Cofilin 1 
expression as anhedonic-like rats (study III). Although this finding is unexpected for 
anhedonic rats, treatment with vortioxetine might induce neuroplasticity changes by 
upregulation of Cofilin 1 in the PFC. 
5.4 BDNF+/- rats for modelling preclinical depression 
5.4.1 Anhedonia and anxiety in BDNF+/- rats 
Study IV aimed to investigate a possible relationship of reduced BDNF levels and MDD 
symptomatology based on the findings that stress reduces BDNF levels62 and BDNF levels are 
decreased in post-mortem tissue of MDD patients152. A battery of tests was used to uncover 
the potential relevance of BDNF in affective behaviours. We found no behavioural differences 
in the EPM, FST and NIH, however, BDNF+/- rats exhibited anhedonic-like behaviour in the 
SPT and anxiety-related behaviour in the OF. Therefore, our study supports an involvement 
of BDNF in the affective symptoms of MDD.  
Anxiety-like behaviour in the OF is in accordance with another congenital BDNF+/- 
rat study finding that BDNF+/- rats spend less time in the centre of the OF but are not different 
to WTs in the EPM and FST158. In contrast a BDNF+/- mouse study reported the opposite 
finding of increased time spent in centre by BDNF+/- mice compared to WT mice154. 
Temporally induced attenuated BDNF levels in rats resulted in increased behavioural despair 
in the FST157. Findings of the temporal model were not observed in the present study and might 
be explained by compensatory mechanisms which are able to take over in the congenital but 
not in a temporally induced model. Still, in the same model anhedonic-like behaviour was 
observed in the SPT as well as decreased locomotor activity in the home cage157, which are 
similar findings to observations in study IV. Thus, across different rat (including our study) 
but not mouse studies, complementary results were found, supporting the use of BDNF+/- rats 
to investigate the role of BDNF in affective dysfunction.  
A reduction of at least 30% of BDNF levels need to be present to observe changes in 
HPA axis activity at basal level297. The BDNF+/- rats in our study show the respective 
reduction159 and consequently, the observed changes in hedonic state and anxiety in BDNF+/- 
rats could be linked to changes in HPA axis function as dysregulation of the HPA axis is often 
found in MDD patients298,299. Finally, altered emotional processing was found in BDNF+/- rats 
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and linked to amygdala activity159 and might explain anxiety-related symptoms in the present 
study as well. 
 Interestingly, we found altered expression of genes relevant in affective disorders in 
BDNF+/- rats. Fkbp5 expression was downregulated in the HPC of BDNF+/- rats, which is 
usually associated with increased feedback sensitivity of the HPA axis and, thus, a healthy 
stress response300. In connection with the affective phenotype of the BDNF+/- rats, a 
desensitisation of the HPA axis’ negative feedback was expected instead.  Similarly, GR 
expression was upregulated in the PFC of BDNF+/- rats although MDD patients show a 
downregulation of GR in the PFC301. However, overexpression of GR in the forebrain was also 
associated with emotional liability, i.e. increased anxiety-like and depressive-like behaviours 
in mice302 and thus, elevated PFC GR levels might contribute to the behavioural phenotype in 
BDNF+/- rats. It has been demonstrated that BDNF alters HPA axis activity by increasing CRH 
expression in the paraventricular nucleus303 and the subsequent high levels of secreted 
glucocorticoids might reduce GR expression in the long-term45. Thus, opposite mechanisms 
may occur in animals with innately low levels of BDNF resulting in increased GR expression 
and the subsequent behavioural phenotype. DISC1 is associated with neuropsychiatric 
disorders  and found to be less functional in schizophrenic patients304,305. Thus, Disc1 
upregulation in the PFC of BDNF+/- rats was unexpected but also observed in a juvenile stress 
model, yet in the HPC306. This suggests that this gene is susceptible to stress and the subsequent 
reduction of BDNF levels and may have a pivotal role in the gene x environment aetiology of 
depression-like behaviour.  
Overall, our study suggests that anhedonia and moderate anxiety-related behaviour is 
associated with lower BDNF levels and may be mediated by the same mechanisms altering 
signalling pathways with GR, Fkbp5, Disc1 and Nrg1. More studies need to be conducted to 
establish whether this relationship of behaviour and gene expression is of causal nature, 
however, our findings supplement a growing body of literature that implicates BDNF in MDD 
pathology. 
5.4.2 Cognitive performance is not impaired 
Furthermore, BDNF is involved in neuronal plasticity and might be involved in the 
development of depression-associated cognitive deficits. However, BDNF+/- rats were not 
impaired in the SAB, evaluating spatial working memory, or MWM, investigating spatial 
long-term memory (study IV). We chose these tests based on the fact that SAB and MWM are 
tasks with a spatial component, which requires HPC function307–309, a brain area central in 
MDD pathology and high on BDNF310,311. However, cognitive impairments may not be 
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induced by congenitally low BDNF on its own, but might require a gene x environment 
interaction. This has been shown in MDD, where the BDNF polymorphism Val66Met 
modulates the impact of stressful life events in MDD pathogenesis32. We additionally found 
Nrg1 levels to be elevated in the PFC of BDNF+/- compared to WT rats. NRG1 is associated 
with spatial learning but also increased in response to stress in the PFC312,313. Thus, attenuated 
BDNF levels evoked a similar effect as stress exposure did. 
5.5 Translational testing 
Translation between preclinical and clinical testing is central to be able to compare results 
across species, such as efficacy of a novel drug treatment. However, the nature of assessing 
symptoms or phenotypes is dissimilar between humans and animals. For example, MDD 
questionnaires in human subjects are equated to forced swim test, tail suspension test or 
sucrose intake in rodents. Therefore, new tests and techniques, such as touchscreen testing, 
which can be used in both humans and rodents, are developed to bridge this gap in translational 
testing. 
5.5.1 Touchscreen testing 
Preclinical touchscreen testing is still a rather young field. Although the task protocols are 
straightforward and uniformly accessible across institutions, protocols are described slightly 
different between studies, which might explain variation in their results. For example, Wistar 
rats needed more than 27 sessions to acquire the simple PD task in a study by Kumar220, 
whereas in study I, Wistar rats only required nine sessions on average and the slowest Wistar 
rat 13 sessions to acquire the task. Possible sources of explanation for these differences in 
performance are (1) differences in food deprivation. Most studies use food deprivation for 
operant conditioning in touchscreen tasks. Often rats are food deprived down to 85–90% of 
their body weight229,262,314. However, we used percent baseline food intake as the guideline for 
food deprivation and payed close attention not to food deprive rats to less than 90% of their 
body weight and some rats did not even lose weight. Furthermore, rats were monitored during 
pre-training and food deprivation was adjusted to the rats’ behaviour, i.e. unmotivated rats 
received a small decrease in their daily amount of food (- 0.5/ -1 g) or an increase if the rat 
appeared rushed. Thus, hunger might influence performance in touchscreen testing and should 
be kept to a minimum also because humans are not food deprived for touchscreen testing. Our 
study showed that rats learn the task well also with less food deprivation, which should be 
aimed for in future rodent studies. Further differences could result from (2) number of sessions 
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per week (with/without break); (3) number of trials per session; (4) passing criterion; (5) 
passing the task individually or on a group level; (5) stimuli used; (6) duration of ITI; (7) 
duration of punishment interval; (8) testing during light or dark phase; (9) loudness of tone; 
(10) house light on/off during ITI; (11) food reward (milk shake, sweet pellets, and by us 
newly introduced: bacon pellets). Hence, more studies and protocol transparency enable 
comparisons of protocol modification and results and could lead to an optimized, and 
consequently unified protocol.  
In study III, we introduced bacon pellets and were consequently able to monitor the 
rats’ hedonic state through SCTs throughout touchscreen testing. We observed that 
touchscreen testing and the accompanying food reduction is perceived mildly stressful since 
control rats decreased their sucrose intake in the initial phase of touchscreen assessment. Rats 
later habituate to be touchscreen tested and therefore initially mildly stressful phase occurred 
predominantly during pre-training and spared the actual task acquisition. We were first to show 
that although touchscreen testing operates on appetitive operant conditioning, the change in 
environment, the food deprivation and possibly touchscreen training itself can be stressful for 
rodents. This might have reduced effect size when comparing supposedly non-stressed control 
rats to CMS exposed animals. 
Still, touchscreen tasks appear to be one of the most translatable and standardized tests 
at present6,213. Accordingly, touchscreen tests applied on clinically relevant animal models are 
a promising approach to close the gap between preclinical and clinical research and hopefully 
promote aetiological understanding of cognitive impairments in diseases and enable tailored 
treatment development. 
5.6 Limitations 
The conducted studies have some limitations, which were not avertable in the most cases due 
to practical matters, but should be kept in mind when interpreting results. 
We did not find reduced BDNF gene expression levels in anhedonic-like compared 
hedonic rats (study III), which may not translate into functional changes due to possible post-
transcriptional and post-translational modifications. Touchscreen testing and consequently 
learning processes might have increased BDNF levels287 which may have masked any 
reductions in BDNF levels in response to stress. 
Vortioxetine receptor occupancy is slightly different between humans and rats (5-
HT1A and 5-HT7 receptor are showing an in vitro binding affinity of only 7-10% of the one for 
humans for vortioxetine)267. Therefore, results from rodent studies might not be exactly 
translational to humans. 
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In our study, we food-deprived rats, which may had consequences on the treatment 
effect of vortioxetine. Vortioxetine was incorporated into the rats’ food chow, which mimics 
closer the clinical route of administration and is simultaneously less stressful than any other 
route of administration. However, rats had to be food restricted for touchscreen testing. 
Consequently, rats received a lower dose of vortioxetine during that period. However, rats had 
already recovered prior to touchscreen testing and therefore we believe that rats had reached a 
steady-state which they maintained even during food deprivation. Furthermore, antidepressant 
efficacy of vortioxetine was demonstrated even during food-deprivation by the SCTs of study 
III.  
In study III vortioxetine was not administered to a non-stressed control group. Ideally, 
this should have been done to separate effects of vortioxetine on its own and in the 
experimental condition. We refrained from treating control rats for the benefit of including a 
vortioxetine low-responder group in touchscreen testing. The resources available allowed to 
include only 40 rats in total in touchscreen testing. 
Experimental conditions, such as food deprivation, touchscreen testing and isolated 
housing were likely mildly stressful for control rats. This may have diminished effect size 
between CMS and the non-stressed control group. However, continuous SCTs testing showed 
that control rats never entered an anhedonic-like state and the greatest decrease in sucrose 
consumption occurred during pre-training and not task acquisition. Thus, the observed effects 
were valid but may have been smaller. 
Another limitation comprises the lack of SCTs during touchscreen learning in study I 
and II. Thus, we cannot exclude that animals spontaneously recovered from CMS exposure 
during touchscreen assessment. However, study III proves that the CMS-induced state 
remained during touchscreen testing and we can most likely conclude that it was similar in 
study I and II. 
Furthermore, cognitive performance could not be assessed before CMS exposure. 
Thus, it is theoretically possible that cognitively inferior rats predominantly entered the 
anhedonic-like group. However, this hypothesis would entail that cognitively impeded 
individuals are more likely to become depressive, which is not supported by the literature.  
Finally, although preclinical touchscreen testing was developed based on the human 
CANTAB tasks, tests across species are not identical. This originates from the circumstance 
that task rules can be simply explained to human subjects but not to animals, which acquire 
the rules through operant conditioning. Thus, different brain areas might be required for 
testing. Furthermore, the nature of the reward differs between humans and animals. Animals 
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are presented with primary rewards, such as food whereas humans receive secondary rewards, 
such as money or the task might be rewarding in itself for humans. 
5.7 Conclusion 
When we talk about depression, we tend to primarily and predominantly think about the 
affective symptoms a person is suffering from. Recently, increased attention has been given 
to depression-associated cognitive impairments, in part due their impact on daily functioning, 
their persistence as residual symptom and their role in treatment response and relapse. 
However, this change in thinking is not currently implemented in therapy and particularly in 
medical treatment. A key to resolve this shortcoming is the implementation of a clinically 
relevant preclinical model of depression including affective and cognitive symptoms. This 
PhD project aimed to establish such an animal model with focus on clinical pertinence and for 
deepening our understanding of the aetiology of depressive symptoms. 
This work suggests that reduced BDNF levels are involved in the aetiology of 
anhedonia, a core symptom of depression, and moderately in the emergence of anxiety, a 
common co-morbidity of MDD. Stress exposure resulted not only in the core symptom 
anhedonia in a proportion of rats, but also in cognitive impairments specifically associated 
with this phenotype. Stress-resilient rats, defined by their hedonic state, also displayed 
cognitive alterations; however, their performance in the translational touchscreen task was not 
impaired. Touchscreen task performance suggests that PFC function might be changed in 
response to stress, thus in both CMS groups; and HPC function in depressive-like rats only. 
Vortioxetine treatment was successful in restoring the hedonic state, thus treating the affective 
symptoms of MDD. The purported pro-cognitive effects of vortioxetine were less evident. 
Vortioxetine’s effect on cognition mirrored in some ways those of resilient rats (increased 
impulsivity); there might have been a pro-cognitive effect (number of animals acquiring dPAL 
task), but it did not restore cognition to control level (number of correction trials). Finally, our 
touchscreen studies contributed to the young and growing field of touchscreen testing. We 
were first to show that the dPAL task is sensitive enough for detecting depression-associated 
cognitive impairments and distinguish those from resilient rats. We further established that 
albino strains are inferior to pigmented strains in touchscreen testing. We were also first to 
show that touchscreen testing and the accompanying food deprivation is mildly stressful on 
the rats, which need to be carefully considered when working with e.g. stress models. In 
addition, we were first to demonstrate that vortioxetine is effective in the CMS model. Thus, 
this work contributed to the field of preclinical touchscreen testing, risk factor and symptom 
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relationships in depression, characteristics of stress-induced cognitive impairments and drug 
treatment applying research tools of high clinical relevance. 
We believe that the conducted studies are clinically pertinent owing to the model of 
choice (rat versus mouse and pigmented versus albino rats); the use of stress (main 
environmental risk factor for developing depression) and reduced BDNF levels (in response 
to stress, but also genetic predisposition (val66met)); and application of touchscreen tasks, 
which were developed based on the human CANTAB test battery. Furthermore, CMS 
exposure elicited a depressive-like phenotype in only a fraction of rats, similar to human 
susceptibility, where stress-experience is not inevitably leading to MDD. Moreover, the pooled 
data of study II and III suggests that only a proportion of depressive-like rats might be 
cognitively impaired, which is also comparable to the human condition. Thus, our approach 
mimics very closely the human situation of depression-associated cognitive impairments 
provoked by a main environmental risk factor of MDD. 
5.8 Perspective 
This project provides a solid basis for future touchscreen studies, in which various factors can 
be modified to further optimize the experimental design and translational value. For example, 
other antidepressants should be evaluated in the CMS model and touchscreen tasks since 
vortioxetine is a relatively new drug and less characterized in humans than other 
antidepressants. This would also help to identify potential other antidepressants with pro-
cognitive effects and provide starting points for novel drug development. 
Furthermore, other preclinical models than the CMS model should be tested with the 
touchscreen operant platform. Different preclinical depression paradigms may model different 
subtypes of MDD and thus allow tailoring of MDD subtype-specific antidepressant treatment. 
Furthermore, the CMS model is labour-intensive and an inbred model, such as the Wistar-
Kyoto rat or BDNF+/- would reduce workload and costs if successful in modelling depression-
associated cognitive impairments as well. It could be promising to test BDNF+/- rats since the 
role of BDNF in antidepressant action is evident and they appear to display the core symptom 
anhedonia. Although, we did not find cognitive impairments in those rats, this might be due to 
classical behaviour paradigms being less sensitive to cognitive impairments than touchscreen 
testing or that stress exposure is required, e.g. by 3-day pre-pubertal juvenile stress paradigm 
to elicit cognitive impairments in BDNF+/- rats.  
The promising value for translational testing was already discovered by the 
pharmaceutical industry and requires now optimization of the experimental design for best 
clinical relevance. Despite preclinical touchscreen testing being more elaborate than classical 
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tests, the high clinical relevance might result in a more reliable drug profile, which is beneficial 
in the long-term, e.g. less failure of drug testing at stage  three in humans accompanied with 
reduced numbers of human subjects for drug testing, and decreased costs in human studies.  
Moreover, more women than men suffer from depression. Although female rats may 
introduce more variance to the results due to their hormonal cycle314, the female-male-ratio in 
depressed patients strongly suggests testing of female rats in preclinical studies, though greater 
group sizes may be required.  
Furthermore, comparisons of the resilient and anhedonic-like phenotype should be 
further elaborated to decipher depression aetiology and get inspiration from the resilient 
phenotype for antidepressant drug development. Here, touchscreen studies should ideally be 
combined with examination of genetic traits, neuroendocrinology and a detailed behavioural 
profile.  
Functional magnetic resonance imaging (fMRI) is another highly translational 
technique that could support the profiling of resilient and anhedonic rodents. fMRI is a 
frequently applied tool in neuropsychological and neuropsychiatric research in humans to 
assess indirectly neuronal activity. Basic fMRI tests are already implemented for rodents159,315 
and could highly contribute towards a better understanding and characterisation of preclinical 
depression models and translation between clinical and preclinical studies.  
Finally, in a very elaborate study, rats could be endocrinologically, behaviourally 
(affective and cognition) and genetically phenotyped before entering the CMS. This would 
clarify if a certain pheno- or genotype is more prone to develop affective symptoms and be 
cognitively impaired as result of stress exposure. This would also answer the question if 
cognitive predisposition contributes to the depression aetiology. 
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A B S T R A C T
Patients suffering from depression-associated cognitive impairments often recover incompletely after remission
from the core symptoms of depression (lack of energy, depressed mood and anhedonia). This study aimed to set
the basis for clinically relevant testing of cognitive impairments in a preclinical model of depression. Hence, we
used the chronic mild stress (CMS) model of depression, which provokes the core symptom of anhedonia in a
fraction of the stress exposed animals, while others remain resilient, and assessed the entire CMS groups' cog-
nitive performance on the touchscreen operant platform. Specifically, we applied the pairwise discrimination
(PD) and reversal task including a retention phase on Wistar and Long Evans controls and CMS exposed Long
Evans rats. We observed differences between the albino Wistar and the pigmented Long Evans strain regarding
performance in the PD and reversal task as well as in memory consolidation. CMS exposure did not alter learning
and memory in the PD and reversal task, even though it altered affective behaviours in the elevated plus-maze
and open field test. This is likely due to the heterogeneity of the CMS group, in which stress exposure elicited the
expected range of phenotypes from anhedonic-like to resilient shown with the sucrose consumption test. Thus,
our study suggests that pigmented rat strains, such as Long Evans, are superior to albino rats in the vision-based
touchscreen studies. Furthermore, we propose investigation of the CMS subgroups in more complex, hippo-
campus-dependent tasks to refine a translational preclinical model of depression-induced cognitive impairments.
Hence, this study increased awareness of strain-specific differences in touchscreen performance and added to the
literature regarding the sensitivity of the PD and reversal task to stress-induced cognitive alterations.
1. Introduction
Major depressive disorder (MDD) is the leading cause of disability
worldwide and the disease has an increasing incidence rate. Currently,
300 million individuals suffer from depression also affecting their social
and economic environment [1]. Anhedonia (loss of interest or experi-
ence of pleasure), depressed mood and lack of energy are the core
symptoms of depression. Additionally, patients may also exhibit other
symptoms, including, suicidal thoughts, feelings of guilt and worth-
lessness as well as cognitive impairments [2]. Depression-related cog-
nitive impairments have been observed in 30–50% of depressed pa-
tients affecting memory, attention and executive function [3–6].
Although cognitive impairments persist after remission from depression
in 94% of these patients [6], they are often disregarded but continue
affecting the patient's quality of life. Cognitive impairments can
augment negative feelings and thoughts, counteract therapy and in-
crease risk of relapse [7,8]. Consequently, development of an anti-
depressant treatment that also generates remission of depression-re-
lated cognitive symptoms is crucial [3,4]. Hence, it becomes critical to
identify a valid animal model for treatment testing [9]. However,
modelling MDD is difficult due to the heterogeneity of the disease
symptoms, the introspective nature of the symptoms and the in-
complete understanding of disease aetiology which arise from complex
gene-environment interactions [9–12]. The literature indicates the
chronic mild stress (CMS) model as one of the most ideal paradigms for
rodents models of depression covering face, construct and predictive
validity [10,12,13]. The CMS paradigm uses unpredictable mild stres-
sors over weeks, mimicking daily stress exposure in humans and eli-
citing anhedonia, a core symptom of MDD [10]. Furthermore, cognitive
impairments have been demonstrated in this model using novel object
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recognition tasks [14], spontaneous alternation behaviour and en-
hanced aversive memory in contextual fear conditioning [15]. Although
these results are promising, their translational value and clinical re-
levance is debatable [12,16]. Especially when addressing such a com-
plex entity as human cognition and its alteration in depression, appli-
cation of highly translational and meaningful tests is indispensable.
Consequently, we address this difficulty by employing a new technique;
the touchscreen operant platform based on appetitive reinforcement
learning. Major advantages over commonly used tests for rodents in-
clude its cognitive phenotyping array adapted from the Cambridge
neuropsychological test automated battery (CANTAB) for cognitive
assessment in humans, its accurate and objective readouts and the
standardized setup [17–19]. In this study, we focused on several
questions to optimize implementation of translational testing in the
CMS model of depression. First, we investigated potential differences in
the suitability of a pigmented rat strain (Long-Evans (LE)) and an albino
strain (Wistar). The latter one has been undergoing the CMS paradigm
in our laboratory for years. Yet, the Wistar albino strain bears risk for
impaired vision [20–22] which could restrict their performance in the
vision-based touchscreen apparatus independent of their cognitive
abilities. Other studies considered this issue previously, but with con-
tradictory results [18,22]. Furthermore, we determined the suscept-
ibility of the LE strain to display depressive symptoms in response to the
CMS paradigm. Finally, we examined the effect of CMS exposure on
touchscreen performance using the LE strain. The touchscreen pairwise
discrimination (PD) and reversal task was applied consisting of two
steps: Visual discrimination and stimulus-reward association learning
was evaluated with the PD touchscreen task, whereas the PD reversal
task assessed perseveration behaviour and new stimulus-reward asso-
ciation learning. Perseveration behaviour is suggested to play an im-
portant role in MDD [23,24] and association learning assesses attention
and executive function [25,26]. Finally, we included re-testing of the
PD reversal task after a 10 day hiatus to assess long-term memory
performance [16].
2. Materials and methods
2.1. Animals
Male Wister (Taconic M&B, Denmark; n = 12) and Long Evans rats
(LE; Janvier Labs, France; n = 28) were 5–6 weeks of age and
100–120 g at arrival in our facility. Animals were housed in groups of
four for the first week followed by single-housing for the time duration
of the experiment. Rats had free access to food and water and kept on a
12 h light-dark cycle (lights on at 6 am). All experiments were con-
ducted according to the Danish National Committee for Ethics in
Animal Experimentation (2013-15-2934-00814).
2.2. Chronic mild stress protocol
A proportion (n = 16) of the LE rats were subjected to the CMS
paradigm 6 weeks after arrival in the facility. The rats were exposed to
a series of unpredictable mild stressors (Table 1) for 5 weeks as de-
scribed in Jayatissa et al. [27] for Wistar rats.
The Wistar rats and the remaining 12 LE rats were not exposed to
the CMS paradigm (controls).
2.3. Sucrose consumption test to assess the rats' hedonic state
Sucrose consumption tests (SCT) were carried out to assess the rats'
hedonic state before and during CMS exposure. After one week of ac-
climatization to the animal facility, the LE rats undergoing the CMS
paradigm were habituated to consume a palatable sucrose solution
(1.5%) for 24 h in one week, and for 1 h following 14 h of food and
water deprivation the next week. Succeeding this habituation phase,
three 1 h SCT were carried out every Friday (following 14 of food and
water deprivation) and sucrose intake was measured for each animal
[28]. The last two sucrose consumption tests were averaged and em-
ployed as baseline sucrose consumption for each rat. Thereafter, stress
exposure was commenced and succeeding SCTs were normalised to the
baseline sucrose consumption creating sucrose consumption indexes.
The final two SCT indexes during CMS exposure were averaged and
used to evaluate the hedonic state of each animal. Animals were
grouped using an a priori criteria for hedonic state [10]. Animals are
categorized as anhedonic-like with a SCT index ≤0.7, whereas a SCT
index ≥0.9 defines a CMS exposed rat as resilient.
2.4. Classical tests for measuring anxiety-like behaviour and working
memory
The phenotype of the CMS exposed LE rats was further assessed
using typical behavioural tests. Phenotyping focused on anxiety beha-
viour and working memory. Testing was conducted in the final week of
CMS exposure in the animals' light phase. The experimental room was
illuminated with red light if not otherwise stated. Testing order was
randomized. Rats were acclimatized to the experimental room for at
least 1 h before testing. The experimental equipment was cleaned with
70% Ethanol between animals. A person blinded to group identity
scored the recorded behaviours.
2.4.1. Elevated plus-maze
Animals were placed in one end of a closed arm (40 cm high wall) of
the plus-shaped maze (arms: 50 × 10 cm, 70 cm elevation from floor)
facing the back wall. Light intensity was 80 lx in the open and 20 lx in
the closed arms. Rats were left to freely explore the elevated plus-maze
(EPM) for 10 min. Behaviour was scored for time spent in the open and
closed arms, number of head dips and arm entries.
2.4.2. Open field
The circular open field (OF) arena measured 120 cm in diameter
with 40 cm high wall. Animals were placed in the centre of the OF and
their movement was recorded for 10 min. The number of central and
horizontal crossings, time to first rearing, number of rears and
grooming were measured.
Table 1
Weekly CMS protocol. The variation of stress duration (indicated in brackets) and different type of stressors used aimed to increase unpredictability of the protocol and prevent
habituation to the stress regime. During the “grouping” stressor, an intruder rat (another rat undergoing the CMS protocol) was added to the cage of the resident rat. The role of the
resident and intruder as well as the pairing rat was changed every week.
Monday Tuesday Wednesday Thursday Friday Saturday Sunday







New cage SCT (1 h), alternating each
week: food or water
deprivation (7 h)
Alternating each week:











Grouping (14 h) Cage tilt 45° (14 h) Wet bedding
(14 h)
a For CMS and non-stressed controls; SCT = sucrose consumption test.
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2.4.3. Spontaneous alternation behaviour assessing working memory
The y-maze consisted of three arms (50 × 18 cm) surrounded with
dark Plexiglas walls (35 cm). The room was dark, but a light was fixed
above the centre of the y-maze resulting in 5 lx illumination in the
centre and 1–2 lx in the arms. The rat was placed at the end of one arm
facing the back wall and recorded for 12 min during free exploration of
all three arms. An arm entry was scored if all four paws of the rat en-
tered the arm. Visiting all three arms consecutively was counted as one
correct alternation. The maximum possible number of correct alterna-
tions was the total number of arm entries minus two. The alternation
ratio was calculated as the number of correct alternations made nor-
malised to the maximum number of possible alternations.
2.5. Translational testing of visual discrimination learning and long-term
memory with the touchscreen operant platform
2.5.1. Apparatus
The sound- and light-attenuating Bussey-Saksida touchscreen op-
erant chambers (Campden Instruments Ltd., Loughborough, UK) con-
tained a trapezoid shaped interior chamber (height 30 cm, length
33.2 cm, width screen 24 cm, width magazine 12.6 cm) with a touch-
sensitive screen on one side and a reward delivery system (magazine)
on the opposite side. A mask covered the screen leaving two windows
(10 × 10 cm) for the rat to touch the screen in a defined area. A spring-
hinged shelf in front of the mask prevented unintentional and hasty
touches by slowing the rat down before reaching the screen. A fan
ensured sufficient ventilation and masking of external noise. The
chambers were further equipped with a grid floor, house and magazine
light, and a tone generator. The touchscreen program was controlled by
Whisker Server and Abett II software (Campden Instruments Ltd.).
2.5.2. Touchscreen pre-training
Rats were gradually food restricted to 80% of their individual free
feeding consumption and body weight was checked daily. Forty stimuli
(white on black background) were randomly used during pre-training
and displayed one at the time leaving the other touchscreen window
blank. Pre-training followed the protocol of Horner et al. [17]. Briefly,
rats underwent “habituation” (free exploration of touchscreen
chamber), “initial touch” (exposure to stimuli, tone and automatic de-
livery of reward pellets (sugar coated 45 mg dustless precision pellets,
BioServ, NY, USA)), “must touch” (response towards the stimulus is
required for reward delivery), “must initiate” (initiation of new trial by
nose poke in food magazine) and “punish incorrect” (response to a
blank touchscreen window is punished by 5-s time out with house light
turning on) to step-wise guide the rats on operating the touchscreen
system. Each trial was followed by an inter-trial-interval (ITI) of 20 s.
Each session lasted maximum 45 min or 75 trials (except “habitua-
tion”). Passing “punish incorrect” by completing 75 trials within 45 min
with at least 60 correct choices (≥80% accuracy) on two consecutive
days completed pre-training and rats were individually moved on to PD
acquisition (Fig. 1).
2.5.3. Pairwise discrimination and reversal learning
In the pairwise discrimination (PD) task, rats had to learn associa-
tion of one touchscreen symbol with a sugary reward pellet (S+) and
another symbol (S−) with a mild punishment (5 s house light on). The
association was independent of symbol location on the screen.
Achieving 80% or more correct choices out of 75 trials within 45 min
on two consecutive days was equipollent with passing the PD task. Rats
were then individually moved on to PD reversal learning. In that task,
the other symbol (S−, PD task) became the rewarding one and the
previously learned rewarding symbol (S+, PD task) would entail the 5-
s time out period with house light on. The same criteria for passing
applied as in PD. Hence, we tested visual discrimination and stimulus-
reward association learning in the PD task, whereas PD reversal as-
sessed perseveration behaviour and new stimulus-reward association
learning.
2.5.4. Retention
After acquiring PD reversal learning, the rats received 10 days
without touchscreen testing and an increase in food that substituted for
the daily amount of reward pellets. Next, rats were re-tested on the PD
reversal task for two days to evaluate the rats' long-term memory
(Fig. 1).
The three groups (Wistar control, LE control, LE CMS) were ba-
lanced across testing chambers preventing possible chamber-specific
differences (illumination, tone intensity or pitch, odour, stimulus ap-
pearance, reward delivery) as cofounding factor on group performance.
Furthermore, the individual testing time-point of the day was changed
daily to avoid daytime specific performance. Rats of all groups occupied
the touchscreen chambers at the same time of the day. On the following
days, the same rats were tested each time 45 min earlier than the day
before. Rats tested first of the day were moved to be tested last on the
next day. Touchscreen sessions were carried out seven days a week
avoiding a possible change in performance due to days without
touchscreen training.
Fig. 1. Overview of experimental pipeline. Consecutive experimental steps including
details of food deprivation and passing criteria for each step of touchscreen pre-training
and training are given.
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2.6. Statistical analysis
Data was analysed using Stata 14 (StataCorp LP, Texas, USA).
Summary statistic was applied for number of sessions to pass PD and PD
reversal task as well as EPM, OF and SAB using student's t-test or
Welch's t-test accounting for violation of homogeneity of variance.
Normality was tested with QQ-plots and Shapiro-Wilk test and violation
lead to application of non-parametric Mann-Whitney test. Outliers were
removed according to Grubb's test (α= 0.05; GraphPad Software Inc.,
California, USA). SCT index was correlated with behavioural data of
EPM, OF and number of sessions to pass PD and PD reversal learning.
For the correlation, data was rank transformed. Repeated measure-
ments data of accuracy and reaction time (RT) were analysed by two-
way repeated measurements ANOVA and possible interaction effects
were post-hoc analysed with Bonferroni-corrected pairwise compar-
isons for each time point. To not distort the mean over time, animals
that passed the touchscreen tasks were kept in the analysis by including
their last readout of accuracy in the mean over time. Outlier perfor-
mances were kept in the analysis because they did not alter significance
level of the results. Data was checked for normality and homogeneity of
variance with QQ- and residual plots. All RT readouts had to be log-
transformed and outlier RTs determined by Grubb's test (α= 0.05;
GraphPad Software Inc.) were removed. Two animals of the Wistar
group were unable to pass pre-training and hence were excluded from
the PD and reversal task.
3. Results
3.1. The effect of CMS on the rats' hedonic state
On an individual basis rats were differently affected by stress and
could be classified as anhedonic-like (3/16), resilient (7/16) or inter-
mediate (6/16) depending on their sucrose consumption (Fig. 2). This
was expected based on previous studies from our laboratory in Wistar
rats [10,15,27]. Hence, once established, the CMS model can be ef-
fectively used across strains.
3.2. Classical behavioural phenotyping of CMS exposed rats reveals altered
anxiety-like behaviour but no changes in working memory
Additionally to the SCT, we assessed anxiety behaviour and working
memory in the whole LE CMS group by comparing them with non-
stressed LE controls in the EPM, OF and spontaneous alternation
behaviour task.
Significant differences between LE controls and LE CMS were ob-
served in the EPM. CMS exposed rats spent less time in closed arms
(p < 0.0001) and more time on open arms (p < 0.0001) than non-
stressed controls. CMS exposed rats also carried out more head dips into
open arms (p < 0.0001) and entered the open arms more frequently
than control rats (p < 0.0001; Fig. 3). Within the CMS group, the SCT
index did not correlate with the time spent in the open or closed arms,
the number of entries into the open arms nor the number of head dips.
The EPM results indicate decreased anxiety in the rats exposed to CMS.
In the OF, LE CMS rats carried out significantly more central
crossings (p= 0.026) and number of grooming bouts (p = 0.034)
compared to non-stressed LE rats. Furthermore, the number of rears
(p = 0.026) and time spend till first rearing (p= 0.040) was sig-
nificantly decreased in CMS exposed LE rats than in controls (Fig. 4).
The apparent decreased anxiety could not be explained by altered lo-
comotor activity between groups (p = 0.935) and did not correlate
with SCT index within the CMS group.
Hence, CMS exposed rats exhibited an anxiolytic rather than an
anxiogenic phenotype.
No effect of stress was observed on the alternation ratio in the
spontaneous alternation behaviour test indicating intact working
memory of CMS LE rats.
3.3. Cognitive performance of Wistar and LE rats and the consequences of
CMS exposure
First, we wanted to assess if strain alone (albino Wistar and pig-
mented LE rats) alters performance in the translational PD and reversal
touchscreen tasks. Secondly, the effect of CMS on cognitive perfor-
mance was assessed by comparing LE controls to LE CMS rats.
3.3.1. Touchscreen task acquisition
Wistar rats took significantly longer to acquire the PD task (t(11.29)
= 5.68, p < 0.001) and the PD reversal task (t(11.87) = 3.54,
p = 0.004) compared to LE controls. No effect of CMS on number of
sessions needed to acquire the PD and reversal task was observed
(Fig. 5A, B).
3.3.2. Learning curves
Detailed analysis, evaluating the rats' performance over time, was
carried out to detect possible changes during learning that may have
been missed by solely analysing the number of sessions needed to ac-
quire the touchscreen tasks.
No effect of CMS exposure was found in PD or PD reversal task
comparing the learning curves of CMS exposed LE rats to non-stressed
LE rats. A significant interaction effect of group x time on accuracy was
found for the learning curves between Wistar and LE controls in the PD
(F(12, 240.00) = 8.78, p < 0.0001) and PD reversal tasks (F(22,
440.00) = 4.14, p < 0.0001). Post-hoc analysis was Bonferroni cor-
rected and determined the sessions in which Wistar and LE controls
differed significantly in their performance (Fig. 5C, D).
3.3.3. Reaction time
We further investigated the mean RT (time between rats initiating a
new trial and making a choice by touching the screen) to check for
group differences in time taken to reach a decision. An interaction effect
of group x time on reaction time was observed for strain comparisons in
the PD task (F(12, 231.15) = 2.04, p = 0.022) and PD reversal task (F
(22, 414.23) = 3.43, p < 0.0001) and for stress in the PD (F(5,
125.47) = 3.40, p = 0.007) and PD reversal task (F(12, 299.26)
= 2.39, p = 0.006) suggesting differences between groups in proces-
sing speed of decision-making. In the PD task, Wistar rats showed a
longer RT than LE controls and this effect diminished over time. In PD
reversal, LE rats needed longer to make their choice until session eight
after which Wistar rats displayed a longer RT. For both PD and reversal
Fig. 2. Sucrose intake of CMS exposed LE rats. The frequency distribution of the rats'
hedonic state was calculated as the mean sucrose intake for the last two weeks of CMS
indexed to prior to stress baseline. A sucrose intake index below 0.7 defines rats as an-
hedonic-like (black bars), above 0.9 as resilient (empty bars) and in between as inter-
mediate phenotype (striped bar).
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task, CMS exposed rats had a longer RT compared to non-stressed LE
rats in the first session after which RT duration was reversed suggesting
quicker decision-making due to stress exposure.
3.3.4. Retention
Finally, long-term memory was assessed by re-testing the PD
reversal task following a 10 d hiatus. Two-way repeated measures
ANOVA on the last PD reversal session, retention session one and re-
tention session two reveals a main effect of strain on accuracy (F(1,
16.47) = −2.35, p= 0.032) with a simple main effect at retention
session one (p= 0.049, Fig. 6A) suggesting that Wistar rats have an
impaired long-term memory compared to LE rats. No effect of stress was
Fig. 3. Behavioural differences in EPM. Shown are time
spent in the closed and open arms as well as number of
head dips in the open arms and open arm entries for both
non-stressed (empty bars ± SEM) and CMS exposed LE
rats (filled bars ± SEM). (***Student's t-test, p < 0.001).
Fig. 4. Behavioural differences in the OF. (A) Number of
central crossings and grooming bouts. (B) Number of rears
and latency to first rearing behaviour. Group mean
(± SEM) is displayed for LE controls (empty bars) and CMS
exposed LE rats (filled bars). (*Student's t-test, p < 0.05).
Fig. 5. Results for PD and PD reversal touchscreen tasks. The number of sessions needed to pass the PD (A) and PD reversal task (B) are displayed as group average (± SEM) and as
individual scores (analysed by Welch's t-test (Wistar vs LE)) or student's t-test (LE control vs CMS). Mean accuracies over sessions (learning curves) are displayed for PD (C) and PD
reversal (D) learning (analysed by two-way repeated measures ANOVA). Statistical results of Bonferroni post-hoc test comparing LE and Wistar controls at each session are indicated with
*p < 0.05, **p < 0.01, ***p < 0.001.
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observed for retention (accuracy over time).
Separate analysis of retention was carried out to distinguish two
different cognitive processes: first, memory was calculated as the dif-
ference in accuracy between the last PD reversal session and the first
retention session comparing performance before and after the break.
Second, relearning was calculated as the difference in accuracy between
the first and second retention session. Analysis revealed a trend for
relearning performance between the LE control and LE CMS group with
t(26) =−1.98, p = 0.058 (Fig. 6B) maybe indicating altered retention
processing due to stress exposure.
4. Discussion
4.1. General
First, we demonstrated that the hedonic state of LE rats was altered
in response to CMS exposure comparable to Wistar rats. All three ca-
tegories of the hedonic state (anhedonic-like, resilient and inter-
mediate) reported in former studies on Wistar rats [10,29–31] and in
others [32,33] were present in the CMS exposed LE rats. Hence, we
could confirm the applicability of the CMS paradigm to different rat
strains without the need for paradigm adjustment emphasizing its ro-
bust and comparable outcome of the MDD core symptom anhedonia.
Moreover, in classical behavioural rodent tests for anxiety, stressed
LE rats displayed less anxiety-related behaviours than non-stressed
controls. CMS rats executed more central crossings, more grooming
bouts, less rears, and showed increased latency to first rearing in the
OF. In the EPM, CMS rats spent more time on the open arms and less on
the closed arms, they showed increased numbers of entries to the open
arms and increased number of head dips. Overall, these findings suggest
that CMS attenuates anxiogenic behaviour in LE rats. The apparent
decreased anxiety behaviour did not correlate with the hedonic state of
the CMS group. Although this co-occurrence is not imperative, an an-
xiogenic effect of CMS exposure could have been expected du the co-
morbidity of depression and anxiety disorders in humans [34–36].
However, reports have shown contradictory findings regarding anxio-
genic [37,38] versus anxiolytic [39,40] behaviour in animals after
stress exposure. The latter two studies interpreted the anxiolytic effect
observed in the stressed group as dampened emotional processing of
sensory input, and, thus, a loss of interest in the environment. Fur-
thermore, the rodent strain, type of stressor, stressor duration and
length of protocol differ greatly between studies, likely driving the
different outcomes and making comparisons difficult. The present CMS
protocol, unlike in the above studies, does not involve electric foot
shock, forced swimming, restraint stress or stressors lasting over 14 h,
which could explain the non-emergence of an anxiogenic phenotype
due to a milder stress protocol in this study. Moreover, the above
mentioned papers did not report about segregation into stress-suscep-
tible, stress resilient or intermediate subgroups in their stress paradigm,
but only of a stress group that seems to be equivalent with the de-
pressive-like phenotype. Parameters of the CMS protocol, such as
stressor intensity, determine the proportion of rats exhibiting a sus-
ceptible phenotype and, hence, the heterogeneous composition and
overall phenotype of the group. A stressed group, in which all rats are
susceptible, models traumatic rather than common daily stressful si-
tuations in humans. Such a model seems inadequate for depression
research since only a proportion of humans develop depression after
experiencing stressful events [41].
Furthermore, there was no significant difference between CMS ex-
posed and control LE rats in the spontaneous alternation behaviour test.
This result conflicts with the study of Henningsen et al. [15], in which
resilient and anhedonic-like rats showed a significantly lower alterna-
tion ratio than controls. It could be that stress-induced impairments in
working memory are rat strain-specific. However, Henningsen et al.’s
study [15] did not include rats that are in between these marginal
phenotypes of resilience and susceptibility making comparisons to our
study difficult.
Stress exposure had no effect on cognitive performance in the PD
and PD reversal task examining number of sessions needed to acquire
the task as well as differences in the learning curves (accuracy over
time). Hence, there seem to be no alterations due to stress exposure in
the domains for visual discrimination learning, perseveration behaviour
and stimulus-reward association learning. Non-stressed LE rats needed
very few sessions to acquire the PD and reversal tasks indicating the
simplicity of these tests for the rats and, hence, likely accounting for a
missing effect of stress exposure. Thus, PD and reversal learning might
not be sufficiently challenging for detecting mild cognitive impairments
but only drastic alterations in cognition (e.g. lesion or pharmaceutical
studies). However, a trend was observed of stress influencing the re-
learning ability during retention. Although both memory and re-
learning performance during retention lead to an average decrease or
increase of over 10% respectively (Fig. 6B), only relearning reached a
close to significant difference between groups. Interestingly, the
average performance of non-stressed LE rats in the first retention ses-
sion after the hiatus still met the passing criterion of 80% for the PD
reversal task, whereas the LE CMS group's average performance was
slightly below criterion (Fig. 6A). This finding could indicate an al-
teration in long-term memory and hence hippocampal function. The
Fig. 6. Retention of PD reversal task. (A) Accuracy of the last session in PD reversal, the first and second session of retention following the 10 d hiatus are shown as mean group
performance as well as the individual performances. Passing criterion of 80% correct choices is indicated with a dotted line. Memory (difference in accuracy between last PD reversal
session and first retention session is indicated with ∙∙∙∙) and relearning (difference in accuracy between first and second retention session is indicated with ―). Memory and relearning are
shown again in more detail with individual and group results (± SEM) in (B). Differences are indicated with *p < 0.05 (two-way repeated measurements ANOVA); #p < 0.060
(student's t-test).
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hippocampus plays a key role in memory formation and is known to be
structurally and functionally altered in depressed patients [42] and
stress-exposed animals [43].
Non-stressed Wistar rats performed inferior to non-stressed LE rats
in the PD, PD reversal and retention of the PD reversal task. Wistar rats
needed more sessions to acquire the PD and the PD reversal task and
their learning curve was in both cases significantly shallower. The
lower performance in the two tasks could be due to impaired cognition
as well as to restricted visual capability. Our results do not allow a
definite differentiation. However, all Wistar rats were able to acquire
these tasks and, hence, their vision was sufficiently efficient to dis-
criminate the visual stimuli. Nevertheless, reduced vision in albino rats
[22] could increase the likelihood for spontaneous involuntary mis-
takes. It should be considered that Wistar rats perform significantly
better than LE controls in the first sessions of PD reversal task, in-
dicating a weaker internalisation of the recently passed PD task. This is
unlikely to be caused by greater cognitive flexibility since superior
performance in the PD reversal task discontinued after the second
session. Hence, we likely observe a phenomenon of decreased cognitive
abilities in the Wistar albino strain combined with poor vision.
After the 10 day hiatus, the first retention session was significantly
lower in accuracy in Wistar compared to LE controls indicating a lower
memory capability in the albino strain. Wistar rats perform below the
criteria (≥ 80% accuracy) in the first retention session (Fig. 6A). They
regain a performance level above criterion on retention session two
ruling out any other interference than cognitive impairments.
RT was predominantly longer for Wistar than for LE controls and
shorter for CMS exposed LE rats than for LE controls (except session one
of PD and reversal tasks). The RT can hint on the processing speed of
decision-making leading to the conclusion of impaired processing speed
in the Wistar strain since a longer RT did not result in improved task
performance. On the other hand, LE controls and CMS exposed rats
showed a similar performance during touchscreen task learning. Given
that controls are considered normal, the decreasing effect of CMS on RT
should be regarded as spontaneous or impulsive behaviour rather than
superior cognitive processing [44–46].
In a similar study by Kumar et al. [22] aiming to make comparisons
between pigmented and albino rat strains, the group found superior
performance in the pigmented to the albino rat strain in the visual
discrimination and reversal task emphasizing the reproducibility of
touchscreen testing. However, in Kumar et al.’s study [22] no differ-
ences in RT were observed between Wistar and LE rats but a longer RT
for the pigmented Lister-hooded as to albino Sprague-Dawley and
Wistar rats. The similar RT between Wistar and LE controls in Kumar
et al.’s study [22] might be caused by a slightly intensified food re-
striction in Kumar et al.’s study [22]. Ideally, food restriction should be
avoided, but it is deemed necessary to motivate the rats engaging with
the touchscreen setup [17]. However, intensified food restriction may
lead to spontaneous, unconsidered decision-making precipitated by
hunger and interfering with diagnostic cognitive assessment.
Interestingly, in Kumar et al.’s study [22], Wistar rats did not ac-
quire reversal learning and overall performance of both LE and Wistar
rats was poorer compared to the current study. For example, LE controls
needed seven sessions (plus three criterion sessions) to achieve the vi-
sual discrimination task on a group level whereas in this study only four
sessions (plus two criterion sessions) were needed for the slowest LE
control rat to pass the PD task. Furthermore, in visual discrimination
reversal learning, Wistar rats were abolished from testing at session 14
because their accuracy level scarcely reached 60% [22]. In our study at
session 14 of PD reversal learning, Wistar rats performed at an average
accuracy level of 80% (Fig. 5D). These pronounced differences in per-
formance level might be due to small differences in the experimental
setup of our study to Kumar's such as longer ITI, different stimulus
symbols, house light off during stimuli presentation, increased number
of trials per session and a consistent session duration of 45 min
throughout pre-training and training, two instead of four stimuli
locations and stringency of pre-training (inclusion of a “punish in-
correct” step during pre-training). These parameters may have allowed
an n = 10 to be sufficient to produce clear results between strains.
Kumar et al. [22] suggested an increased N number might have been
responsible to track differences between strains in their study compared
to the study of Bussey et al. [18], which did not find differences in
performance between albino and pigmented strains. Hereby, we could
confute this possibility and further shed light on the influence of in-
trinsic touchscreen parameters on task performance.
Hence, the current study adds to the growing resource of data in the
rather young touchscreen field. Comparisons between studies reveal
which parameters may increase performance in the touchscreen
chambers and, thus, accelerating optimization of protocols. A well
evaluated standard protocol for touchscreen testing should be the ob-
jective, enabling comparisons across institutions, reproducibility of
studies and giving possibility of increased quality in meta-analysis.
4.2. Limitations
A limitation of this study was that CMS exposure was not continued
during touchscreen pre-training and training. Hence, spontaneous re-
covery from stress effects may have occurred. Literature reports spon-
taneous recovery from CMS exposure by 4–5 weeks [10]. However,
introduction to the new element of touchscreen pre-training might have
prolonged stress experience and extended the period to recovery.
Furthermore, the low number of animals in the stressed group did
not allow for subdividing them into the three categories of the hedonic
state. Hence, the heterogeneity of the stressed group including anhe-
donic-like, intermediate and resilient animals may have masked de-
pression-related cognitive impairments. Moreover, the correlation of
hedonic state with cognition or anxiety was inconclusive due to the low
animal number and the high variance of the data.
4.3. Conclusion
This study replicated the findings of Kumar et al. [22] emphasizing
the reproducibility of touchscreen testing in different labs. Further, our
study underlined the validity of the CMS model across strains without
the need of additional strain-specific adaptations. Moreover, key points
of implementation were successfully disclosed allowing optimized
testing of CMS animals' cognition with the touchscreen task: Pigmented
rats should be used for testing in a vision-dependent touchscreen setup
to be able to distinguish cognitive deficits from visual ones. Further,
stress alone results only in a trend during retention phase but not during
task acquisition. This suggests testing of the distinctive subgroups of the
CMS paradigm since cognitive impairments might be specific to the
depressive-like phenotype and not observable in the heterogeneous
CMS group. Moreover, a complex touchscreen task should preferably be
used for detecting even mild cognitive impairments. In particular, a
hippocampus-dependent task would be relevant based on the consistent
literature matching alterations in hippocampal function and structure
in individuals with depression.
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Depression-associated cognitive impairments persist after remission from affective 
symptoms of major depressive disorder (MDD), decreasing quality of life and increasing risk 
of relapse in patients. Conventional antidepressants are ineffective in restoring cognitive 
functions. Therefore, novel antidepressants with improved efficacy for ameliorating 
cognitive symptoms are required. Translational animal models are in demand for tailoring 
such antidepressants. The chronic mild stress (CMS) model is a well-validated preclinical 
model of depression and known for eliciting the MDD core symptom “anhedonia” in stress-
susceptible rats. Thus, cognitive performance was assessed in rats susceptible (depressive-
like) or resilient to CMS and in unchallenged controls. The rodent analogue of the human 
touchscreen Paired-Associates Learning (PAL) task was used for cognitive assessment. Both 
stress groups exhibited a lack of response inhibition compared to controls while only the 
depressive-like group was impaired in task acquisition. The results indicate general stress 
effects, as well as specific depression-associated effects on cognition in the CMS model. 
Hence, we propose that the application of a translational touchscreen task on an etiologically 
relevant, preclinical MDD model, displaying depression-associated cognitive impairments, 
provides a novel platform for pro-cognitive and clinically pertinent antidepressant drug 
screening. 
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Introduction 
Major depressive disorder (MDD) is the leading cause of disability worldwide affecting 300 
million people and constituting a major socio-economic burden to society1. The core 
symptoms of MDD are lack of energy, depressed mood and anhedonia, a decreased 
sensitivity or anticipation to reward2,3. Additionally, depressed patients can exhibit a plethora 
of other manifestations including feelings of guilt and worthlessness, altered sleep 
architecture, change in body weight, suicidal thoughts, or impairments in cognition, 
primarily in attention, executive function and memory4,5. After remission from the affective 
symptoms of MDD, these cognitive impairments still persist in 30–60% of patients4–7 and 
were found to be the longest present residual symptom8. Cognitive impairments are a major 
contributor to the disabling impact of MDD9 and, thus, in patients with persistent cognitive 
impairments quality of life is decreased and risk of relapse elevated4,10. Accordingly, 
treatment of depression associated cognitive impairments in addition to the affective 
symptoms is considered crucial for complete remission4,5,7,10.  
 Although many resources have been directed towards depression research, the causal 
mechanisms of MDD remain unknown due to a variety of symptoms emerging from the 
complex gene x environment interaction. A major environmental risk factor for developing 
MDD is the exposure to stress11. Stress can cause neuropsychological changes which can 
lead, in predisposed individuals, to an excessive or prolonged stress response and increased 
risk for mental diseases, such as depression11–13. The hypothalamic-pituitary-adrenal (HPA) 
axis is hyperactive in most MDD patients. Increased amounts of circulating glucocorticoids 
are released to cope with stressors and to endeavour maintenance of homeostasis. The 
hippocampus, which is central in memory formation, is sensitive to prolonged high levels of 
glucocorticoids. MDD patients show memory impairments and a decreased hippocampal 
volume, which is associated with the duration and number of depressive episodes14–18. Both, 
hippocampal atrophy and memory impairments might be a direct consequence of stress in 
MDD patients. Moreover, chronically elevated cortisol levels, as a consequence of prolonged 
stress exposure, can impair cognition in non-depressed individuals19. This highlights the 
possibility that stress is a causal factor in the development of depression-associated cognitive 
impairments. To gain further insight into the relationship of stress and cognitive impairments 
in depression, a preclinical stress model exhibiting depression associated cognitive 
impairments is indispensable6. A number of preclinical models of depression apply stressors 
(etiological validity) to provoke a depressive-like phenotype. Some milder paradigms, such 
as the chronic mild stress (CMS) model, also enable the segregation of a stress-resilient 
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subgroup, which allows investigation of distinct stress- and depression-related effects as well 
as the study of potential resilience mechanisms. Comparable studies are impossible in 
humans since stress intensity, nature and duration, as well as time point in life of stress 
experience, differ greatly between subjects. Depressed patients are often medicated and a 
“resilient” group with comparable stress experience is difficult to identify. These 
confounding parameters and obstacles are controlled for in preclinical MDD models 
applying defined stress paradigms. The CMS model, mimicking daily stress experience in 
humans, is a highly validated preclinical model of depression, well known for the 
manifestation of the MDD core symptom of anhedonia (face validity). Additionally, CMS 
exposed rats exhibit other depressive-like symptoms such as changes in sleep architecture, 
changes in body weight, decreased sexual activity and altered aggression behaviour20–22. 
Impaired CMS-induced working memory and increased conditioned contextual fear response 
were shown  with classical rodent behavioural tests20. Such studies indicated that impaired 
cognition is associated with a stress-induced or depressive-like phenotype. However, the 
translational value and clinical relevance of the classical behavioural tests used in these 
studies is poor. Therefore, a highly translational method, the touchscreen operant platform, 
for assessing cognition in rodents was applied in the present study. These touchscreen tasks 
were developed based on the Cambridge Neuropsychological Test Automated Battery 
(CANTAB), the most frequently applied cognitive test battery in MDD patients6. Further 
advantages of the rodent touchscreen platform include standardized experimental equipment 
and tasks, objective readouts, minimization of experimenter’s bias, a cognitive test battery 
and high throughput23,24. In the present study, we applied the different Paired-Associates 
Learning (dPAL) task which has been used in preclinical models of schizophrenia and 
Alzheimer’s disease, and is known for being a hippocampus-dependent task25,26. Hence, we 
investigated if the highly translational touchscreen platform is sensitive for detecting 
cognitive impairments in stress exposed rats. Furthermore, we determined if the impairments 
observed are the consequence of general stress exposure or specifically associated with the 
depressive-like phenotype by including stress-susceptible and stress resilient rats in the 
study. This will provide insight in the relationship of stress, mood (anhedonia) and cognitive 
symptoms. The aim of this study was to establish a clinically relevant platform for 
developing and tailoring pro-cognitive antidepressant treatments. 
 We hypothesized to observe cognitive impairments in both stress exposed groups in 
the dPAL task. Additionally we expected the stress-susceptible, depressive-like, rats to be 
impaired in a different cognitive area or more severely than the CMS resilient rats. These 
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cognitive impairments might possibly be observed in attention, executive function or 
memory. 
Results  
Hedonic state changes in response to stress 
Rats exposed to CMS segregated into anhedonic-like and resilient phenotypes based on their 
sucrose consumption test (SCT) index. The CMS groups responded differently to stress in 
respect to their sucrose consumption (interaction effect of group x weeks of CMS: χ2(16) = 
41.84, p = 0.0004; Figure 1). The CMS anhedonic-like group significantly decreased in 
sucrose intake over the course of stress exposure compared to non-stressed controls 
(Bonferroni-corrected group-wise comparisons p < 0.0001) and CMS resilient rats 
(Bonferroni-corrected group-wise comparisons p < 0.0001). The non-stressed control and 
CMS resilient group did not differ statistically significant from each other. The SCT results 
show that stress provoked clearly distinct phenotypes. Only a fraction of rats became 




Paired-associates learning touchscreen task 
Learning of the dPAL task 
Learning behaviour until attaining dPAL acquisition criterion was evaluated with summary 
statistics comparing non-stressed controls, CMS anhedonic-like and resilient rats. 
 Anhedonic-like rats might have needed more trials (Mean (M) = 1821.40 trials, SD = 
153.56) to acquire the dPAL task than controls (M = 1305.80 trials, SD = 176.11; trend in 
Figure 1. Sucrose 
consumption during CMS. 
The weekly sucrose 
consumption, normalised to 
baseline, is shown as group 
mean (± SEM). Statistically 
significant group-wise 
Bonferroni-corrected 
comparisons over all time 
points are indicted by 
***p < 0.001 (Control: 
n = 11, Resilient: n = 11, 
Anhedonic: n = 10). 
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main effect of group: F(2,26) = 3.26, p = 0.054; Figure 2A). Although the total number of 
correction trials to acquire the dPAL task was higher in the anhedonic-like group (M = 
1176.90 trials, SD = 263.90) than in controls (M = 953.90 trials, SD = 316.63) or resilient 
rats (M = 992.89 trials, SD = 192.67; Figure 2B), the difference was not statistically 
significant. 
 The time to collect the touchscreen reward pellet (collection latency) did not differ 
significantly between groups, nor did the median time to respond to the stimuli on the screen 
(response latency; Figure 2C) or the number of screen touches additionally to the one for 
making a choice (redundant screen touches per trial). 
 We examined the highest number of correct trials that the rats were able to carry out 
in a row within a session. This parameter was used to assess sustained attention and is in the 
following referred to as “maximum consecutive correct trials per session”. CMS anhedonic-
like rats carried out significantly more maximum consecutive correct trials per session (M = 
8.55 trials, SD = 0.24) than controls (M = 7.43 trials, SD = 0.29; LSD post-hoc p = 0.005; 
main effect of group: F(2,26) = 4.65, p = 0.019; Figure 2D).  

























































































































Figure 2. Summarized touchscreen parameters of dPAL task acquisition. (A) Absolute number of trials 
needed to pass the dPAL task. (B) Absolute number of correction trials needed for learning the dPAL 
task. (C) Median response latency to touchscreen stimuli. (D) Average number of maximum 
consecutive correct trials per session. Group means (± SEM) and individual results are shown. LSD 
post-hoc comparisons are indicated with *p < 0.05, **p < 0.01. 
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These results suggest that anhedonic-like rats have a different strategy for learning the 
touchscreen task compared to non-stressed controls and CMS resilient rats. Overall, CMS 
anhedonic-like, but not resilient rats, exhibited impaired learning behaviour. 
dPAL task acquisition over time 
The total number of trials (trials plus correction trials) required to learn the dPAL task was 
split into ten equal bins. Thus, the variable number of sessions, and consequently the total 
number of trials, between individual rats was normalised to ten time points (bins) for each 
rat. This permitted a more direct comparison of individual rats and the progress of different 
behavioural parameters in the learning task as well as statistical analysis with repeated 
measurements ANOVA. 
 The accuracy of learning (F(5.72,165.88) = 63.04, p < 0.0001; Figure 3A) and 
number of trials (F(2.76,80.10) = 46.91, p < 0.0001; Figure 3B) significantly increased over 
time with increasing bin number. No differences for these parameters were observed among 
groups. The number of correction trials (F(2.75,79.68) = 47.44, p < 0.0001) significantly 
decreased over time. There is therefore no apparent difference between groups on the 
performance in the learning phase of this task. 
 During the initial trials learning the dPAL task the CMS resilient rats executed more 
redundant screen touches than controls or CMS anhedonic-like rats (interaction effect of 
group x bin: F(5.04,73.12) = 3.35, p = 0.009; Figure 3C). Furthermore, the number of 
redundant screen touches per trial significantly decreased over time for all groups 
(F(2.52,73.12) = 10.92, p < 0.0001). 
 Interestingly, the CMS anhedonic-like animals executed more consecutive correct 
trials (M = 12.42 trials, SD = 5.99) than non-stressed controls (M = 10.58 trials, SD = 5.18; 
LSD post-hoc p = 0.016) or CMS resilient rats (M = 10.92 trials, SD = 5.25; LSD post-hoc 
p = 0.048; main effect of group: F(2,29)  = 5.64, p = 0.009; Figure 3D). 
 A trend in group x bin interaction was observed for collection latency (F(5.56,80.59) 
= 2.18, p = 0.058). Collection latency decreased significantly with increasing bin number 
(F(2.78, 80.59) = 9.07, p < 0.0001). 
 Median response latency also decreased significantly over time (F(3.13,90.64) = 
12.99, p < 0.0001). Maximum number of consecutive correct trials (F(4.78,138.75) = 17.16, 
p < 0.0001) significantly increased over time with increasing bin number. Both parameters 
indicate task improvement over the course of dPAL task acquisition. 
 These results show that all groups were able to learn the task over time, but 
differences in learning strategies between groups were evident. 
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Figure 3. Learning of the dPAL task over time. Total number of trials (trials plus correction trials) are 
split into bins of ten. (A) Accuracy over time. (B) Number of trials (black) and total number of trials 
(trials plus correction trials; grey). (C) Number of redundant screen touches per trial. Post-hoc 
comparisons compared to the CMS resilient group respectively are indicated by ***p < 0.001, **p < 
0.01, *p < 0.05, and controls versus anhedonic-like by #p < 0.06. (D) The maximum number of 
consecutive correct trials. LSD post-hoc comparisons between groups are indicted by *p < 0.05. Group 
means are shown (± SEM).  
Learning behaviour within the course of an average dPAL session 
All sessions of one animal were averaged to a single session. This session was then split into 
six equal blocks by the total number of trials (trials plus correction trials). This allowed for 
the analysis of learning behaviour within the course of a session. 
 Accuracy (Figure 4A) and number of trials were not significantly altered over the 
course of a session or between groups. However, the number of correction trials decreased 
significantly with increasing session block (F(5,145) = 3.18, p = 0.009). 
 Non-stressed controls executed less redundant touches per trial than CMS resilient 
and anhedonic-like rats in the first third of a session (interaction effect of group x session 
block: F(4.78,69.34) = 3.40, p = 0.009). The number of redundant touches per trial decreased 
within the course of a session (F(2.39,69.34) = 7.22, p = 0.0007; Figure 4B).  
 During the progression of a session, thus with increasing block number, maximum 
number of consecutive trials increased significantly (F(5,145) = 14.61, p < 0.0001; Figure 
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4C) as well as median response latency (F(1.59,46.16) = 10.19, p < 0.0001; Figure 4D). 
Collection latency varied with block number (F(3.22,93.38) = 2.25, p < 0.0001). 
 Thus within a session, primary readout parameters, like accuracy and number of 
trials, seemed not to change, but secondary parameters did, such as decreased number of 
correction trials and redundant touches, increased number of consecutive correct trials and 
median response latency. 
 
Figure 4. Learning parameters within the course of a session. (A) Percent of correct choices. (B) 
Number of redundant screen touches per trial. Post-hoc group-wise comparisons are indicated by **p 
< 0.01, *p < 0.05 comparing to the control group, respectively. (C) Maximum number of consecutive 
correct trials. (D) Average median response latency. Group means (± SEM) over the course of session 
blocks are displayed. 
 
Retention of the dPAL task assessing long-term memory 
Following dPAL acquisition and a 10-day hiatus, animals were retested on the dPAL task 
over two days to assess long-term memory performance. The final session of dPAL 
acquisition as well as the two retention sessions were included in the analysis (mixed model 
repeated measurements ANOVA). 
 Accuracy of performance was significantly decreased in the first retention session 
after the hiatus (M = 74.30%, SD = 6.42) compared to accuracy at time of acquisition (M = 
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80.27%, SD = 6.21; post-hoc p = 0.002). However, accuracy increased from the first 
retention session to the second retention session (M = 80.47%, SD = 5.83; post-hoc p = 
0.0001; main effect of session: χ2(9) = 16.17, p = 0.0003; Figure 5A). 
 Next, memory (difference in accuracy between the last session passing dPAL 
criterion and the first retention session) and relearning (difference in accuracy between the 
first and second retention session) were analysed separately with one-way ANOVA. Neither 
memory nor relearning performance differed statistically between groups. Individual 
changes in accuracy are shown in Figure 5B. 
 Hence, results show changes in performance due to the 10-day hiatus, but long-term 




In the present study, translational testing applying the touchscreen operant platform revealed 
cognitive impairments in the anhedonic-like, but not in the resilient subgroup of CMS 
exposed rats. This was mainly apparent from the trend that anhedonic-like rats appear to be 
Figure 5. Long-term memory and 
relearning performance in the dPAL 
task. (A) Accuracy is shown for the 
last session before the 10 d hiatus 
and the two retention sessions 
afterwards. Changes in group 
accuracy are displayed for memory 
(∙∙∙∙) and relearning (―). Passing 
criterion is indicated at 80% 
accuracy. (B) The rats’ individual 
changes in accuracy from last dPAL 
criterion session to the first 
retention session (memory) and 
first to second retention session 
(relearning). Group means (± SEM) 
and individual results are displayed. 
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slower at acquiring the dPAL task compared to controls, whereas resilient rats appear to 
required comparable time to learn the dPAL touchscreen task as controls. However, CMS 
resilient rats displayed increased impulsive behaviour, as suggested from a higher number of 
redundant screen touches, than non-stressed controls and anhedonic-like rats. This suggests a 
differential but still efficient learning ability in the resilient group compared to controls. The 
results show that the cognitive impairments are specific to the depressive-like phenotype 
making it an excellent model for testing antidepressant drugs aiming to target both 
depressive and cognitive symptoms of MDD. 
 To our knowledge, the use of translational touchscreen testing in depression and 
anxiety models is not established6 and, hence, the different parameters of touchscreen testing 
are discussed in detail here. 
 As shown previously27–29, CMS induces reduced reward sensitivity, which is 
demonstrated by reduced sucrose consumption in a subgroup of stress exposed rats, whereas 
another subgroup is resilient and remains hedonic. Reduced reward sensitivity is believed to 
be the biological underpinning of the MDD core symptom anhedonia30.  
 This study aimed to determine whether cognitive ability is altered in response to 
stress generally or specifically in association with the anhedonic-like phenotype, which 
appears more susceptible to the detrimental stress effects. The anhedonic-like rats tended to 
require more trials to acquire the dPAL task than non-stressed control rats, however, stress 
exposed resilient rats performed similar to controls. Hence, a trend of impaired learning 
seems specific to the depressive-like phenotype and not a consequence of stress exposure in 
general. Interestingly, the anhedonic-like group appears to split into two subgroups with 
respect to their touchscreen performance. Four rats needed evidently more trials than the 
remaining six rats of the group, which performed around the mean level of the resilient 
group (Figure 2A). These distinct performances within the anhedonic-like group may model 
that only a proportion of depressed patients display cognitive impairments. These findings 
potentially endorse the CMS model as preclinical model of MDD, because the cognitive 
impairments seem to be specifically associated with the incidence of anhedonia and not as a 
general consequence of CMS exposure. 
 It could be argued that prolonged dPAL acquisition in the anhedonic-like group is 
due to reduced motivation. However, reward collection latency did not differ between groups 
indicating similar motivation to consume the reward and perform the touchscreen task. 
Similarly, cognitive impairments in MDD patients are ascribed to deficits in cognition and 
not to a lack of motivation7,31. 
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 Median response latency did not differ significantly amongst groups although non-
stressed controls appear to take longer to respond than resilient and anhedonic-like rats 
(Figure 2C). A similar trend of prolonged response latency in the dPAL task was found in 
sham compared to hippocampus lesioned mice32. Furthermore, temporal deactivation of the 
dorsal hippocampus with lidocaine significantly decreased response time in the dPAL task 
accompanied with decreased accuracy33. These findings may suggest impaired hippocampal 
functioning of CMS exposed rats in the dPAL task. This is supported by another study from 
our group, in which non-stressed controls took longer to respond than CMS exposed rats in a 
pairwise discrimination touchscreen task29. Hence, we interpret increased response latency in 
non-stressed controls as more comprehensive cognitive appraisal before making an active 
response in the touchscreen task. 
 Surprisingly, on average, anhedonic-like rats were able to perform a higher number 
of maximum consecutive correct trials than non-stressed controls. This was also evident 
from the learning curve, where anhedonic-like rats executed more consecutive correct trials 
than controls and resilient rats although all three groups increased the number of consecutive 
correct trials in the course of learning. This finding is counterintuitive since anhedonic-like 
rats tended to show overall inferior performance in the dPAL task acquisition. Furthermore, 
the opposite result was found in the human continuous performance test where untreated 
MDD patients reached a lower score of correct responses than treated MDD patients or 
healthy controls indicating decreased vigilance34. Still, maximum consecutive trials is 
parameter that reveals cognitive differences between the CMS resilient and the depressive-
like phenotype. 
 The total number of correction trials needed to acquire the dPAL task was not 
significantly different between groups. However, anhedonic-like rats needed on average 
more correction trials than controls or resilient rats (Figure 2B), which might indicate 
learning deficits and is concordant with faster task acquisition in the controls and resilient 
rats. Regarding the learning curves, the number of correction trials decreased over time, as 
well as within a session, indicating improved task comprehension over time (Figure 3B). 
 Added numbers of redundant screen touches may suggest increased impulsive or 
habit-like behaviour and decreased control of executive function, which is a feature of the 
prefrontal cortex (PFC)35,36. The number of redundant screen touches per trial did not differ 
in summary statistic, although the average number of touches was lower in controls than in 
the two CMS groups. However, over the course of task acquisition resilient rats showed an 
increased number of redundant screen touches per trial, followed by anhedonic-like rats and 
then controls. This significant difference was evident in the beginning of dPAL learning and 
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diminished towards passing criterion in the dPAL task (Figure 3A). Similarly, within a 
session, the number of redundant screen touches decreased over time with controls executing 
the least number of redundant touches (Figure 4B). Ideally, we would expect only one touch 
per trial. Contrary to Talpos et al.26 suggesting that the dPAL task may not be sufficiently 
sensitive for detecting failures in response inhibition as an effect of LSD treatment, we 
suggest from our present findings that an increased number of redundant touches display a 
failure in response inhibition in CMS exposed rats. In a classical operant learning study, 
stress exposed rats shifted from effortful decision-making to increased habit-like behaviour, 
which was accompanied by atrophy in the medial PFC and associative striatum and 
hypertrophy in the sensorimotor striatum37. Dias-Ferreira et al.37 explained this behavioural 
shift as a coping strategy to avoid demanding, goal-directed behaviour during stress 
exposure. Thus, the present findings might suggest redundant screen touches as an indicator 
of utilization of different coping strategies and PFC functioning. Both CMS groups, 
especially the resilient group, seem to abandon demanding in favour of habitual behaviours 
whereas unchallenged controls confide to a greater extent on appraisal. 
 All groups showed a decrease in accuracy in the first retention session compared to 
their performance in the final dPAL session before the 10-day hiatus. Although the 
anhedonic-like group showed a greater decrease in accuracy (-13.6%) than CMS resilient (-
10.2%) or controls (-8.9%; Figure 5B), no effect of group on memory performance was 
observed, indicating intact long-term memory in the CMS groups or failure to reach 
significance due to the high variance, especially in the control group.  
 It was unexpected that there was no effect of stress or anhedonia on long-term 
memory. Formation of long-term memory and object-in-place tasks are hippocampus-
dependent38,39 and both are main components of the rodent dPAL task25. It was shown that 
dPAL retrieval is impaired in rodents with dysfunctional dorsal hippocampi33 as well as 
dPAL performance was impaired in mild cognitive impairment patients displaying altered 
hippocampal function in an fMRI version of the PAL task40. The hippocampal structure is 
known to be altered in depressed patients, e.g. decreased hippocampal volume in MDD 
patients, and memory is known to be impaired in these patients as well17,41. Moreover, subtle 
substructural changes in the hippocampus of CMS exposed rats exist42, neurogenesis is 
decreased in the dentate gyrus by CMS exposure and recovered after antidepressant 
treatment43. Hence, altered long-term memory in the CMS depressive-like group may have 
been expected in the dPAL task. However, CMS exposure commenced long before dPAL 
retention and alternative brain structures could have taken over the role of the hippocampus. 
This theory is supported by a study in which only post- but not pre-acquisition hippocampal 
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lesioning severely impaired dPAL performance in mice44. Furthermore, lesioning is a severe 
manipulation compared to general stress exposure and, thus, likely led to smaller effects in 
the present study. The finding by Kim et al.44 most likely explains why only minor 
impairments in hippocampus-relevant readouts were observed in the present study.  
 Another brain region that was shown to be involved in dPAL acquisition45 and 
altered in MDD patients46–48 is the PFC. In the present study, the increased number of 
redundant touches and the tendency of shortened response latency in the CMS groups 
indicate a lack of response inhibition, a function of the PFC. Hence, we conclude that the 
PFC was likely impaired by CMS exposure and such effects were observable in the dPAL 
touchscreen task.  
 Structural changes in the hippocampus16,17,49,50 and frontal cortex51–53 have been 
observed in depressed patients using neuroimaging. Consistent with this, preclinical imaging 
of CMS resilient and anhedonic-like animals suggests reorganization of the hippocampus 
depending on the hedonic state42. These findings are supported by our behavioural data 
showing an increased acquisition time of anhedonic-like rats in the hippocampus-dependent 
dPAL task. The present study has demonstrated that stress exposure directly induced 
cognitive impairments, especially in susceptible individuals. This may shed more light on the 
causal relationship of stress as a risk factor in disease development. 
 The behavioural changes observed in the present study were salient in visuo-spatial 
learning and attention. These processes appear to be a major contributor to disability in life 
functioning in humans even after half a year of remission from depression7. Hence, the 
present study is of high clinical relevance. Moreover, we applied chronic stress, which is a 
major risk factor in MDD, to provoke a depressive-like phenotype. Thus, clinical relevance 
and translational value of the present study is further supported. 
 
A limitation of the present study is that the SCT test was abandoned during the touchscreen 
testing due to the sugary touchscreen pellets desensitising the rats for consumption of a 
dilute 1.5% sucrose solution. Hence, anhedonic-like rats could have recovered from their 
depressive-like state. However, it is known that rats recover spontaneously only after 4–5 
weeks following cessation of CMS21. Furthermore, it is likely that the continuation with a 
modified CMS protocol during touchscreen testing delayed spontaneous recovery. Moreover, 
food restriction accompanying touchscreen testing may have added to the delaying effect of 
the modified CMS protocol. Muscat and Willner54 have shown that a two-week over-night 
stress protocol elicited comparable hedonic phenotypes as the original CMS protocol. They 
applied similar over-night stressors as in our modified CMS protocol. Hence, it appears 
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likely that spontaneous recovery after cessation of the original CMS protocol was prevented 
by the modified version in the present study. 
 Another limitation is that baseline cognition was not assessed in the rats before stress 
exposure commenced for logistic reasons, thus we cannot exclude that a cognitive 
predisposition directed the development of a certain stress phenotype.  
 
In summary, the present study demonstrated that cognitive impairments tend to be 
specifically associated with the depressive-like phenotype. These impairments were not a 
result of lacking motivation but can be attributed to cognitive deficits. In both CMS groups, 
response inhibition was impaired indicating deficits in executive functions as result of stress 
exposure. Surprisingly, anhedonic-like rats showed superior sustained attention, which was, 
however, not reflected in their overall performance. Furthermore, outcomes of the stress 
resilient group revealed differences in cognitive strategies compared to the depressive-like 
group, which potentially may be integrated in human studies and therapy. 
 To our knowledge, this is the first study to show that the touchscreen dPAL task can 
potentially be applied to detect depression-associated cognitive impairments in a preclinical 
MDD stress rat model. Accordingly, the present study suggests CMS anhedonic-like rats, 
assessed with touchscreen tasks, as a translational, standardized and well-validated platform 
for developing and screening novel pro-cognitive antidepressant treatment regimens, which 
are deemed necessary for obtaining higher remission rates of MDD and reducing risk of 
relapse. 
Materials and Methods 
Animals 
Male Long Evans rats (LE; Janvier Labs, France) were 5–6 weeks and 100–120 g at arrival 
to our facility. Originally, 174 LE rats (n (control) = 24, n (CMS) = 150) were purchased and 
used for different studies.  
Animals were housed four per cage for one week and afterwards they were single-housed. 
Rats were kept on a 12-h light/dark cycle (lights on at 6:00 am) with free access to food and 
water (otherwise stated). All experiments were conducted according to and approved by the 
Danish National Committee for Ethics in Animal Experimentation (2013-15-2934-00814). 
A timeline of the experiment is shown in Figure 6.  
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Figure 6. Experimental timeline. Depiction of the different stages of the experiment and their duration. 
Touchscreen pre-training included 8 days of gradual food restriction to 80% of ad libitum intake, 
followed by operant conditioning in the touchscreen setup. The acquisition of the touchscreen dPAL 
task was conducted until passing criterion was reached and retention was determined in two 
additional dPAL sessions after 10-day hiatus without testing. (SCT–sucrose consumption test, CMS–
chronic mild stress, dPAL–different paired-associates learning, Ø–average time for rats to learn the 
relevant stage). 
 
Chronic Mild Stress paradigm 
Baseline sucrose consumption test 
The SCT was carried out to assess the rats’ hedonic state during stress exposure. Animals 
were acclimatized to the facility for one week. In the next two weeks, rats were habituated to 
SCTs by drinking a palatable sucrose solution (1.5%) semi-weekly for 1 h following 14 h of 
food and water deprivation. Thereafter, weekly SCTs were carried out twice and averaged to 
a baseline sucrose consumption for each rat individually (Figure 6). Animals were split in 
two groups with equal group mean and standard deviation (SD) of their baseline sucrose 
consumption. CMS exposure was initiated for one of the groups and the other group was 
housed in a separate room and left unchallenged. Weekly SCTs were conducted throughout 
the CMS paradigm. 
CMS paradigm and hedonic state 
Rats entering the CMS paradigm were exposed to a series of stressors lasting between 5–14 
h43. Stress duration and type of stressors were varied across a two-week protocol (Figure 7) 
to increase unpredictability of stressors and avoid habituation. During the stressor 
“grouping”, a CMS rat was transferred to the home cage of another CMS rat (resident-
intruder). Grouping partners were exchanged weekly and individual rats were alternated in 
being resident or intruder. After 10 weeks of CMS, the stress exposed group was divided in 
subgroups depending on their sucrose index (mean of last two SCTs during CMS / baseline 
SCT). Rats were categorized as stress-susceptible, thus anhedonic-like, with a SCT index ≤ 
0.7 and as stress resilient with a SCT index ≥ 0.9 based on an a priori criteria used in 
previous studies21. Rats with a change in sucrose consumption in between these marginal 
phenotypes were excluded. According to these criteria, approximately 19% of CMS rats 
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showed a resilient phenotype and 41% an anhedonic-like phenotype. Consequently, 58 rats 
would have been needed to undergo the CMS paradigm to obtain the number of rats 
subjected to this touchscreen study. 
 Once touchscreen training began, the CMS protocol was modified (Figure 7) to 
avoid interference with training. Food and water deprivation were abandoned since this 
would be a confounding factor on the motivation for obtaining sugar pellet rewards, 
furthermore stressors were only applied during the night. 
 
 
Figure 7. Original and modified two weeks CMS protocol. The listed stressors were applied for the 
duration (h) indicated by the respective number. Black bars show the original stress protocol and 
white bars the touchscreen adapted CMS protocol. Crosshatched bars indicate that these stressors 
were applied in the second week of the two-week repeated schedule replacing the black bars shown 
for the same time point. The SCT and the 14 h food and water deprivation on day 4–5 were applied to 
the stress as well as control group. 
Touchscreen operant platform 
Learning and memory was assessed with the translational touchscreen platform applying the 
PAL task. 
Apparatus 
The Bussey-Saksida operant chambers (Campden Instruments Ltd., Loughborough, UK) are 
sound- and light attenuated boxes including a trapezoid shaped interior (height 300 mm, 
length 332 mm, width screen 240 mm, width magazine 126 mm). A touch-sensitive screen 
was covered by a mask leaving three windows open (height 100 mm, width 60 mm) and built 
in opposite a reward delivery system (magazine). A spring-hinged shelf (90°) was installed 
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below the mask windows to slow the rat down before touching the screen and avoiding hasty 
choices. The chambers were further equipped with a house and magazine light, a metal grid 
floor, a tone generator and a fan, which ensured sufficient ventilation and masked external 
noise. The touchscreen program was controlled by Whisker Server Abett II (Campden 
Instruments Ltd.). 
Touchscreen pre-training 
Initially rats were pre-trained using the touchscreen setup before learning the actual dPAL 
task. Rats were food restricted to reinforce operant conditioning. Food was gradually 
decreased by 5% every second day to 80% of free feeding consumption. On the last two 
days, rats were habituated to consume five touchscreen reward pellets (sugar coated, 45 mg 
dustless precision pellets, Bio Serv, Flemington, NJ, USA) in their home cage. Body weight 
was monitored daily. Touchscreen training was carried out every day during the light phase 
in a session of 45 min or 75 trials maximum (except for “habituation” step). All rats were 
moved to the testing room 30 min prior to touchscreen training. Pre-training consisted of five 
steps24. First, in the “habituation” step, rats were left in the touchscreen box with house light 
off for 30 min and had to consume five reward pellets from the food magazine. Second, 
“initial touch”, rats automatically received one reward pellet every 30 s or three reward 
pellets if the rat touched the stimulus (randomly, one of the three touchscreen windows was 
illuminated). Reward collection was followed by a 20 s inter-trial-interval (ITI) after which 
the next trial would automatically start. Rats were moved on to “must touch” if they touched 
the stimulus ≥ 30 times in one session (passing) or, alternatively, if they touched the stimulus 
≤ 5 times per session on two consecutive days (failing). In “must touch”, the rat had to touch 
the stimulus in order to receive a reward pellet. If the rat was new to “must touch” or had 
less than 40 touches the day before, peanut butter was introduced to each screen window 
prior to session start to draw attention to the screen. If the rat touched the stimulus ≤ 5 times 
per session on two consecutive days (failing), it was moved back to “initial touch” (only if it 
had failed “initial touch”) or passed on to “must initiate” if it touched the stimulus 75 times 
within a session. “Must initiate” was similar to “must touch”, additionally the rat had to 
initiate each trial by nose poking in the food magazine. Finally during “punish incorrect”, a 
touch on the two non-illuminated windows on the screen resulted in a 5 s time-out period 
with house light on, followed by the ITI. To pass, the rat had to accomplish 75 trials within 
45 min with at least 60 correct touches to the illuminated window (≥ 80% accuracy) for two 
consecutive days. The rat was stressed again for 3 h (“grouping”) the day following pre-
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training as a reminder of the original stress protocol and hence received one day without 
touchscreen testing. 
Different paired-associates learning task 
dPAL training24 began the day after grouping. In this task, three symbols (white on black 
background) should be associated with one of the touchscreen windows, respectively (Figure 
8A). A session followed the same rules as in “punish incorrect”, but instead of one 
illuminated and two blank windows in each trial, two windows displayed two of the three 
symbols. One of the symbols would be in its correct window, whereas the other one in an 
incorrect window. The remaining window was left blank (Figure 8B). This resulted in six 
different experimental trials, which were randomly balanced within a session. A correct 
response was registered if the rat touched the symbol that was displayed in the correct 
location. An incorrect response was followed by a 5 s time-out with house light on. After the 
ITI, a correction trial was initiated, meaning the previous incorrectly responded trial was 
displayed again. If the rat responded incorrectly to the correction trial, another one would be 
displayed until the rat managed a correct choice. Criterion to pass was accomplished by 
completing 75 trials (not counting correction trials) within 45 min, with 80% accuracy, on 
two consecutive days. 
 
Retention 
Passing dPAL was followed by 10 days without touchscreen testing and an increase in food 
accounting for the lack of reward pellets. After the 10-day hiatus, rats were retested on the 
dPAL task for two days. 
Statistical Analysis 
SCT data were analysed without the baseline SCT applying mixed effects model for repeated 
measurements with post-hoc Bonferroni-corrected pairwise group comparisons. dPAL 
Figure 8. Different paired-associates 
learning task scheme. (A) Each symbol is 
shown in its correct location (L): spider-
L1, plane-L2, flower-L3. (B) An example 
trial is displayed with one symbol (spider) 
in its correct location, and one symbol 
(plane) in an incorrect location. 
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summary statistics was evaluated with Shapiro-Wilk test for residual normality and Levene’s 
test for homogeneity of variance with non-significant results allowing for statistical analysis 
by ANOVA and LSD post-hoc analysis. dPAL repeated measurements data were analysed 
using univariate repeated measurements ANOVA and Greenhouse-Geisser correction if 
sphericity was violated. Retention was analysed applying multivariate repeated measures 
ANOVA. Moreover, memory and relearning performance were analysed by one-way 
ANOVA, and assumption of normality and homogeneity were reviewed. Rats that did not 
pass the dPAL task were removed from summary statistics and retention only (two CMS 
resilient and one control rat). Data of summary statistic and retention were analysed for 
outliers with Grubb’s test (α = 0.05) and ROUT test (Q = 1%; GraphPad Prism 6, GraphPad 
Software Inc., California, USA) and revealed no outliers. Statistical analysis was conducted 
with RStudio (RStudio Inc., Massachusetts, USA) and rdata.online (Montreal, Canada). Data 
was displayed with GraphPad Prism 5. 
Data availability 
The datasets generated and analysed during the current study are available from the 
corresponding author on reasonable request. 
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Abstract 
Depression-associated cognitive impairments affect daily functioning in major depressive 
disorder (MDD). Furthermore, cognitive impairments are the most prevalent and persistent 
symptom during remission from a depressive episode and thus increase the risk of relapse. 
Consequently, development of antidepressant drugs alleviating cognitive impairments is 
vital. The multimodal antidepressant drug, vortioxetine, has been approved for having a pro-
cognitive effect on top of mitigating the affective symptoms of depression. In the present 
study, chronic mild stress (CMS) exposed, anhedonic-like rats were submitted to chronic 
treatment with vortioxetine. In more than half of the treated rats, the affective symptom, 
anhedonia, was relieved. These treatment high responders as well as low responders, 
untreated anhedonic-like and non-stressed controls were subjected to translational 
touchscreen testing for assessing their cognitive performance. Rodent touchscreen testing 
was developed based on the human Cambridge Neuropsychological Test Automated Battery 
(CANTAB) test battery, the most frequently used tool for assessing cognition in depression 
research. Our data show that vortioxetine improves some aspects of learning, but not 
memory performance. Notably, vortioxetine induces a shift from appraised cognitive 
evaluation to stereotypic, habit-like behaviour in the touchscreen paired-associates learning 
task. To supplement the observed neurobehavioral results, expression of genes important for 
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stress responses, neuropsychiatric disorders and synaptic plasticity were investigated. Minor 
alterations in prefrontal cortex and hippocampal gene expression patterns were found in 
association with anhedonia or vortioxetine treatment. The present study benefits from using 
clinically relevant approaches, such as the CMS paradigm and translational touchscreen 
testing. In summary, our findings suggest vortioxetine mediates an antidepressant-like effect 
in the validated CMS model and affects cognition in some domains, but further 
investigations are needed to clarify this further. 
1 Introduction 
Worldwide, around 300 million people suffer from depression, constituting major depressive 
disorder (MDD) as the leading burden of disability worldwide1 and additionally impacting 
the patients’ socio-economic environment. The relapsing nature of the disease as well as the 
insufficient treatment responses of only 50%, to a two-step treatment regimen, add to the 
devastating burden of the disease2. Core symptoms of MDD are lack of energy, depressed 
mood and an attenuated anticipation or experience of pleasure (anhedonia). Additionally, 
patients suffer from a variable number of associated symptoms, such as impaired cognitive 
abilities, primarily in attention, executive functions and memory. These cognitive symptoms 
persist in 30–60% of treated patients after remission from the affective MDD symptoms. 
Furthermore, cognitive impairment is the most persisting residual symptom of depression 
and, hence, it continues to decrease daily functioning and quality of life after remission3–6. 
Moreover, persistent cognitive impairment augments risk of relapse and is increasingly 
regarded as core component rather than an epiphenomenon of depression7,8. Recovering from 
cognitive symptoms is associated with a rapid remission from depression9, further 
underlining the importance of restoring cognitive impairments when treating depression.  
 However, current antidepressant treatment focuses mainly on alleviating the 
affective state, thus, neglecting cognitive impairments10. Treated MDD patients show 
improved cognitive performance compared to untreated patients, but fail to accomplish the 
performance level of healthy controls11. Therefore, development of novel, pro-cognitive 
antidepressants are vital for complete remission of MDD. Thus, the demand is high for 
clinically relevant drug screening in a well-validated preclinical depression model exhibiting 
depression-associated cognitive impairments. In a previous study (Martis, L.-S., Brision, C., 
Holmes M., Wiborg O.; unpublished data), we demonstrated that the chronic mild stress 
(CMS) paradigm fulfils exactly these criteria. The CMS model is well known for exhibiting 
the MDD core symptom anhedonia (face validity) evoked by stress exposure (etiological 
validity). Additionally, CMS anhedonic-like rats display depression-associated cognitive 
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impairments. They take longer to acquire a translational touchscreen task than non-stressed 
controls. Hence, cognitive impairments are specific to the depression-like phenotype and in 
the present study we follow up by assessing the novel antidepressant drug vortioxetine in the 
CMS model.  
 Vortioxetine was approved in 201312. On top of alleviating mood symptoms, a direct 
pro-cognitive effect was ascribed to vortioxetine via its multimodal mechanism of action13. 
Vortioxetine operates as a serotonin (5-HT) transporter (SERT) inhibitor; 5-HT3, 5-HT7 and 
5-HT1D receptor antagonist; 5-HT1B receptor partial agonist and 5-HT1A receptor agonist14. In 
rodents, vortioxetine improves spatial working memory, visuo-spatial memory and 
contextual fear memory besides increasing synaptic plasticity and decreasing behaviour 
despair15–19. In MDD patients, executive functions, attention, speed of processing, verbal 
learning and memory functions, as well as affective symptoms, have been shown to be 
recovered by vortioxetine treatment20. The CMS model shows good predictive validity with 
antidepressant, such as desipramine or escitalopram21,22 and thus, we investigated in the 
present study if vortioxetine can restore the hedonic phenotype of CMS exposed, anhedonic-
like rats. Furthermore, cognition of non-stressed controls, untreated and vortioxetine treated 
CMS anhedonic-like rats was assessed in the different paired-associated learning (dPAL) 
touchscreen task, a standardized and translational tool in clinical as well as in preclinical 
research23,24. The rodent touchscreen platform involves appetitive operant condition and was 
developed based on the human Cambridge Neuropsychological Test Automated Battery 
(CANTAB); the most frequently applied cognitive assessment tool in depression research4. 
Finally, hippocampal (HPC) and prefrontal cortex (PFC) gene expression was analysed to 
link neurobehavioral alterations with underlying molecular changes. Genes that are known to 
play a role in MDD and psychiatric disorders and/or the stress response, such as the 
mineralocorticoid receptor (Mr), glucocorticoid receptor (Gr), FK506 binding protein 5 
(Fkbp5), glycogen synthase kinase 3 beta (Gsk3b), disrupted in Schizophrenia 1 (Disc1), 
homer scaffolding protein 1-3 (Homer1-3) and brain-derived neurotrophic factor (Bdnf) as 
well as genes important in cognition and neuronal plasticity, such as neuroregulin 1 (Nrg1), 
Shank 1-3, Spinophilin and Cofilin 1 were analysed.  
 In short, this study aimed to investigate the effect of vortioxetine on the affective 
state, cerebral gene expression and cognitive performance in a translational touchscreen task. 
Furthermore, the relationship between the affective state and cognitive functions was 
evaluated. 
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2 Materials and Methods 
2.1 Animals 
Male Long Evans (LE) rats (n = 242; Janvier Labs, France) were 5–6 weeks of age weighing 
100–120 g at arrival in our facility (Translational Neuropsychiatry Unit, Aarhus University). 
Rats were acclimatized housed in groups of four for one week, followed by single housing 
for the remainder of the experiment. Animals had free access to food and water (otherwise 
stated) and kept on a 12 h light-dark cycle (lights on at 6 am). All experiments were 
conducted according to and approved by the Danish National Committee for Ethics in 
Animal Experimentation (2013-15-2934-00814). 
2.2 Chronic mild stress paradigm 
2.2.1 Sucrose consumption test 
Sucrose consumption tests (SCTs) were carried out to assess the hedonic state of each rat 
during stress exposure and antidepressant treatment. First, animals were habituated to drink a 
palatable sucrose solution (1.5%) by exchanging their regular drinking water with sucrose 
solution for 15 h in one week and for 1 h in the following week. The 1 h exposure was 
preceded by a 14 h food and water deprivation. Thereafter, three weekly baseline 
measurements were conducted (1 h SCT following 14 h of food and water deprivation) and 
averaged to a SCT baseline for each rat individually. After removing animals with a baseline 
≤ 10 mg due to a potential floor effect, rats were split (same baseline group mean and SD) in 
a control (n = 44) and CMS group (n = 175). Stress exposure for the latter group commenced 
after SCT baseline acquisition. Weekly SCTs were continued throughout the experiment. In 
the following, SCT indexes (SCT normalised to baseline) were used to determine CMS 
susceptible, i.e. anhedonic-like, rats and eventually high and low responders to 
antidepressant treatment. For clarification of the experimental pipeline, a simplified outline 
is illustrated in Figure 1.  
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Figure 1. Simplified experimental pipeline. Sucrose consumption tests (SCTs) were conducted 
throughout the experiment to measure baseline sucrose intake, alterations in sucrose consumption 
due to chronic mild stress (CMS; determining anhedonic-like rats) and subsequent antidepressant 
treatment with vortioxetine (determining the 30% highest and lowest responders to treatment). SCTs 
also revealed the rats  response to touchscreen testing, which included food reduction, pre-training, 
dPAL task acquisition and retention. Brains were collected for gene expression studies at the end of 
the behavioural testing. 
2.2.2 Stressors 
The CMS paradigm was initiated after the third SCT baseline measurement (Figure 1) and 
the animals’ body weight was monitored weekly. Rats placed in the CMS group were 
exposed to several mild stressors in a 2-week repeated protocol (Table 1) to provoke a 
depressive-like phenotype. Variation of stressor duration and exposure time point increased 
the unpredictability of the stressors, hence, decreased habituation to the stress protocol. 
 
 
Table 1. Two-week chronic mild stress (CMS) protocol. Mild stressors and their duration are shown. 
Duri g groupi g , o e CMS rat i truder  as i trodu ed to the ho e age of a other CMS rat 
(resident). Grouping pairs as well as acting as resident or intruder was alternated weekly. 
 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
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*For CMS and non-stressed controls, +Alternating weekly. 
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 After five weeks of CMS, stress exposed rats with a SCT index (SCT/baseline SCT) 
≤ 0.7 for both, the last SCT and the average of the last two SCTs were categorized 
anhedonic-like according to an a priori cutoff25,26 and remained in the study together with 
the non-stressed control rats (SCT index ≥ 0.9). 
 After nine weeks of CMS, a modified CMS protocol was applied to adjust for 
touchscreen training during daytime (Figure 1). The stressors “water and/or food 
deprivation” were removed from the modified CMS protocol to avoid interference with the 
touchscreen food reward and food deprivation accompanying touchscreen training. 
Furthermore, stressors were only applied during the night leaving the day for touchscreen 
assessment. Every Friday, the SCT was carried out followed by 4 h of grouping and light 
stressors. Thus, touchscreen testing was discontinued for that day. The modified CMS 
schedule (Supplementary Table 1) was changed every second week to prevent habituation to 
the milder stress protocol. 
2.3 Drug administration 
After five weeks of CMS, two-thirds of the 54 anhedonic-like animals (i.e. 34 rats with an 
average SCT index of week four and five ≤ 0.7) were treated with the antidepressant 
vortioxetine (Figure 1). Standard rat chow (Altomin 13324, Brogaarden, Denmark) was 
supplemented with vortioxetine (Carbosynth Ltd., UK) at a concentration of 1.8 g/kg rat 
chow. The original CMS paradigm was continued during treatment for all anhedonic-like 
rats for four more weeks. Then, treated rats were subdivided into high responders 
(responders; the 30% of animals with the greatest recovery determined by the weekly SCT 
indexes, i.e. n = 10) and treatment poor responders (low-responders; the 30% of animals with 
the lowest response to treatment determined by the weekly SCT indexes) and subjected to 
touchscreen testing. 
2.4 Touchscreen operant platform 
2.4.1 Apparatus 
The sound- and light-attenuating Bussey-Saksida touchscreen operant chambers (Campden 
Instruments Ltd., Loughborough, UK) contained a trapezoid shaped interior (height 300 mm, 
length 332 mm, width screen 240 mm, width magazine 126 mm). A touch-sensitive screen 
was located at the wide side of the interior box and a reward delivery system (magazine) at 
the opposite small side. A mask covered the touchscreen leaving only three windows (100 x 
60 mm) for the rat to touch the screen. A spring-hinged shelf (90°) in front of the mask 
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slowed the rats down preventing hasty and unconsidered choices to the screen. A fan ensured 
sufficient ventilation and masking of external noise. The chambers were further equipped 
with a grid floor, house and magazine light, and a tone generator. The touchscreen program 
was controlled by Whisker Server and Abett II software (Campden Instruments Ltd.). 
2.4.2 Food reduction and touchscreen pre-training 
Three baselines of ad libitum food intake were obtained for each rat. Rats were gradually 
food deprived to 75% of their individual baseline consumption (Table 2). The rats’ body 
weight was monitored daily to ensure they maintain at least 90% of their body weight during 
food deprivation. Additionally, rats were introduced to peanut butter (Bilka, Denmark) and 
bacon pellets (45 mg dustless precision pellets, Bio Serv, Flemington, NJ, USA) used for 
operant conditioning during touchscreen testing. 
Table 2. Gradual food restriction regime prior to touchscreen pre-training. Parallel to food restriction, 
rats were habituated in their home cage to peanut butter (PB) as well as to bacon pellets (BP) used as 
reward in touchscreen (TS) testing.  
Day of food restriction 1 2 3 4 5 6 7 8 TS 1 
% of baseline food intake 95 95 90 90 85 80 80 75 75 
Habituation to      BP BP PB PB 
 
Pre-training began after day eight of food restriction. In four steps, the rats were conditioned 
to operate the touchscreen chamber (Figure 2). Each rat was tested once daily Saturday to 
Thursday with a session lasting maximum 45 min or 75 trials. In the first pre-training step, 
“initial touch”, rats received automatically a bacon pellet after 30 s of stimulus presentation 
(randomly one of the three windows was illuminated). Three instead of one reward pellet 
would appear if the rat touched the screen during stimulus presentation. Reward pellet 
dispensation always coincided with stimuli disappearance, a tone and food magazine 
illumination throughout touchscreen assessment. After reward collection a 20 s inter-trial-
interval (ITI) started. A new trial followed. Rats passed “initial touch” by executing 30 or 
more screen touches. Rats, which failed to touch the screen, were also moved on to the next 
step to encourage them in an active participation and with the option to return them to 
“initial touch” (Figure 2). In “must touch”, rats had to touch the screen to receive one reward 
pellet. Before session start, peanut butter was applied to all three windows to attract the rats 
to the screen. Peanut butter was not applied anymore if rats completed ≥ 40 trials in a 
previous “must touch” session. Rats passed by completing 75 screen touches, thus 75 trials, 
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within 45 min. Rats with a low number of trials were moved back to “initial touch” to 
increase their motivation if they had not passed “initial touch” before (Figure 2). In the third 
step “must initiate”, rats had to initiate each trial after the ITI by poking into the illuminated 
food magazine. Otherwise, the trial followed the concept of “must touch”. Finally, in “punish 
incorrect”, rats only received the reward touching the illuminated window. A touch to a 
blank window was punished by a 5 s time out interval with house light on and followed by 
the ITI. Such an incorrect trial was ensued by a “correction trial” in which the same window 
as before was illuminated. Passing “punish incorrect” by completing 75 trials (excluding 
correction trials) within 45 min with at least 60 correct choices (≥ 80% accuracy) on two 
consecutive days equalled the end of pre-training.  
 Rats were kept on 80% of their baseline food intake for pre-training and the dPAL 
task. Only during initial touch, food was reduced further by 5% accounting for the high 
availability of reward pellets during this step.  
 
Figure 2. The four stages of touchscreen pre-training (1-4). Passing criteria to move on to the next 
stage are indicated next to the arrows. Peanut butter was added to the screen when the rat entered 
ust tou h  or if it perfor ed ≤ 40 tou hes i  the last ust tou h  sessio . 
2.4.3 Paired-associates learning touchscreen task 
Cognitive performance was assessed applying the dPAL task. The rat had to associate a 
symbol (white on black background) with a specific location on the touchscreen. In each 
trial, only two of the three symbols (spider, flower, plane) would be displayed, one at its 
correct location (S+) and the other symbol at an incorrect location (S-). The third window 
was left blank (Figure 3). A touch to S+ resulted in reward pellet delivery followed by the 
ITI. S- was ensued by a 5 s time out with house light on, the ITI and a correction trial. The 
six trial types resulting from the stimulus-location association pairs were balanced over the 
course of a session. dPAL criterion was achieved by completing 75 trials (excluding 
correction trials) with at least 60 correct trials (≥ 80% accuracy) within 45 min on two 
consecutive days. Rats that did not acquire the task within 46 session were marked as failing 
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the task by an a priori criterion from a previous study (Martis, L.-S., Brision, C., Holmes, 
M., Wiborg, O.; unpublished data). 
 
2.4.4 Retention of the dPAL task  
Passing the dPAL task was ensued by a 10-day hiatus without touchscreen testing and an 
increase in food substituting for the touchscreen pellet deficiency. Next, rats were re-tested 
on the dPAL task for two days assessing long-term memory. 
2.5 Cerebral gene expression 
2.5.1 Tissue collection 
Rats were decapitated within 1–3 days (Mean = 1.3 days) after completing the dPAL 
retention testing. Culling took place in the afternoon (2–4 pm) and the last feeding the day 
before at 1 pm. The brain was removed. Prefrontal cortex (PFC), dorsal and ventral 
hippocampus (HPC) were collected and frozen with powdered dry-ice immediately. 
2.5.2 RNA extraction and cDNA synthesis 
Tissue was stored at -80 °C until extraction of RNA with the ParisTM RNA and protein 
isolation kit (Ambion, TX, USA). The isolation procedure is well-established in our 
laboratory and was processed as previously described27. The RNA concentration and the 
purity were determined by a NanoDrop 1000 spectrophotometer (Thermo Fischer Scientific, 
Delaware, USA). Before cDNA synthesis, the RNA concentration of the samples was 
adjusted to match the sample with the lowest concentration determined by the NanoDrop 
spectrophotometer. RNA was reversely transcribed using random primers and Superscript IV 
Reverse Transcriptase (Invitrogen, CA, USA) following manufacturer’s instructions and 
with a RNA input concentration per reaction of 129 ng/µl and 12.8 ng/µl for PFC and HPC, 
respectively. The cDNA samples were stored undiluted at -80 °C until quantitative real-time 
Figure 3. The different paired-associates learning 
task s o je t-location association pairs. (A) The 
three symbols are shown in their correct 
location (L) on the touchscreen (Spider-L1, 
Plane-L2, Flower-L3). (B) An example trial of the 
six possible trial types. The spider is displayed in 
its correct location L1 (S+), whereas the plane is 
presented in an incorrect location (S-). The third 
window is blank.  
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polymerase chain reaction (real-time qPCR) analysis. Samples from PFC were diluted 1:48 
and samples from HPC 1:10 with DEPC-treated water prior to real-time qPCR analysis. 
2.5.3 Real-time qPCR  
Real-time qPCR was carried out on individual samples in 96-well PCR-plates using the 
Mx3005P (Stratagene, La Jolla, CA, USA) and SYBR Green as described previously28. The 
gene expression of eight different reference genes (18s rRNA, ActB, CycA, Gapd, Hmbs, 
Hprt1, Rpl13A and Ywhaz) and 15 different target genes (Gr, Mr, Bdnf, Fkbp5, Disc1, 
Gsk3b, Nrg1, Shank1-3, Homer1-3, Spinophilin and Cofilin 1) were investigated. Essential 
gene specific data about primer sequence and amplicon sizes are given in Supplementary 
Table 2. Briefly, each SYBR Green reaction (10 μl total volume) contained 1 × SYBR Green 
master mix (Sigma-Aldrich, St. Louis, MO, USA), 0.5 μM primer pairs, and 3 μl of diluted 
cDNA. The thermal conditions for the PCR were 3 min at 95 °C to activate the hot-start 
iTaqDNA polymerase, followed by 40 cycles of 10 s denaturation at 95 °C, 30 s annealing at 
60 °C, and 60 s extension at 72 °C. Each run was completed by dissociation curve analysis to 
confirm the amplification specificity and absence of primer dimers. A standard curve 
performed in duplicate was included on each plate. For data normalization, we first measured 
mRNA levels for the reference genes. Stability comparison of the expression of the eight 
reference genes was conducted with the Normfinder software (http://www.mdl.dk)29 and the 
best combination selected. Values for each individual were normalized with the geometric 
mean of the reference genes ActB and Rpl13A (PFC) as well as Hprt and CycA (HPC), 
respectively. 
2.6 Statistical Analysis 
SCT data were analysed with univariate repeated measurements ANOVA and group 
comparisons were Bonferroni corrected. SCT data are displayed and were included in the 
analysis until the time point when the first animal completed the experiment and took no 
longer part in the SCTs.  
 Number of redundant screen touches resembles the amount of additional screen 
touches per trial to the one needed to make a choice. Redundant number of screen touches 
were normalised to the total number of trials (trials plus correction trials). 
 Summary statistics of the dPAL task (3.2.1) were analysed applying two-way 
ANOVA (hedonic state x treatment) or by rank aligned two-way ANOVA if assumptions of 
normality (assessed with QQ-plots) or homogeneity of variance (assessed with Bartlett’s 
test) were violated. Animals that did not acquire the dPAL task within 46 sessions (one 
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control, three anhedonic-like rats, one responder, one low-responder) had to be excluded 
from this analysis due to missing data points, e.g. number of trials needed to acquire the task. 
Furthermore, outliers determined by Grubbs (α = 0.05) or ROUT (Q = 1%) test (Prism 6, 
©2012 GraphPad Software Inc., California, USA) were excluded. 
 Repeated measurements data analysing learning behaviour across the task (3.2.2) 
and learning behaviour within a session (3.2.3) included all animals (acquiring and failing 
dPAL acquisition). The data were analysed with repeated measures ANOVA of type III if 
significant interaction effect was present, otherwise with type II. Mauchly’s sphericity test, if 
significant, led to Greenhouse-Geisser (ε < 0.75) or Huynh-Feldt correction. Post-hoc 
comparisons were carried out with Fisher’s least significant difference (LSD).  
 Retention data (accuracy of the final session of dPAL acquisition and both retention 
sessions) were analysed with multivariate repeated measures ANOVA. In a separate analysis 
of memory performance (difference in accuracy of the final dPAL session and first retention 
session) and relearning performance (difference in accuracy of first and second retention 
session) were analysed by two-way ANOVA just as summary statistics.  
 Normalised target genes were displayed as percent of control group mean (PFC data) 
or percent of dorsal HPC control mean (dorsal and ventral HPC data). The effect of the 
hedonic state and treatment on PFC, dorsal and ventral HPC gene expression was examined 
with a two-way ANOVA or rank aligned two-way ANOVA. Differences between dorsal and 
ventral HPC gene expression were analysed with Student’s t-test.  
 Statistical analysis was performed with RStudio (Version 0.99.892, Boston, USA) 
and data displayed with GraphPad Prism 5 (©1992-2007, GraphPad Software, Inc). 
3 Results 
3.1 Hedonic status changes in response to CMS and Vortioxetine 
treatment 
Non-treated CMS anhedonic-like rats consumed significantly less sucrose solution over the 
course of all SCTs than non-stressed control rats (p < 0.0001). Vortioxetine treated 
anhedonic-like rats responded individually to antidepressant treatment. Some rats (65%) 
responded well and their sucrose intake was not statistically significant different from non-
stressed controls, but significantly increased compared to non-treated anhedonic-like rats (p 
< 0.0001). Rats that responded poor to vortioxetine, thus low-responders, consumed 
significantly less sucrose than responders (p < 0.0001) or non-stressed controls (p < 0.0001), 
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but were not statistically significantly different to untreated anhedonic-like rats (interaction 
effect of group x time: χ2(45) = 187.31, p < 0.0001; Figure 4). 










































Figure 4. Sucrose consumption test throughout the experiment. The sucrose consumption index 
displays the sucrose consumption of the respective week of CMS normalised to baseline sucrose 
intake prior to CMS exposure. (A) Treatment start with the antidepressant vortioxetine in two-thirds 
of anhedonic-like rats. (B) Food deprivation for touchscreen testing was initiated for all four groups. 
(C) Start of touchscreen pre-training followed by dPAL acquisition for all four groups. Group means (± 
SEM) are displayed. Pairwise group post-hoc comparisons over the entire course of CMS exposure are 
indicated with ***p < 0.001 (Non-stressed control: n = 10, anhedonic-like: n = 10, treatment 
responder: n = 10, treatment low-responder: n = 10). 
 
3.2 Paired-associates learning touchscreen task 
3.2.1 Learning of the dPAL task 
The period to acquire the dPAL task, indicated by the aggregated number of trials, did not 
differ significantly between groups (Figure 5A). 
 Two-way ANOVA revealed that treatment increased the number of redundant screen 
touches compared to non-treated animals (main effect of treatment: F(1,28) = 9.74, p = 
0.004). This treatment effect is possible driven by a trend of hedonic state x treatment 
interaction effect (F(1,28) = 3.93, p = 0.057), where responders appear salient (Figure 5B). 
 Median response latency was altered due to a hedonic state x treatment interaction 
effect (F(1,29) = 9.03, p = 0.005; Figure 5C). Specifically, anhedonic-like rats (Bonferroni p 
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= 0.013), responders (Bonferroni p = 0.0001) and low-responders (Bonferroni p = 0.0010) 
responded faster to touchscreen stimuli than non-stressed control rats. Furthermore, 
treatment alone shortened median response latency (F(1,29) = 17.58, p = 0.0002; Figure 5C). 
 No difference for collection latency (Figure 5D), number of correction trials or 
maximum number of consecutive correct trials per session were observed between groups. 
Six animals (one non-stressed control, three anhedonic-like rats, one responder and one low-
responder) did not pass dPAL and, thus, were excluded from this analysis. 












































































































Figure 5. Acquisition of dPAL until passing criterion. (A) The overall number of trials needed to acquire 
the dPAL task. (B) Redundant touches executed per trial (trial or correction trial) besides the one for 
choosing a stimulus. (C) Median response latency to react to the stimuli. (D) Collection latency of 
touchscreen reward. Individual results and group means (± SEM) are shown. Two-way ANOVA main 
effects and LSD post-hoc comparisons are indicated by *p < 0.05, **p < 0.01, ***p < 0.001. 
 
3.2.2 dPAL task acquisition over time  
Touchscreen data from the first until the last dPAL session of each rat were divided in ten 
equal bins by the combined number of trials plus non-correction trials. Thus, the varying 
number of sessions between rats to acquire the task was normalised to ten time points (bins) 
for each rat allowing statistical analysis with repeated measurements ANOVA. 
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 The percent of correct trials (accuracy) increased significantly with increasing 
number of bins (F(4.68,168.32) = 49.34, p < 0.0001), indicating learning of the dPAL task, 
but no effect of group on accuracy performance was observed (Figure 6A). 
 The number of trials performed increased significantly over time with growing bin 
number (F(3.82,137.34) = 63.09, p < 0.0001), whereas the number of correction trials 
decreased significantly by bin number (F(3.08,110.73) = 48.37, p < 0.0001; Figure 6B), 
further indicating learning, however, with no statistically significant differences between 
groups. 
 Non-stressed control rats responded slower to stimuli compared to anhedonic-like 
rats (Bonferroni p = 0.002), low-responders (Bonferroni p < 0.0001) or responder 
(Bonferroni p < 0.0001), whereas vortioxetine responders showed the shortest median 
response latency compared to non-stressed controls, anhedonic-like rats (Bonferroni p = 
0.002) and low-responders (Bonferroni p = 0.029; main effect of group: F(3,36) = 3.24, p = 
0.033). Median response latency decreased significantly over the course of dPAL acquisition 
(main effect of time: F(4.32, 155.40) = 9.14, p < 0.0001 ; Figure 6C), thus, suggesting 
response latency as readout of cognitive processing rate, which decreases with increasing 
understanding of the touchscreen task. 
 Vortioxetine responders executed the highest number of redundant screen touches 
per trial compared to control rats (Bonferroni p < 0.0001) and anhedonic-like rats 
(Bonferroni p < 0.0001). Vortioxetine low-responders performed more redundant screen 
touches than control (Bonferroni p = 0.022) or anhedonic-like rats (Bonferroni p = 0.005; 
main effect of group: F(3,36) = 3.10, p = 0.039). The number of redundant screen touches 
decreased over the course of dPAL acquisition (main effect of time: F(2.46,88.45) = 5.67, p 
< 0.0001; Figure 6D). 
 Maximum number of consecutive correct trials per session increased over the course 
of dPAL acquisition (F(4.58,165.05) = 24.19, p < 0.0001), with no statistically significant 
difference between groups. Collection latency was not significant for group or time 
suggesting equal motivation to participate in the dPAL task. 
3.2.3 Learning behaviour within the course of a dPAL session 
All sessions of one animal were averaged to a single session. This session was then split into 
six equal blocks by the total number of trials (trials plus correction trials). This allowed for 
the analysis of learning behaviour within the course of a session. 
 Within the course of a session, accuracy did not significantly change over time, nor 
depending on group. The number of trials executed within the course of a session changed  
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Figure 6. Behavioural parameters over the course of dPAL task acquisition. (A) Percent of correct 
choices. (B) Number of trials (black) and number of total trials (trials plus correction trials, grey). (C) 
Median response latency. (D) Number of redundant screen touches per trial. Group means (± SEM) 
are shown with +  i di ati g a sig ifi a t differe e of the respe ti e group to the three other groups 
a d ~  a sig ifi a t differe e to controls and anhedonic-like rats (Bonferroni post-hoc comparisons). 
 
depending on session block (main effect of session block: F(5,180) = 3.38, p = 0.006; Figure 
7A). 
 Non-stressed controls needed significantly less correction trials within a session 
compared to  responders (Bonferroni p < 0.0001) and low-responders (Bonferroni p < 
0.0001) and a trend to anhedonic-like rats (Bonferroni p = 0.054). Anhedonic-like rats 
needed significantly less correction trials than vortioxetine responders (Bonferroni p = 
0.015) and showed a trend to low-responders (Bonferroni p = 0.063; main effect of group: 
F(3,36) = 3.05, p = 0.041; Figure 7A). The number of correction trials significantly 
decreased by session block (main effect of session block: F(5,180) = 3.71, p = 0.003) 
indicating learning within the course of a session. 
 Vortioxetine responders executed more redundant touches per trial (correction or 
non-correction trial) than the control group (Bonferroni p < 0.0001) or anhedonic-like rats 
(Bonferroni p < 0.0001), but not significantly more than low-responders. Low-responders 
carried out more redundant screen touches than  control (Bonferroni p = 0.020) or 
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anhedonic-like rats (p = 0.005; main effect of group: F(3,36) = 3.12, p = 0.038; Figure 7B). 
The number of redundant touches decreased significantly over the course of a session (main 
effect of session block: F(1.73,62.22) = 9.65, p < 0.0001). 
 Non-stressed controls took longer to execute their choice, as observed by median 
response latency, than anhedonic-like rats (Bonferroni p = 0.010), responders (Bonferroni p 
< 0.0001) or low-responders (Bonferroni p < 0.0001; main effect of group: F(3,36) = 4.15, p 
= 0.013; Figure 7C). Median response latency increased within a session (main effect of 
session block: F(1.68,60.44) = 9.57, p < 0.0001). 
 Collection latency was not significantly different between groups and independent of 
session block. 
 Rats were able to perform more consecutive correct trials with increasing session 
block (main effect of session block: F(4.41,158.82) = 15.85, p < 0.0001; Figure 7D), but no 
difference in the number of maximum consecutive trials was observed between groups. 
 




















































































































































Figure 7. Touchscreen parameters within the course of an average session. (A) Number of trials (black) 
and correction trials (grey). (B) Number of redundant touches per trial (trial or correction trial). (C) 
Median response latency. (D) Maximum number of consecutive correct trials over the course of a 
session. Group means (± SEM) are displayed. Bonferroni post-hoc tests are indicated with *p < 0.05, 
#p < 0.06, +  i di ati g a significant difference of the respective group to the three other groups, ~  a 
significant difference to responder and low-responder or ^  to o trol a d a hedo i -like rats 
(Bonferroni post-hoc comparisons). 
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3.2.4 Memory of the dPAL task 
 Long-term memory performance was assessed by re-testing the rats in dPAL 
following a 10-day hiatus after dPAL acquisition. Included in the analysis was accuracy of 
the last session of dPAL acquisition before the break as well as the two dPAL retention 
sessions after the break. An interaction effect of group x session (χ2(6) = 16.17, p = 0.013) on 
accuracy performance was observed. Post-hoc comparisons revealed that on retention 
session one, vortioxetine responders reached a significantly lower accuracy level than 
controls (p = 0.036) and anhedonic-like rats (p = 0.021) and a trend to low-responders (p = 
0.055; Figure 8A). 
 Additionally, individual changes in accuracy due to memory (difference in accuracy 
between last dPAL acquisition session and first retention session) and relearning (difference 
in accuracy between the two retention sessions) were evaluated. The hedonic state 
significantly associated with memory performance (F(1,30) = 5.19, p = 0.030; Figure 8B) 
and a trend in hedonic state x treatment on memory was observed (F(1,30) = 3.06, p = 
0.090). Although statistically valid, the association of hedonic state and memory was 
unexpected examining the mean group performances (Figure 8B). Thus, a one-way ANOVA 
was performed to extract group difference in memory performance. Memory performance 
was significantly different between groups (F(3, 30) = 3.41, p = 0.030). Treatment 
responders (-13.56 ± 5.65%) showed a lower memory performance compared to low-
responders (-6.74 ± 6.04%, Bonferroni p = 0.046). No effect of group was found for 
relearning performance with neither two-way nor one-way ANOVA (Figure 8B). 
3.3 Cerebral gene expression 
Expression levels of genes in the PFC as well as the dorsal and ventral HPC were 
investigated. We were interested in genes known to be involved in the stress response and/or 
altered in neuropsychiatric diseases, such as Mr, Gr, Bdnf, Fkbp5, Disc1, and Gsk3b, and, 
furthermore, in gene expression related to neuronal plasticity, learning and memory, such as 
Nrg1, Cofilin 1, Spinophilin, Shank and Homer. Alterations in gene expression levels were 
analysed in response to vortioxetine treatment and hedonic state. Furthermore, differences 
between dorsal and ventral HPC gene expression were examined. Supplementary Table 3 
contains all gene expression levels for the four groups and all tissues. 
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3.3.1 Prefrontal cortex gene expression 
The expression of Cofilin 1, which is highly expressed in neurons and involved in growth 
cone dynamics, was increased in the anhedonic-like rats (Bonferroni p = 0.022) compared to 
controls (interaction effect of hedonic state x treatment: Frank(1,28) = 5.51, p = 0.026). 
Furthermore, hedonic rats displayed a lower gene expression than anhedonic rats (main 
effect of hedonic state: Frank(1,28) = 6.60, p = 0.016; Figure 9). 
 Gr signalling in the PFC is involved in an appropriate stress adaptation and mood 
regulation30. A trend of treatment reducing Gr gene expression was observed (F(1,27) = 
4.07, p = 0.054; Figure 9). 
 PFC gene expression was not statistically different for Mr, Fkbp5, Disc1, Gsk3b, 
Bdnf, Shank 1-3, Homer1-3, Nrg1 or Spinophilin. 
 
Figure 8. Retention of the dPAL 
task. (A) Accuracy of each rat 
including the last dPAL session 
(task acquisition) before the 10-
day hiatus, the first and second 
retention session. The dotted line 
(∙∙∙) indicates the drop in group 
accuracy due to the hiatus 
(memory performance) and the 
continuous line (―) presents the 
group relearning performance. 
(B) Individual memory and 
relearning performance are 
shown. Group means (± SEM) are 
displayed, main effect of hedonic 
state and post-hoc statistics are 
indicated by *p < 0.05, #p < 0.06. 
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3.3.2 Hippocampal gene expression 
Gsk3b modulates LTP and LTD and its expression is commonly inhibited by 
antidepressants31,32. Here we found that in the dorsal HPC, Gsk3b expression tended to be 
driven by an interaction effect of hedonic state x treatment: F(1,32) = 4.03, p = 0.053). In the 
ventral HPC, Gsk3b expression tended to be decreased in rats with anhedonic phenotype 
(trend of hedonic state: F(1,33) = 3.48, p = 0.071). Gsk3b gene expression was higher in the 
ventral HPC compared to dorsal HPC (t(35) = -3.13, p = 0.004; Figure 9). 
 Disc1 is involved in neuronal development and alteration in its function are 
associated with psychiatric diseases. Here, Disc1 gene expression was increased in the 
ventral to dorsal HPC (t(34) = -4.72, p < 0.0001). In the ventral HPC, a trend of hedonic 
state x treatment interaction was found (F(1,31) = 3.46, p = 0.072; Figure 9).  
 Homer and Shank are scaffolding proteins, which form a complex and are 
abundantly found at the post-synaptic density. Both proteins are involved in maturation of 
dendritic spines33. Homer3 expression appears decreased in vortioxetine treated compared to 
non-treated rats in the ventral HPC (trend of treatment: F(1,33) = 4.03, p = 0.053; Figure 9). 
No statistical difference in gene expression was observed in the dorsal HPC or between the 
dorsal and ventral HPC. 
 In the dorsal HPC, Homer2 gene expression was decreased in groups with 
anhedonic-like phenotype (main effect of hedonic state: F(1,33) = 5.63, p = 0.024; Figure 9), 
and no effect of treatment or hedonic state was observed in the ventral HPC. No difference in 
gene expression was revealed between dorsal and ventral HPC. 
Ventral HPC gene expression was decreased compared to dorsal for Homer1 (t(35) = 
3.01, p = 0.005; Figure 9), but otherwise increased for Shank1 (t(34) = -3.99, p = 0.0003), 
Shank2 (t(32) = -3.58, p = 0.001), the neuronal growth factor Nrg1 (t(32) = -5.84, p < 
0.0001), and tentatively for Shank3 (t(34) = -1.88, p = 0.068). 
 Important in the (cognitive) adaptation to stress34, Mr expression tended to be 
decreased in groups with anhedonic-like phenotype in the dorsal HPC (trend of hedonic 
state: F(1,33) = 3.47, p = 0.072; Figure 9) with no other effect on Mr expression due to 
hedonic state, treatment nor tissue. 
 In the dorsal HPC, treatment tended to increase Bdnf gene expression compared to 
non-treated animals (trend of treatment: F(1,30) = 3.87, p = 0.058; Figure 9). No other 
alterations in Bdnf gene expression were observed. 
 Gene expression was not statistically significant altered depending on tissue, hedonic 
state or treatment for Fkbp5, Gr, Spinophilin, or Cofilin 1 in the HPC.  
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4 Discussion 
In the present CMS study, non-stressed controls, anhedonic-like rats and vortioxetine treated 
anhedonic-like rats were evaluated with respect to their hedonic state, their cognitive 
performance in the dPAL touchscreen task and by cerebral gene expression profiling. 
Vortioxetine has a strong antidepressant effect and recovered the hedonic state in a major 
proportion of the treated rats. All groups were able to acquire the dPAL task. No differences 
in primary touchscreen task readouts were observed between groups, however, for secondary 
readouts, such as redundant screen touches, median response latency or number of correction 
trials significant group differences were observed. PFC and HPC gene expression was 
associated with  the hedonic state or showed trends of treatment. Differences between ventral 
and dorsal HPC expression levels were observed.  
4.1 Vortioxetine recovers the hedonic state  
CMS exposed rats decreased sucrose intake over time indicating a reduced reward sensitivity 
and, hence, mirroring the MDD core symptom anhedonia. Administration of the 
antidepressant vortioxetine recovered the hedonic state in a major fraction of anhedonic-like 
rats (65%), whereas the remaining rats responded poorly and remained in an anhedonic-like 
state. Hence, vortioxetine was effective in recovering the hedonic state in anhedonic-like 
CMS exposed rats. Previous research found vortioxetine to be ineffective in the CMS 
model14, however, vortioxetine was administered by intraperitoneal injections once daily 
(Papp, personal communication). The relatively short half-life of vortioxetine in rodents14 
may have made this drug schedule ineffective. In the present study vortioxetine was mixed 
into the diet and, hence, this route of drug administration ensured a continuous drug 
exposure. To achieve full SERT occupancy we used a dosing of 1.8g/kg food chow35.  
 
Figure 9. Prefrontal cortex (PFC) and hippocampal (HPC) gene expression levels. Genes of interest are 
normalised to reference genes and displayed as percent of control mean for the PFC or as percent of 
the dorsal HPC of the control group for the ventral and dorsal HPC. Individual data points as well as 
group means (± SEM) are displayed. Statistical significance is indicated for main effects and between 
tissue differences (angular brackets) and Bonferroni corrected post-hoc comparisons by 
****p < 0.0001, **p < 0.01, *p < 0.05 and trends by the respective number.  
Bdnf – Brain-derived neurotrophic factor; Gsk3b – Glyceraldehyde-3-phosphate dehydrogenase; 
Homer – Homer scaffolding protein. 
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4.2 Vortioxetine affects cognition 
We investigated whether the vortioxetine-induced alleviation of the hedonic state is 
associated with alterations in cognitive performance. Vortioxetine is known to augment 
cognitive functions targeting 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors14. This pro-
cognitive efficacy was considered to be due to direct actions on cognitive processes rather 
than to be secondary to remission from affective symptoms20. However, in this study 
vortioxetine did not alter primary touchscreen parameters (accuracy, number of trials) in 
either responder or low-responder groups compared to non-stressed controls or anhedonic-
like rats. Evaluating cognitive performance within an average dPAL session revealed that 
non-stressed controls needed less correction trials than the vortioxetine groups and a 
tendency to anhedonic-like animals indicating inferior cognitive performance in the latter 
groups compared to controls. Thus, vortioxetine treatment seemingly did not improve 
cognitive performance in anhedonic-like rats. However, it should be noted that an increased 
number of untreated anhedonic-like rats (n = 3) did not pass the dPAL task within 46 
sessions whereas only one animal failed to pass in any of the other groups. The inability to 
acquire the dPAL task may suggest cognitive impairment in the anhedonic-like group only 
and hence a pro-cognitive effect of vortioxetine treatment. 
 Importantly, latency for collecting reward pellets did not differ between groups 
suggesting no difference in motivation to participate in the touchscreen task. Possible 
motivational differences between anhedonic-like and hedonic animals are likely masked by 
food deprivation accompanying touchscreen testing. Thus, cognitive impairments were not 
cofounded by lack of motivation.  
 Consistently, median response latency was reduced in untreated anhedonic-like rats 
and both treatment groups compared to controls. During task acquisition, vortioxetine 
responders displayed the shortest median response latency and controls the longest latency. 
Similarly within an average session, control animals had the longest response time and 
untreated anhedonic-like rats took longer to respond than vortioxetine responders. Prolonged 
median response latency in the control group is consistent with a previous touchscreen 
studies in which control animals displayed a longer median response latency compared to 
CMS exposed rats25, suggesting increased cognitive appraisal, before executing a choice in 
control animals. Consecutively, reduced response latency in the anhedonic and vortioxetine 
treated groups can be considered as impulsive behaviour, executing a less evaluated, 
spontaneous choice. Reduced response latency may indicate impaired HPC functioning since 
inactivation of the dorsal hippocampus with lidocaine and scopolamine significantly 
shortened reaction time in the rat dPAL task as well36 and is in line with the well-known 
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important role of HPC in visuospatial learning tasks37,38. An alternative explanation could 
comprise frontostriatal reorganization resulting in a shift from effortful goal-directed to 
habitual behaviour. Such changes were previously observed after stress exposure39 and might 
resemble the reduced response latency observed in the present study. Noticeably, responders 
to vortioxetine treatment displayed the shortest response latency of all groups suggesting a 
relationship of treatment response and decreased appraisal. 
 A shift to habit-like or impulsive behaviour is further supported by the number of 
redundant screen touches per trial. Consistently, vortioxetine treated rats executed more 
redundant touches than any other group. Thus, vortioxetine administration, and in particular 
treatment response, seems to coincide with increased impulsive behaviour. This may 
resemble a lack of control of executive function, which is part of PFC functions. 
 In order to address long-term memory trial accuracy was re-tested after a 10-day 
hiatus subsequent to passing dPAL. Statistic revealed an effect of hedonic state on memory 
performance, although group mean of hedonic control rats was comparable to anhedonic-like 
treated and untreated rats and thus, relevance of this finding is debatable. Vortioxetine 
responders showed the greatest decrease in accuracy (around twice as much) after the 10-day 
hiatus than any of the three other groups and performed significantly worse than low-
responders. Hence, a high response to vortioxetine treatment was associated with poor 
memory performance. Interestingly, non-stressed controls were the only group able to restore 
performance to dPAL passing criterion level (≥ 80% accuracy) on the second day of 
retention. All other groups still performed below 80% accuracy and the untreated anhedonic-
like group even decreased in accuracy on the second day of retention. 
4.3 Hedonic state and vortioxetine treatment affect cerebral gene 
expression 
mRNA levels of genes known to be altered in neuropsychiatric diseases and associated with 
neuronal plasticity were measured in the PFC, dorsal and ventral HPC. For example, Disc1 is 
a scaffolding protein involved in neurodevelopmental signalling and suggested as candidate 
gene in mental illnesses, such as bipolar disorder and schizophrenia40,41. In our study, Disc1 
mRNA levels were higher in the ventral compared to the dorsal HPC. In the ventral HPC, an 
interaction trend may indicate a regulatory association of the hedonic state and vortioxetine 
treatment on Disc1 gene expression. These changes correspond to the literature reporting 
DISC1 alterations to be involved in the pathology of mental illnesses, cognitive deficits and 
dendritic arborisation, all of which are also known to be often a consequence of stress 
exposure42,43  
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 DISC1 regulates downstream GSK3B expression. In the present study, Gsk3b 
mRNA was also upregulated in the ventral compared to the dorsal HPC, which could be 
linked to the increased Disc1 gene expression. Gsk3b expression is known to be inhibited by 
most antidepressant treatments, e.g. SSRIs, and its dysregulation is implicated in 
depression32,44–46. Therefore, an increased expression of Gsk3b in the untreated anhedonic-
like and possibly the low-responder group was anticipated. In the ventral HPC, an 
unexpected trend of decreased Gsk3b mRNA in dependence of the anhedonic-like phenotype 
(untreated and treated) compared to the hedonic phenotype (controls and responder) was 
observed. A possible explanation for this converse finding might be downregulated Gsk3b 
mRNA expression in the anhedonic phenotype as response to elevated Gsk3b protein levels. 
However, this theory needs to be supported by further experiments assessing protein 
concentrations. Lower Gsk3b levels were also found in a juvenile stress model, which 
models predisposition to neuropsychiatric diseases47 and thus supports the finding of lower 
Gsk3b expression in the stressed, anhedonic groups. In the dorsal HPC, and interaction trend 
of hedonic state and treatment was found with vortioxetine responders potentially displaying 
increased Gsk3b levels compared to all other groups, particularly the low-responders. Gsk3b 
upregulation is associated with impairments in spatial memory, object recognition and long-
term potentiation, which are all components of the dPAL task48–52. Consequently, increased 
Gsk3b gene expression levels in the dorsal HPC may underlie the observed memory 
impairments during dPAL retention in the vortioxetine responder group compared to low-
responders. It remains unresolved how vortioxetine recovered the hedonic state, while Gsk3b 
levels are elevated. However, it should be noted that Gsk3b levels were only measured at the 
experimental endpoint and not during remission from the depressive-like phenotype and, 
hence, a temporal dynamic increase in Gsk3b levels after chronic vortioxetine treatment 
might explain this discrepancy. 
 Homer proteins, which are scaffolding proteins facilitating post-synaptic signalling, 
are vital for learning and memory functions53. Moreover, decreased scaffolding Homer1 
expression is associated with an enhanced stress response and susceptibility to psychiatric 
diseases such as MDD54,55. In this study, Homer1 was higher expressed in the dorsal than in 
the ventral HPC possibly in response to spatial learning required for dPAL acquisition, a 
function of the dorsal HPC56. In the dorsal HPC, Homer2 expression was decreased for 
anhedonic rats (treated and untreated). Homer2 is required for alcohol-seeking57 and, thus, 
reduced pleasure seeking in anhedonic rats (treated and untreated) may be reflected by their 
decreased Homer2 levels. In contrast to the present study finding decreased Homer3 
expression in the ventral HPC of treated rats, a single dose of vortioxetine, has recently been 
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reported to induce a transient increase (at 8 h post-treatment) of Homer3 in the frontal 
cortex58. Currently, we do not know the mechanisms responsible for regulation of Homer3. 
 Cofilin 1 is a key regulator in growth cone dynamics and, thus, in neuronal plasticity 
important for learning and memory71,72. In the PFC, Cofilin 1 expression was upregulated in 
anhedonic-like rats compared to controls and in general upregulated in the anhedonic-like 
compared to the hedonic phenotype. Excessive up- or down-regulation of Cofilin 1 was 
associated with impaired synaptic plasticity and learning deficits72. Thus, altered Cofilin 1 
gene expression might suggest subthreshold cognitive impairments associated with 
anhedonia, especially in untreated rats. 
Bdnf is involved in neuronal plasticity59. Its expression levels are reduced following 
stress exposure as well as in PFC and HPC post-mortem tissue of MDD suicide victims60,61. 
Furthermore, antidepressant treatment elevates Bdnf levels and, in turn, treatment efficacy 
appears dependent on Bdnf levels62–64. Consequently, the trend of higher Bdnf levels in the 
dorsal HPC of vortioxetine treated animals is in accordance with the literature. 
 Mr expression is an important player in the stress response, HPA axis activity and 
MDD. Increased MR function is associated with resilience whereas decreased Mr levels 
suggest stress-susceptibility for developing depression65. Stimulation of Mr expression 
improved memory and executive function in MDD patients66. Thus, Mr expression may be a 
target for relieving MDD symptoms and cognitive impairments67. In the present study, a 
trend for increased Mr expression was found in the hedonic rats (controls and responders) 
compared to anhedonic rats (treated and untreated). Hence, susceptibility to CMS including a 
low treatment response could be associated with reduced Mr expression in the HPC.  
 Likewise, Gr expression plays an important role in the HPA axis’ negative feedback 
loop and an appropriate stress response68,69. In this study, no differences were found for Gr 
expression in the HPC. In the PFC, Gr expression was downregulated by vortioxetine 
treatment. This was unexpected since knockdown of GR in rat PFC resulted in an altered 
stress response and consequent depressive-like behaviour30. Furthermore, Gr levels were 
found decreased in the PFC of depressed and schizophrenic patients70.  
Expression levels of Nrg1, Shank and Spinophilin, genes involved in neuronal 
plasticity, were not statistically different between groups and possibly reflecting on the small 
cognitive differences observed in this study. Furthermore, Fkbp5 mRNA levels, a modulator 
of the HPA axis’ negative feedback loop73, were similar across groups indicating no effect of 
stress, hedonic state or vortioxetine on Fkbp5 expression. 
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4.4 Touchscreen testing 
The present touchscreen study was the first to monitor the hedonic state throughout 
touchscreen testing and food restriction. Operant conditioning is based on appetitive learning 
and hence assumed to be only mildly straining23,74. However, the non-stressed control group 
decreased their sucrose consumption in response to food restriction and touchscreen testing 
(Figure 4). This decline in the hedonic state of control rats illustrates how stressful 
touchscreen testing is experienced by the animals. Nevertheless, the sucrose consumption of 
control rats never decreased below the anhedonia threshold and finally rats seemed to 
habituate and restore sucrose consumption. Consequently, dPAL results are likely unaffected 
since the initial mildly stressful response to touchscreen testing occurred mostly during pre-
training. However, effect size between non-stressed controls and CMS animals might have 
been reduced. Moreover, it was demonstrated that vortioxetine treated groups, in particular 
responders, maintained their phenotype during touchscreen testing although food reduction 
entailed a lower treatment dose. Furthermore, continued SCTs revealed that the modified, 
milder CMS protocol was sufficient to maintain the anhedonic-like phenotype during 
touchscreen testing. Continuous SCTs were possible by replacing the sugar with bacon 
reward pellets and, thus, avoiding desensitization to the lower concentrated sucrose solution. 
To our knowledge, this was the first touchscreen study to show that not only sweet rewards, 
such as sugar pellets or milkshakes entail for successful operant conditioning. This might 
become crucial, in addiction, diabetes or reward studies and expands the applicability of 
touchscreen testing. 
4.5 Conclusion 
Our study expands on the relatively new drug treatment approach of antidepressants 
targeting depression-associated cognitive impairments. Hence, the effect of vortioxetine on 
the hedonic state as well as on cognition was assessed. In contrast to a previous report 
(reviewed in Sanchez et al.14), we have shown that vortioxetine recovers the hedonic state in 
anhedonic-like rats and hence demonstrated its efficacy in a well validated preclinical model 
of depression. This is an important finding since vortioxetine is approved for clinical 
application and since the CMS model is recognized for high predictive validity26,75,76. 
Moreover, cognitive performance was assessed with the touchscreen operant platform, which 
was developed with focus on its translational value. Hence, clinical relevance and additional 
useful advantages, such as objective readout, standardization and minimal experimenter’s 
bias, suggest the platform as an optimal tool in cognitive research. In the present study 
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beneficial cognitive effects of vortioxetine treatment were not prominent in the translational 
touchscreen dPAL task involving object-in-place learning and memory. Vortioxetine 
responders displayed inferior long-term memory. Vortioxetine’s potential effect on cognition 
requires more detailed evaluation since the observed effects, such as shortened reaction time 
and a shift to habitual behaviour might be beneficial in a different context than dPAL 
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Supplementary 
Supplementary Table 1. Modified chronic mild stress (CMS) protocol during touchscreen pre-training 
and acquisition. Stressors were applied during the night phase since touchscreen testing took place 
during the day. On Fridays, the SCT (including all animals) followed by grouping (only CMS animals) 
were carried out during the light phase. 
Protocol Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
A Strobe 
light (6 h) 
Wet bedding  
(14 h) 
Light on  









(2 x 2 h) and 
light on (1 h) 
Cage tilted 







Light on (2 
h), strobe 
light (5 h) 
Light on  









(2 x 3 h) and 
light on (1 h) 
Cage tilted 







Light on (3 h, 
1h, 2 h), 
Strobe light 











(3 x 2 h) and 
light on (1 h) 
Light on  






light (6 h) 
Wet bedding  
(14 h) 
Light on  









(2 x 2 h) and 
light on (1 h) 
Cage tilted 







Light on (3 
h), strobe 











(2 x 2 3) and 
light on (2 h) 
Cage tilted 







Light on (3 h, 
1h, 2 h), 
Strobe light 











(3 x 2 h) and 
light on (1 h) 
Light on  





* For CMS and non-stressed controls. 
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Supplementary Table 2. Characteristics of gene-specific real-time qPCR primers 
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Supplementary Table 3. Target gene expression levels. Target genes were normalised to reference 
genes and calculated as % of the control group mean (for prefrontal cortex, PFC) or the control group 
mean of the dorsal hippocampus (HPC; for ventral (v) and dorsal (d) HPC). For each gene, group mean 
(± SD) and sample size n (in brackets) are displayed. 
Tissue Target gene Control Anhedonic Responder Low-responder 
PFC Mr 100.0 ± 16.7 (7) 90.6 ± 11.2 (9) 95.3 ± 10.5 (9) 90.9 ± 7.7 (7) 
 Gr 100.0 ± 16.9 (7) 99.9 ± 8.3 (9) 89.3 ± 9.6 (9) 94.4 ± 9.9 (7) 
 Fkbp5 100.0 ± 73.0 (8) 140.8 ± 69.8 (10) 104.4 ± 55.9 (10) 108.1 ± 62.0 (8) 
 Disc1 100.0 ± 49.3 (8) 111.9 ± 39.2 (10) 94.5 ± 67.5 (10) 108.7 ± 47.3 (8) 
 Gsk3b 100.0 ± 10.4 (7) 108.8 ± 26.2 (9) 108.5 ± 13.8 (9) 98.6 ± 9.5 (7) 
 Bdnf 100.0 ± 13.3 (7) 106.9 ± 18.4 (10) 96.7 ± 23.1 (9) 101.7 ± 8.4 (7) 
 Nrg1 100.0 ± 9.7 (7) 113.6 ± 16.3 (10) 102.2 ± 11.8 (9) 102.9 ± 6.0 (7) 
 Homer1 100.0 ± 43.5 (8) 121.1 ± 30.9 (10) 96.8 ± 36.5 (10) 104.0 ± 27.7 (8) 
 Homer2 100.0 ± 14.9 (7) 103.6 ± 26.7 (10) 91.1 ± 9.5 (9) 96.9 ± 12.1 (7) 
 Homer3 100.0 ± 16.5 (7) 111.1 ± 28.1 (9) 101.0 ± 10.7 (9) 96.0 ± 37.1 (8) 
 Shank 1 100.0 ± 16.0 (7) 104.4 ± 10.4 (9) 95.1 ± 7.3 (9) 98.4 ± 13.2 (7) 
 Shank 2 100.0 ± 15.1 (7) 93.4 ± 11.9 (9) 93.3 ± 9.0 (9) 87.6 ± 30.0 (8) 
 Shank 3 100.0 ± 16.6 (7) 92.3 ± 8.3 (9) 95.7 ± 15.3 (9) 81.4 ± 26.9 (8) 
 Spinophilin 100.0 ± 46.2 (8) 109.6 ± 25.5 (9) 99.3 ± 43.7 (10) 100.4 ± 42.1 (8) 
 Cofilin 1 100.0 ± 45.2 (8) 137.1 ± 10.3 (10) 131.4 ± 9.1 (8) 130.1 ± 14.1 (7) 
dHPC Mr 100.0 ± 19.4 (9) 79.2 ± 34.6 (10) 97.9 ± 44.7 (10) 77.6 ± 26.9 (8) 
 Gr 100.0 ± 39.9 (9) 90.0 ± 40.8 (10) 126.7 ± 42.5 (9) 98.3 ± 23.7 (7) 
 Fkbp5 100.0 ± 34.6 (8) 97.1 ± 34.8 (10) 112.5 ± 34.4 (9) 91.2 ± 32.8 (8) 
 Disc1 100.0 ± 29.4 (9) 93.7 ± 35.1 (10) 93.2 ± 50.1 (9) 96.7 ± 39.7 (8) 
 Gsk3b 100.0 ± 6.3 (8) 100.9 ± 10.5 (10) 119.4 ± 34.5 (10) 92.0 ± 17.3 (8) 
 Bdnf 100.0 ± 11.7 (8) 119.8 ± 12.9 (9) 124.7 ± 32.1 (9) 126.5 ± 25.0 (8) 
 Nrg1 100.0 ± 36.5 (9) 79.0 ± 12.6 (8) 90.2 ± 18.1 (10) 98.1 ± 21.1 (8) 
 Homer1 100.0 ± 38.3 (9) 90.6 ± 10.9 (9) 110.8 ± 25.9 (10) 97.2 ± 21.9 (8) 
 Homer2 100.0 ± 24.7 (9) 82.6 11.8 (10) 103.3 ± 38.3 (10) 79.8 ± 21.0 (8) 
 Homer3 100.0 ± 29.6 (9) 108.0 ± 24.6 (10) 101.0 ± 24.3 (10) 124.6 ± 34.1 (8) 
 Shank 1 100.0 ± 47.2 (9) 108.9 ± 19.0 (9) 100.3 ± 42.3 (10) 94.9 ± 34.0 (8) 
 Shank 2 100.0 ± 31.6 (9) 95.0 ± 25.1 (10) 92.2 ± 41.4 (10) 83.7 ± 25.2 (7) 
 Shank 3 100.0 ± 14.7 (9) 86.6 ± 23.2 (10) 104.4 ± 19.0 (9) 95.5 ± 14.4 (7) 
 Spinophilin 100.0 ± 34.0 (9) 117.9 ± 21.8 (9) 105.9 ± 22.7 (9) 109.7 ± 37.1 (8) 
 Cofilin 1 100.0 ± 7.8 (8) 86.9 ± 25.3 (10) 88.5 ± 31.0 (10) 100.7 ± 6.5 (7) 
vHPC Mr 86.7 ± 16.3 (9) 81.0 ± 27.7 (10) 93.3 ± 26.2 (9) 73.1 ± 19.7 (8) 
 Gr 108.9 ± 13.8 (8) 101.0 ± 26.6 (9) 101.4 ± 28.9 (10) 93.5 ± 47.0 (8) 
 Fkbp5 106.6 ± 19.1 (6) 108.5 ± 54.1 (9) 105.1 ± 43.6 (8) 112.2 ± 46.1 (8) 
 Disc1 236.0 ± 163.7 (9) 167.5 ± 92.3 (9) 153.1 ± 78.2 (3) 261.8 ± 200.8 (8) 
 Gsk3b 134.0 ± 39.0 (9) 119.1 ± 26.8 (10) 132.3 ± 38.6 (10) 105.7 ± 26.5 (8) 
 Bdnf 102.0 ± 55.5 (9) 121.1 ± 36.0 (10) 109.1 ± 33.9 (10) 124.5 ± 28.7 (8) 
 Nrg1 196.4 ± 110.0 (9) 162.1 ± 74.0 (9) 164.2 ± 73.7 (9) 187.6 ± 88.0 (8) 
 Homer1 85.3 ± 14.3 (9) 86.0 ± 18.4 (10) 99.9 ± 12.7 (9) 74.2 ± 21.0 (8) 
 Homer2 91.6 ± 16.4 (9) 89.3 ± 23.6 (10) 91.7 ± 32.8 (10) 89.0 ± 29.0 (8) 
 Homer3 119.4 ± 50.7 (9) 123.0 ± 37.0 (10) 86.7 ± 25.4 (10) 108.8 ± 33.3 (8) 
 Shank 1 155.9 ± 80.5 (9) 161.8 ± 90.9 (10) 145.0 ± 68.4 (9) 130.4 ± 65.7 (8) 
 Shank 2 130.2 ± 49.8 (9) 115.9 ± 40.1 (9) 116.3 ± 20.7 (8) 132.9 ± 55.3 (8) 
 Shank 3 133.6 ± 72.7 (9) 123.5 ± 66.4 (10) 93.2 ± 70.2 (10) 101.0 ± 37.8 (8) 
 Spinophilin 129.4 ± 42.8 (9) 121.5 ± 38.7 (10) 110.8 ± 32.3 (10) 112.7 ± 26.6 (8) 
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Abstract 
Major depressive disorder (MDD) is a leading contributor to the global burden of disease. 
However, the causal relationship of risk factors, such as genetic predisposition or experience 
of augmented stress and subsequent pathology of MDD, remain unknown. Numerous studies 
in humans and rodents have implicated brain-derived neurotrophic factor (BDNF) in MDD 
pathology, as a genetic risk factor and a factor regulated by stress. Until now, the majority of 
preclinical studies have employed genetically modified mice as their model of choice. 
However, mice display a limited behavioural repertoire and lack expression of circulating 
BDNF, which is present in rats and humans. Furthermore, few studies have investigated the 
relationship between altered BDNF levels and expression of genes associated with affective 
disorders.  We found that heterozygous BDNF rats (BDNF+/-), which have reduced BDNF 
levels in the brain and plasma, displayed anhedonia, a core symptom of MDD, and mild 
signs of anxiety but no behavioural despair or cognitive impairments. This was accompanied 
by changes in the expression of genes that are implicated in modulation of the stress 
response and affective disorders. Hence, glucocorticoid receptor, neuregulin 1 and disrupted-
in-schizophrenia 1 gene expression were upregulated in the prefrontal cortex of BDFN+/- 
rats, whereas FK506 binding protein 5 levels were decreased in the hippocampus. We 
conclude that a reduction in BDNF levels alters expression of genes associated with affective 
disorders, which may contribute to the development of depressive-like symptoms.  
1 Introduction 
Major depressive disorder (MDD) is the leading cause for disability worldwide affecting 300 
million people and their socio-economic environment.1 Stressful life events, such as constant 
stress at work or family disharmony, can trigger MDD development, especially in 
predisposed individuals.2–5 By implication, MDD pathology emerges from a gene x 
environment interaction eliciting a heterogeneity of symptoms.6 Heritability of MDD is 
presumed to be 30-40%.7 However, many genes which exert  small effects on their own may 
interact to contribute to the overall pathogenesis of MDD;8 confounding the identification of 
MDD-specific candidate genes. Furthermore, MDD patients display high comorbidities with 
other neuropsychiatric diseases, such as anxiety disorders, which additionally enhances the 
complexity of MDD.9,10 Hence, the aetiology of MDD pathogenesis is still insufficiently 
understood, which precludes the tailoring of antidepressant treatment and reduces drug 
efficacy. 
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 Brain-derived neurotrophic factor (BNDF), involved in neural circuit function and 
plasticity,11 was identified as a possible contributor to MDD pathogenesis and drug 
efficacy.12,13 The BDNF polymorphism Val66Met, linked to reduced BDNF activity,14,15 was 
shown to have a strong interaction with stressful life events in MDD pathogenesis.15 
Moreover, stress, which is known as major environmental risk factor for MDD 
development,4,5,16 reduces BDNF levels in the hippocampus (HPC).17 The HPC is a brain 
region that also shows reduced plasticity in environmentally-induced preclinical MDD 
models18 and atrophy in humans with MDD.19 Furthermore, reduced BDNF levels in 
prefrontal cortex (PFC) and HPC were found in post-mortem tissue of MDD patients;20 
whereas antidepressant treatment elevated BDNF levels in the HPC.21 Similarly, serum 
BDNF was decreased in depressed patients and elevated following medication.13,22 
Moreover, infusion of BDNF in the midbrain induced an antidepressant-like effect23 and 
antidepressant drug efficacy was shown to be BDNF level dependent.24–26 Hence, these 
findings promoted preclinical research into MDD using mice with genetically reduced 
BDNF expression. 
 However, these preclinical studies resulted in inconsistent findings with genetically-
reduced levels of BDNF provoking depressive-like phenotypes in only a limited proportion 
of mouse studies.26–28 One possible explanation may be that mice, unlike humans and rats, do 
not express peripheral BDNF.29 Peripheral administration of BDNF in mice altered gene 
expression in the brain and produced an antidepressant-like and anxiolytic behavioural 
response.30 Thus, peripheral BDNF levels might contribute to the pathogenesis and treatment 
of depression and highlight that rats may be a more appropriate species to investigate the 
relationship between BDNF and MDD. Furthermore, rats exhibit a more extensive 
behavioural repertoire than mice and are considered translationally more relevant to humans. 
Finally, most behavioural tests are designed to characterize rat behaviour,31 making the 
interpretation of BDNF mouse studies difficult. Rats heterozygous for the BDNF gene 
(BDNF+/-) express lower BDNF levels in the brain and periphery32 and may be a more 
relevant preclinical model, overcoming the inconsistent findings in mice and generating 
more translational results.  
 Therefore, the present study aimed to determine the direct effect of reduced BDNF 
levels on behavioural alterations and disease-related gene expression levels in the brain. Rats 
heterozygous for the BDNF gene were behaviourally phenotyped for anxiety and depressive-
like behaviours. Reduced plasticity and altered release of hypothalamic neuropeptides in 
response to lower BDNF levels might impair the homeostasis of the hypothalamic-pituitary-
adrenal (HPA) axis, which is an important regulator of the stress response, and often altered 
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in patients with affective disorders.2,33,34 Thus, we measured the expression of genes involved 
in regulating the stress response (the glucocorticoid receptor (GR), mineralocorticoid 
receptor (MR), corticotropin releasing hormone (CRH), and FK506 binding protein 5 
(FKBP5)) and expression of genes relevant in neuropsychiatric diseases (disrupted in 
schizophrenia-1 (Disc1), glycogen synthase kinase 3 beta (GSK3B) and neuregulin 1 
(NRG1)). We hypothesized these genes would be differentially regulated in BDNF+/- rats 
compared to controls and be associated with depressive- and/or anxiety-like behaviours.  
2 Material and Methods 
2.1 Animals 
All animal experiments were approved by the University of Edinburgh Ethical Review 
Committee and studies were carried out in strict accordance with the UK Home Office 
Animals (Scientific Procedures) Act 1986 and the European Communities Council Directive 
of 22 September 2010 (Directive 2010/63/EU). 
 Animals were generated by crossing male Sprague-Dawley (Hsd:SD) rats that were 
heterozygous for a BDNF knockdown mutation (HET, SD-BDNFtm1sage; generated using zinc 
finger nuclease technology, SAGE®Labs, St Louis, MO, USA) with control female SD rats 
(SAGE®Labs, St Louis, MO, USA). Litters comprised of BDNF+/+ wild type rats (WT) and 
BDNF heterozygous rats (BDNF+/-). BDNF+/- (n = 13) and WT rats (n = 14) were 11-12 
weeks old and weighed an average of 384 ± 49 g at the beginning of behavioural testing 
(except for Morris water maze (MWM) test). For the MWM test, a separate cohort of 5 WT 
and 10 BDNF+/- rats were employed (30 weeks of age). Another group of 10 BDNF+/- and 9 
WT rats at 11-13 weeks of age were used for testing brain gene expression levels. Animals 
were housed in mixed genotype groups of 3-4. Rats had free access to food and water and 
were kept on a 12 h light/dark cycle (lights on at 7:00 am). All of the following behavioural 
tests are listed in the order that they were conducted and took place in the first half of the 
light cycle (except Sucrose preference test (SPT) which was assessed over 48 h).  
The behavioural test battery was conducted in the following order: sucrose preference test, 
elevated-plus-maze, novelty induced hypophagia, spontaneous alternation behaviour, open 
field and forced swim test. This order was chosen to minimize the interference of stressful 
tests with other tasks. 
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2.2 Sucrose preference test 
The sucrose preference test (SPT) measures the hedonic state of each animal. Rats were 
habituated to drink a palatable sucrose solution (1.5%) for two days. A bottle of water and a 
bottle of the sucrose solution were made available in the animals’ home cage. One and a half 
days after habituation, animals were single-housed and exposed to two bottles, one with 
water and one with the sucrose solution, for 48 h. Bottle position (left/right) was 
counterbalanced across cages and switched after 24 h during habituation and test phase. 
Water and sucrose solution consumption, body weight and food intake were measured after 
48 h. 
2.3 Elevated plus-maze 
Anxiety-related behaviour was assessed in the elevated plus-maze (EPM) 3–5 days after the 
first SPT. Rats were habituated in their home cage to the experimental room 1 h prior to 
testing. The EPM consisted of a maze shaped like a plus sign (arm size: 10 cm width, 45 cm 
length) and elevated 66 cm from the floor. Two opposing arms, the closed arms, were 
enclosed with high walls (50 cm height), the two other arms were open, leaving a central 
area (10 x 10 cm) in the middle of the EPM. Illumination in the closed arms was 2.5 lux and 
45 lux in the open arms. In a randomized order, rats were positioned in the centre of the 
EPM facing a closed arm. Each rat could explore the maze for 5 min. EPM was cleaned with 
70% ethanol between animals. Distance travelled and time spent in open or closed arms as 
well as head dips and rearing were recorded using ANY-maze automatic tracking software 
(ANY-maze, Stoelting Co.,Wood Dale, IL, USA). 
2.4 Novelty induced hypophagia 
The novelty induced hypophagia (NIH) task tested anhedonic-like behaviour (decreased 
motivation to consume a reward) and anxiety-related behaviour (fear of eating in a novel and 
open environment). Eight days after the EPM test, rats were habituated to eat a chocolate 
chip (280 mg; Milk chocolate chips, Wm Morrison Supermarket PLC, Bradford, UK) in 
their home cage on four consecutive days. On the following day, the animals were moved to 
the experimental room 30 min prior to testing. The room illumination was adjusted to 
approximately 65–70 lux. After acclimation to the experimental room, a chocolate chip was 
positioned at the one end (35 lux) of an experimental box (66 cm length, 28 cm width, 40 cm 
height, non-transparent) and the rat was placed at the other end of the box (24–25 lux). 
Latency to consume the chocolate chip was manually scored from recorded videos. Rats 
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which did not consume the chocolate chip within the time limit were listed with the full 
experimental duration of 15 min. Two animals were tested in parallel and boxes were 
cleaned with 70% ethanol between animals. 
2.5 Spontaneous alternation behaviour test 
The spontaneous alternation behaviour (SAB) task assesses working memory in rodents. The 
SAB test was carried out 5 days after the NIH task and according to Henningsen et al..35 
Animals were acclimatized to the testing room 45 min prior to testing. Light intensity was 
10–13 lux in the arms (49 cm length, 17 cm width, 32 cm height) and 17 lux in the triangular 
centre of the Y-shaped maze (120° angles). Each rat was placed at the end of the same arm 
facing the back wall and allowed to explore the Y-maze for 10 min. Arm entries (all four 
paws in arm) were recorded using ANY-maze automatic tracking software (ANY-maze, 
Stoelting Co.,Wood Dale, IL, USA). The primary readout was alternation ratio, which was 
calculated by the number of alternations (visiting all three arms consecutively) divided by 
the maximum possible alternation score (number of arm entries minus two). A high 
alternation ratio shows that the rat is not re-entering an arm that was previously visited, 
indicating good working memory. The apparatus was cleaned with 70% ethanol between 
animals. 
2.6 Forced swim test and open field 
The forced swim test (FST) is primarily used to investigate immobility behaviour (floating 
with minimum movements to keep the head above water) indicating a rat’s propensity to 
surrender to a seemingly hopeless situation. On the contrary, swimming (horizontal 
movements throughout the cylinder) or struggling (vertical movements with the forepaws, 
usually against to cylinder wall) are counted as active escape attempts of the situation. 
Increased immobility is associated with a depressive-like phenotype.36 On day one of FST, 4 
weeks after the SAB test, rats were acclimatized to the testing room (150 lux) 1 h prior to 
testing. In parallel, two rats were immersed in transparent cylinders (20 cm diameter, 50 cm 
height) filled with water (38 cm depth; 24  ± 1 °C) for 15 min. The water was renewed 
between rats. On the following day, the rats’ locomotor activity was assessed in the open 
field (OF). Rats were acclimatized to an adjacent room with dim illumination containing an 
OF (97 x 97 cm) for 1 h. The OF was divided into a centre area (31 cm from the edge, 30 
lux), an outer area (12 cm from edge, 25 lux) and a middle area in between the centre and the 
outer area. Each rat was placed in the centre of the OF and tracked using ANY-maze 
automatic tracking software (ANY-maze, Stoelting Co.,Wood Dale, IL, USA) for 10 min. 
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Time spent and distance travelled in each zone as well as number of fecal boli were 
measured. After the OF test, the rat was transferred to the room of the FST and exposed to 7 
min of forced swimming. Predominant behaviour (immobility, swimming or struggling) was 
scored manually from recorded videos with time-sampling technique (5 sec) by an examiner 
blindfolded to group identity until score reliability was within 10%. Diving was scored as 
struggling. 
2.7 Morris Water Maze 
Spatial learning and memory, as well as reversal learning was examined in the MWM (2 m 
diameter, 0.5 m height) with a naïve cohort of rats (5 WT, 10 BDNF+/-). Rats were trained to 
find a hidden Atlantis escape platform (12 cm diameter; Ugo Basile, Italy) for five days with 
two trials per day. Each rat was released from one of four release points in a pre-determined 
random order. Rats had up to 120 s to find and mount the platform and were guided there if 
they failed to find it. Latency, swim speed and distance were recorded using Actimetrics 
Watermaze software (Actimetrics, IL, USA). On day six (24 h after the last test), each rat 
received a 60 s probe trial in which the escape platform was absent, but rose up after 60 s (to 
prevent extinction of the location). During the probe trial, % time spent in quadrant, % 
thigmotaxis (swimming within 15 cm of the pool edge), swim speed and number of platform 
crossings were analysed.  On day seven and eight, perseverant behaviour was assessed using 
a reversal protocol in which the platform was moved to a randomly determined location 
(middle of one of the four quadrants). Rats received two swims on day seven and one swim 
on day eight.  
To assess visual ability, a trial in which the platform was visible (i.e. the water level was 
lowered) was conducted two weeks after the probe trial with curtains pulled around the maze 
to hide spatial cues (both groups reached the platform in under 12 ± 2 s; data not shown). 
2.8 Tissue collection and RT-qPCR 
Quantitative PCR (qPCR) was used to investigate the cerebral expression of genes associated 
with neuropsychiatric disease and hypothalamic-pituitary-adrenal (HPA) axis regulation. 
Naïve WT and BDNF+/- rats were culled by decapitation. The HPC and PFC were quickly 
removed from the right hemisphere, immediately frozen on dry ice and stored at -80 °C. 
Approximately 70–80 mg (PFC) and 50-60 mg (HPC) of tissue was homogenised in Qiazol 
Lysis Reagent (Qiagen GmbH, North Rhine-Westphalia, Germany) according to the 
manufacturer’s instructions. RNA was then isolated from the supernatant using the RNase 
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MiniKit (250) (Qiagen GmbH) with an on column DNAse step to reduce possible sample 
contamination with DNA (Qiagen GmbH). RNA quantification and integrity (absorbance at 
280/260 nm > 2.10, 260/230 nm > 1.45) was analysed by Nanodrop (Spectrophotometer ND-
1000, Software ND-1000 V3.8.1; NanoDrop Technologies Inc., Delaware, USA). High-
Capacity cDNA Reverse Transcription Kit (4368814, Applied Biosystems, ThermoFisher, 
Massachusetts, USA) was used for reverse transcription PCR, by adding 500 ng of RNA to 
10 μl of reverse transcription reagent, resulting in a final volume of 20 μl. Samples were 
incubated for 10 min at 25 °C, 120 min at 37°C, 5 min at 85 °C, cooled down to 4 °C and 
stored at -20 °C. For the qPCR, cDNA was diluted 1:20 with diethyl pyrocarbonate treated 
water and triplicates of 2 μl of the sample and 8 μl of master mix (Roche, LightCycler 480 
Probes Master, Baden-Württemberg, Germany) with TaqMan Gene expression Assays 
(Applied Biosystems, ThermoFisher) were used. Reference genes and target genes are listed 
in Table 1. The thermal conditions for the qPCR were 5 min at 95 °C, followed by 50 cycles 
of 10 s denaturation at 95 °C and 30 s annealing at 60 °C. Finally, qPCR was completed with 
30 s extension at 40 °C. 
 A standard curve of eight two-fold dilutions was run for each target and reference 
gene on the same plate as the respective samples. PCR efficiency was calculated from the 
standard curve’s slope and outliers within the triplicate were excluded if standard deviation 
(SD) of the triplicates was > 0.4. A combination of reference genes were chosen based on 
good correlation with other reference genes and low variance within the reference gene 
across groups and tissue. Hence, an average of the relative concentration of Actb and Hprt137 
were used to normalise target genes. 
2.9 Statistical analysis 
Behavioural and qPCR data (normalised to WT group mean) were analysed with Student’s t-
test or Welch’s unequal variance t-test if the assumption of homogeneity of variance was 
violated. Normality was assessed with QQ-plots and Shapiro Wilk test, and if violated, data 
was log-transformed or non-parametric Mann-Whitney U test was applied. Two BDNF+/- 
animals were excluded from the SPT because their total fluid intake was < 5 g within 48 h, 
which could be due to a measurement error. Repeated measurement data of the MWM was 
analysed with multivariate repeated measures ANOVA. Outliers were removed according to 
Grubb’s (α = 0.05, two-sided) or ROUT test (Q = 1%; GraphPad Prism 6, GraphPad 
Software Inc., California, USA). Data analysis was carried out in Stata (Stata 14.0, 
StataCorp, Texas, USA). Graphs were created with GraphPad Prism 5.  
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Table 1   Details of genes and primers used for qPCR. 
Used gene 
abbreviation 






Nuclear receptor subfamily 3, group C, 
member 1 coding for glucocorticoid 
receptor 
Rn00561369_m1 73 Target gene 
MR 
(Nr3c2) 
Nuclear receptor subfamily 3, group C, 
member2 coding for 
mineralocorticoid receptor 
Rn00565562_m1 79 Target gene 
Crh Corticotropin releasing hormone Rn01462137_m1 112 Target gene 
Fkbp5 FK506 binding protein 5 Rn01768371_m1 74 Target gene 
Disc1 Disrupted in schizophrenia 1 Rn00598264_m1 73 Target gene 
Nrg1 Neuregulin 1 Rn01482168_m1 86 Target gene 
Gsk3b Glycogen synthase kinase 3 beta Rn01444108_m1 96 Target gene 




Rn01527840_m1 64 Reference 
gene 








3.1 BDNF+/- rats exhibit anhedonia but not behavioural despair 
3.1.1 Forced swim test reveals no difference in behavioural despair 
The FST assesses behavioural despair indicated by a longer time spend passively coping, i.e. 
immobile, relative to actively coping behaviours, i.e. swimming or struggling, in an 
unescapable situation. No difference between genotypes was observed for time spent 
immobile, engaged in swimming or struggling behaviour. Salient is the bimodal distribution 
in the WT group for struggling behaviour and the low immobility scores of the WT group 
(nearly 40% of WT animals have a lower immobility score than the minimum score for 
BDNF+/-; Figure 1). 













































Figure 1. Behavioural parameters during the forced swim test. Time spent engaged in immobility, 
swimming and struggling during 5-s time intervals during 7 min FST. Group mean (± SEM) as well as 
individual scores are shown.  
3.1.2 BDNF+/- rats exhibit anhedonic behaviour in the sucrose preference test 
The SPT assesses the hedonic state of the rats by measuring the preference for a sucrose 
solution over water intake. No significant difference was observed in total fluid intake 
between the WT and BDNF+/- rats (Figure 2A). Sucrose preference, i.e. sucrose solution 
consumption normalised to total fluid intake, was significantly different between groups 
(t(14.61) = 2.82, p = 0.013) with BDNF+/- animals exhibiting a lower sucrose preference than 
WT animals (Figure 2B), thus indicating increased anhedonic-like behaviour in the BDNF+/- 
rats compared to WT controls. Food intake and percent change in body weight (both 































































Figure 2. Sucrose preference test. (A) Total fluid consumption. (B) Percent normalised sucrose 
consumption, i.e. sucrose preference. The individual results are plotted with mean (± SEM) for each 
group. Statistical significance between groups is indicated with *p < 0.05. 
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3.1.3 Novelty induced hypophagia is similar between genotypes 
In the NIH test, the drive to consume a palatable chocolate reward competes with the fear of 
a novel environment and thus assesses anxiety- as well as anhedonic-like behaviour38. No 
significant difference was found for reward collection latency between WT (254.69 ± 183.40 
s, Median = 220) and BDNF+/- rats (344.00 ± 334.54 s, Median = 202). This data support no 
differences in a combined readout on anhedonic-like behaviour and anxiety-related 
behaviour between WT and BDNF+/- rats. However, three BDNF+/- rats did not consume the 
chocolate reward within the time limit (900 s) and hence the time limit was used as their 
collection latency although the true value could have been much higher.  
3.2 BDNF+/- rats display mild anxiety-like behaviour 
3.2.1 BDNF+/- rats display normal anxiety-like behaviour in the elevated plus-
maze 
Anxiety-like behaviour was evaluated in BDNF+/- and WT rats since MDD is often 
accompanied by anxiety. The % distance travelled in the open arms, % time spent in the 
open arms and % number of open arm entries was similar across genotypes (Figure 3).  
 However, WT rats (10.37 ± 3.13 m) travelled a significantly greater total distance 
(t(25) = 2.37, p = 0.026) in the EPM than BDNF+/- animals (7.56 ± 3.04 m). This effect is 
likely due to WT rats (7.32 m ± 2.61 m) travelling a greater distance compared to BDNF+/- 
rats (5.17 ± 2.55 m) in the closed (t(25) = 2.16, p = 0.041), but not in the open arms. A trend 
in number of entries to the closed (U = 1.779, p = 0.075), but not open arms, was observed 
between WT (14.46 ± 7.11 entries, Median = 11) and BDNF+/- animals (9.08 ± 5.25 entries, 
Median = 8). A trend (t(25) = 1.98, p = 0.059, data log-transformed) in rearing behaviour 
was observed with WT animals (6.42 ± 10.12 s, Median = 11.8) spending more time rearing 
than their BDNF+/- littermates (10.79 ± 8.25 s, Median = 9.05). Time spent head dipping into 
open arms was similar between groups. WT rats (2.77 ± 3.00 boli, Median = 2) produced 
significantly more faecal boli (U = 2.371, p = 0.018) than BDNF+/- rats (0.31 ± 0.63 boli, 
Median = 0) during testing on the EPM. Body weight of the animals, which can influence 
behaviour in the EPM, was not significantly different between genotypes at the time of 
testing. In sum, the primary readouts of the EPM suggest equal anxiety-like behaviour 
between genotypes, but decreased locomotor activity in the BDNF+/- rats.  
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Figure 3. Behavioural parameters in the EPM. Distanced travelled in the open arm, time spend in the 
open arm and number of open arm entries normalised to total distance travelled, duration of 
experiment and number of arm entries to closed and open arm respectively. Group mean (± SEM) and 
individual scores are shown, *p < 0.05, #p < 0.06 indicate significance level. 
3.2.2 BDNF+/- rats show increased anxiety-like behaviour in open field test 
The open field (OF) test assesses the conflict between anxiety-related behaviour (fear of 
open and lit areas) and a desire to explore. Furthermore, the OF allows assessment of 
locomotor activity, which could be a cofounder, for example in the FST.36 BDNF+/- rats 
(Median = 2.10 s) spent less time in the centre than their WT littermates (Median = 9.70 s; 
t(12.13) = 3.31, p = 0.006; Figure 4A). BDNF+/- rats (21.29 ± 16.97 s) also spent less time in 
the middle zone (t(25) = 2.28, p = 0.031) than WT rats (41.29 ± 27.70 s). Accordingly, 
BDNF+/- rats (574.59 s ± 21.14, Median = 574.85) spent more time in the outer zone 
(t(16.39) = -2.38, p = 0.030) than WT animals (540.76 ± 47.05 s, Median = 564.80). 
However, WT animals travelled a greater total distance (t(25) = 3.21, p = 0.004) than 
BDNF+/- animals in the OF test (Figure 4B) suggesting decreased locomotor activity in 
BDNF+/- animals than in WT rats. Since locomotor activity could interfere with the time 
spent in a zone, % distance travelled in each zone was analysed. Similarly to time spent in a 
zone, BDNF+/- rats (Median = 2.60%) travelled less in the centre zone (U = 1.99, p = 0.047; 
Figure 4C) than their WT littermates (Median = 4.55%); and less distance in the middle zone 
(t(25) = 2.36, p = 0.027; BDNF+/-: 10.31 ± 6.68%; WT: 16.19 ± 6.27%). Subsequently, 
BDNF+/- rats (86.95 ± 8.90%) travelled more in the peripheral zone (t(25) = -2.47, p = 0.021) 
compared to WT rats (78.38 ± 9.10%). These data support greater anxiety-like behaviour in 
the BDNF+/- rats than in their WT littermates. No significant difference between genotypes 
was found for number of faecal boli in the OF. 
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Figure 4. Open field behaviour. (A) Time spent in centre zone of the OF. (B) Total distance travelled in 
the OF. (C) Percentage distance travelled in centre zone. Significant differences between genotypes 
are indicated with *p < 0.05, **p < 0.01. Individual results and group mean (± SEM) are displayed. 
3.3 BDNF+/- rats exhibit normal cognitive performance 
3.3.1 BDNF+/- rats exhibit normal working memory 
The alternation ratio (number of sequentially alternating arm entries normalised to the total 
number of arm entries), a readout of spatial working memory, did not differ between the 
genotypes (WT: 70.97 ± 7.54%; BDNF+/-: 67.13 ± 16.89%). Results were not cofounded by 
a difference in total number of arm entries between WT (21.31 ± 7.02 entries) and BDNF+/- 
(15.57 ± 8.68 entries) rats. No difference in distance travelled in the Y-maze was observed 
between the two groups (WT: 19.32 ± 4.84 m; BDNF+/-: 17.42 ± 7.60 m). Hence, this data 
suggest no difference in working memory or locomotor activity between BDNF+/- and WT 
rats. 
3.3.2 BDNF+/- rats show normal performance in the Morris water maze 
Spatial learning and memory performance, as well as perseverance behaviour was assessed 
in the MWM task because cognitive deficits have been frequently reported in depression. 
BDNF+/- rats showed a similar learning curve as WT controls. Both groups improved 
performance over time by decreasing their latency to find the platform in the water 
(F(4,55.27) = 13.55, p < 0.0001; Figure 5A). When the platform was removed the day after 
acquisition, BDNF+/- and WT controls showed comparable performance for % time in target 
quadrant (WT: 34.33 ± 10.51%; BDNF+/-: 37.00 ± 7.53%), number of platform crossings 
(WT: 2.4 ± 2.07 crossings; BDNF+/-: 1.3 ± 1.16 crossings), thigmotaxis (WT: 15.4 ± 8.99%; 
BDNF+/-: 21 ± 12.58%), and swim speed (WT: 21.60 ± 3.85 cm/sec; BDNF+/-: 22.63 ± 1.92 
cm/sec). Both groups improved performance during reversal learning (F(2,27) = 18.68, p < 
0.0001), but no difference in reversal learning latency was found between groups (Figure 
5B). WT (39.00 ± 7.93%) and BDNF+/- (39.20 ± 13.03%) rats spent similar time in the 
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original target quadrant during reversal learning. Thus, BDNF+/- rats display intact spatial 
learning and memory as well as normal perseverative behaviour. 






















































Figure 5. Morris water maze test. (A) Learning phase of finding the hidden platform (mean of two trials 
per day). (B) Reversal learning of finding the platform in a new location. 
3.4 Locomotor activity 
As many of the tests in behavioural mazes can be confounded by the general locomotor 
activity of the rats, it is important to determine if there is an alteration in general activity 
between genotypes. There was no difference in the total distance travelled in the Y-maze 
(section 3.3.1) or swim speed in the water maze (section 3.3.2) suggesting similar locomotor 
activity across genotypes. However, BDNF+/- rats moved less in the OF (Figure 4B) and in 
the EPM (section 3.2.1) compared to the WT controls. Thus, when altered locomotor activity 
between genotypes was present in tasks, it was accounted for in the respective analysis. 
3.5 Gene expression 
To test whether reduced BDNF levels alter expression patterns of a selection of genes 
thought to underpin the depressive phenotype, we investigated mRNA expression of genes 
involved in affective disorders and relevant for an appropriate stress response in the PFC and 
HPC of naïve WT and BDNF+/- rats. Gene expression was upregulated in the PFC of 
BDNF+/- rats compared to WT animals for GR (t(17) = -2.30, p = 0.035), Nrg1 (t(17) = -2.25, 
p = 0.038) and Disc1 (t(17) = -4.71, p = 0.0002) displayed in Figure 6. There were no 
significant differences between the mRNA levels of MR, Crh, Fkbp5 and Gsk3b in the PFC 
of WT and BDNF+/- rats (Supplementary Table 1). In the HPC, Fkbp5 mRNA expression 
was reduced in BDNF+/- animals compared to WT animals (t(9.45) = 3.09, p = 0.012; Figure 
6). However, no significant difference in HPC mRNA expression was identified for GR, 
MR, Crh, Nrg1, Disc1 and Gsk3b between WT and BDNF+/- rats (Supplementary Table 1). 
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Figure 6. Gene expression. Presented are the individual and group (± SEM) gene expression levels (as 
% of WT group mean) from the prefrontal cortex (PFC) and hippocampus (HPC). Statistical significance 
is indicted with *p < 0.05, ***p < 0.001. 
4 Discussion 
In the present study, we showed that BDNF+/- rats display depressive-like behaviour, 
decreased locomotor activity and altered mRNA expression of genes in the PFC and HPC 
compared to WT animals. Anxiety-like behaviour, behavioural despair and cognition was 
comparable between BDNF+/- and WT littermates. 
Depressive-like behaviour was assessed by testing for anhedonia, a core symptom of MDD. 
Sucrose consumption is frequently used to evaluate the hedonic state of an animal.39 In the 
present study, BDNF+/- rats consumed less sucrose solution in favour of a higher water intake 
compared to WT controls. Hence, reduced BDNF levels resulted in an anhedonic-like state 
and, thus, BDNF+/- rats exhibit a depressive-like phenotype. 
  The NIH test evaluates the conflict between avoidance of open and lit areas and the 
desire for consuming a food reward.38 No difference for NIH was observed between 
genotypes. However, all WT rats consumed the reward whereas 20% of the BDNF+/- group 
did not, which might indicate increased anxiety or decreased motivation or sensitivity for the 
reward in BDNF+/- rats, consistent with an anhedonic-like phenotype that we found in the 
SPT. Interestingly, Schmidt and Duman30 observed a shortened collection latency in the NIH 
test in WT mice after peripherally administering BDNF, but unaltered behaviour in the 
sucrose consumption test in these mice, suggesting an anxiolytic effect of BDNF 
administration with no effect on the hedonic state. These opposite effects compared to the 
present study might be due to differences in methodology, such as the nature of the reward or 
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the duration of testing, as well as peripheral administration versus knockdown (KD) of 
BDNF. Also the model, mouse versus rat, could have an essential effect of BDNF on the 
behaviour, since mice do not naturally express peripheral BDNF, which can influence brain 
gene expression and affective behaviour30. The importance of the model is further 
emphasized by the findings that temporal KD of BDNF in the dentate gyrus of rats40 but not 
mice41 during adulthood resulted in a decrease of sucrose consumption. Finally, reduced 
reward sensitivity in BDNF+/- rats was also shown in a test of cocaine seeking behaviour,42 
strengthening the results of the present study. 
 In this study, no difference in anxiety-related behaviour was found in the EPM. 
Anxiety disorders are frequently observed as comorbidity in MDD patients and, hence, the 
depressive-like behaviour in BDNF+/- rats may have been accompanied by increased anxiety. 
Peripheral BDNF administered to mice was shown to have an anxiolytic effect in the EPM,30 
however, another study, also with BDNF+/- rats, failed to observe altered anxiety behaviour 
in the EPM43 and therefore substantiating our results. Nevertheless, in the present study, 
BDNF+/- rats spent less time in the centre or middle area of the OF, and significantly more 
time in the periphery than their WT littermates. Although this behaviour was accompanied 
with decreased locomotor activity in BDNF+/- rats, the % distance travelled in each zone 
reflected the findings of time spent in a specific zone. Our OF results are supported by 
another study,43 in which BDNF+/- rats spent less time in the centre of the OF and showed 
decreased locomotor activity. Thus, findings in BDNF+/- rats support anxiety-like behaviour 
in the OF but not in the EPM.  
 Cognitive impairments are often seen in MDD44 and reduced BDNF levels have 
been implicated with impaired spatial memory.45 In the SAB test, cognitive impairments 
were linked to the anhedonic-like phenotype in a preclinical MDD stress model.35,46 
Conversely, we found that working memory was intact in the BDNF+/- group compared to 
WT rats as examined in the SAB test. These results are supported by BDNF+/- rats displaying 
intact spatial learning and memory as well as normal perseveration in the MWM test. Thus, 
BDNF+/- rats displayed intact cognition although reduced BDNF might attenuate neuronal 
plasticity.25 
 In the present study, BDNF+/- rats did not show behavioural alterations compared to 
controls in the FST, which is a common test used in preclinical depression research. 
However, the FST was developed to assess antidepressant drug efficacy rather than 
depression symptomatology and is sensitive to acute antidepressant treatment while only 
chronic treatment is efficacious in MDD patients.36 Therefore the FST may not be the best 
test for assessing the enduring effects of genetic manipulations. 
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 A selection of cerebral genes were chosen to investigate the neurobiological 
underpinnings of the behavioural alterations observed in the BDNF+/- rats. Firstly, genes 
involved in regulating the stress response by modulating the HPA axis were examined since 
it was shown that BDNF affects HPA axis activity in healthy individuals47. MR expression is 
associated with a predisposition to show resilience or susceptibility to stress and 
depression48,49. MR and GR regulate HPA axis activity. Increased expression of GR is 
associated with increased sensitivity of the HPA axis and thus a healthy stress response49,50. 
Both genes are transcription factors and therefore are important regulators of gene 
expression. Fkbp5 competes with glucocorticoids to bind to GR and, thus, modulates the 
negative feedback sensitivity of the HPA axis as well.51 Crh mRNA expression can be taken 
as activity readout of the HPA axis since it is part of the activation cascade resulting in the 
downstream release of the corticosteroid stress hormones. BDNF expression modulates CRH 
levels and, hence, HPA axis function.52 Increased levels of Crh can induce a depressive-like 
phenotype and, thus, Crh might be involved in MDD aetiology.50 Secondly, genes associated 
with affective disorders were investigated. In schizophrenia, bipolar disorder and MDD, 
translocation and loss of function of Disc1 was shown53–55. Overexpression of Disc1 in the 
mouse ventral HPC resulted in a depressive-like phenotype56. Disc1 downstream regulates 
Gsk3b and altered expression pattern in the latter one was associated with neuropsychiatric 
diseases, such as MDD and anxiety disorder57. Finally, NRG1 drives neuronal plasticity and 
was identified as a susceptibility gene in neuropsychiatric diseases and associated with 
cognitive impairments58. In the present study, gene mRNA expression was upregulated in 
BDNF+/- rats compared to WT controls in the PFC for GR, Nrg1 and Disc1, whereas no 
differences were observed on MR, Crh, Fkbp5 or Gsk3b mRNA levels between the groups. 
The mRNA levels of the same genes were also assessed in the HPC. Here, only Fkbp5 
expression was reduced in BDNF+/- compared to WT rats. MDD patients show a 
downregulation of GR mRNA in the frontal cortex59 and, hence, we would have expected a 
down- rather than an upregulation of GR in BDNF+/- rats. Furthermore, polymorphisms in 
FKBP5 leading to an increased expression of the gene were found in MDD patients.51 
Increased binding of Fkpb5 to GR reduces the sensitivity of the HPA axis and results in a 
prolonged stress response, such is often found in patients with depression.51 Therefore, 
downregulation of Fkbp5 mRNA in the BDNF+/- group was unexpected and did not result in 
altered GR mRNA expression in the HPC. Furthermore, loss of function of Disc1 is 
associated with mental disorders. In the present study, Disc1 mRNA was upregulated by 
26% in the PFC of BDNF+/- animals. Furthermore, Nrg1 was also upregulated in the PFC of 
BDNF+/- rats. Nrg1 is a growth factor involved in synaptic plasticity underlying cognitive 
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processes, such as spatial learning.58,60 NRG1 protein was found upregulated in the PFC of 
rats exposed to chronic unpredictable mild stress and these rats displayed depressive-like 
behaviour in the FST and SPT.61 Thus, increased Nrg1 gene expression in BDNF+/- rats is 
complementary to the literature and implicates the role of BDNF in association with Nrg1 
expression in the context of depression. 
 Although, mRNA levels for GR, Fkbp5 and Disc1 were regulated in a different 
direction than expected, we found that those genes, as well as Nrg1, were differently 
expressed as a consequence of lower BDNF levels. However, to fully understand the 
functional consequences of these unexpected changes, we will need to determine the 
corresponding protein levels.  
Overall, we have shown that a genetically induced reduction of BDNF levels lead to a 
depressive-like phenotype as well as alterations in expression levels of genes that are 
relevant for psychiatric disorders. In future studies, a combination of stress and genetic 
manipulation might be ideal to provoke a more differentiated phenotype. However, the 
present study established a solid basis for future research, with the rat as a better model for 
preclinical studies than the abundantly studied mouse, due the similarity of BDNF 
expression in rats and humans. Moreover, our study suggests a link of decreased BDNF 
levels with the MDD core symptom of anhedonia. It is also demonstrated that BDNF 
expression levels regulate expression of Disc1, Nrg1, GR and Fkbp5 genes, relevant in 
affective disorders and a healthy stress response. Thus, the present study adds to the complex 
field of entangling the role of BDNF in the development and pathology of MDD. 
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Supplementary 
Supplementary Table 1   Gene expression. Displayed are the normalised gene expression levels as % 
WT control mean (group mean ± standard deviation) in the prefrontal cortex (PFC) and hippocampus 
(HPC). *indicates statistically significant differences between groups. 
Brain region Gene WT BDNF+/- 
PFC GR* 100 ± 9.6 109.6 ± 8.5 
 MR 100 ± 5.2 106.6 ± 13.6 
 CRH 100 ± 17.1 111.0 ± 16.2 
 FKBP5 100 ± 10.2 92.9 ± 11.9 
 NRG1* 100 ± 10.7 110.9 ± 10.3 
 DISC1* 100 ± 12.7 125.7 ± 11.1 
 GSK3B 100 ± 11.0 111.7 ± 8.2 
HPC GR 100 ± 6.6 105.5 ± 12.5 
 MR 100 ± 9.7 101.6 ± 9.3 
 CRH 100 ± 12.9 91.8 ± 14.0 
 FKBP5* 100 ± 1.8 87.6 ± 12.6 
 NRG1 100 ± 11.3 93.8 ± 11.3 
 DISC1 100 ± 9.4 99.7 ± 15.6 
 GSK3B 100 ± 5.0 104.5 ± 6.0 
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